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Abstract 
This thesis is concerned with the question of whether developing countries such 
as the People‘s Republic of China (PRC) are well prepared for the ethical and 
legal conduct of human population genetic research (HPGR) with specific regard 
to vulnerable target group protection. It highlights important issues such as 
whether the current frameworks of Western developed countries can provide 
adequate protections for target groups in human population genetic research. 
One fundamental question is who may suffer harm in this kind of research. Most 
bioethical scholars focus on individual participants but it is argued here that the 
interests of target groups are also seriously implicated in this kind of research. 
Since the target groups of HPGR are almost always vulnerable groups from 
isolated and rural areas of developing countries, the ethical and legal 
frameworks for human subject protection may need to be reconsidered in order 
to eliminate, or at least reduce, the vulnerability of those groups. Accordingly, 
given the dominance of the current ideology of Western developed countries, a 
critical study of vulnerable population protection is necessary to identify 
whether this ideology is appropriate in this context. This thesis aims to propose 
recommendations on the ethical and legal frameworks of biomedical research in 
developing countries with specific consideration of vulnerable group protection 
and cultural sensitivity. The PRC is used as an example to investigate current 
regulations for both human subject protection and group protection in 
developing countries. The thesis argues for an alternative model for group 
protection in the context of human population genetic research in developing 
countries.  
Translations of titles, authors, and publishers from Chinese works are unofficial, 
and the laws in this thesis are up to date at April 2011. 
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Chapter 1 – Introduction 
The Human Population Genetic Research Project (HPGR) seeks to identify the 
diversity and variation of the human genome and how human group and 
individual genetic diversity has developed. Since HPGR targets specific groups to 
discover variation, it also raises many pressing ethical and legal concerns. This 
thesis focuses on concerns raised by the application of the current dominant 
Western ethical and legal frameworks on human research subject protection to 
HPGR. It discusses target group protection in HPGR and examines it in the 
context of developing countries, specifically, the People‘s Republic of China. It 
argues that the current understanding of universal values on human research 
subject protection needs to be modified to take account of the particular 
challenges presented by HPGR in developing countries. 
1.1 Introduction to Human Genes and Genetic 
Information 
On 25 April 1953, the article, Molecular Structure of Nucleic Acids - A Structure 
of Deoxyribose Nucleic Acid, was published in the well-known British scientific 
journal Nature by a young pair of scientists, James D. Watson and Francis H. C. 
Crick.1  It has been said that their names have ‗joined Darwin and Copernicus 
among the immortals,‘2 and the new era of biology began. Their discovery of the 
DNA double helix is thought to be the greatest single scientific achievement of 
the 20th century and a new milestone of human history. 
It has been a dream to explore the secrets of life, to solve the puzzles of death, 
growing old and sickness; to eradicate disease, to improve living standards and 
prolong human life. For a long time, people have been seeking to solve these 
puzzles, but although a great deal of financial and personal effort has been 
expended, and despite quite significant progress having been made in some 
                                         
1
 Watson, J. D. & Crick, F. H. C. 1953, " Molecular Structure of Nucleic Acids - A Structure of 
Deoxyribose Nucleic Acid ", Nature, vol. 171, no. 4356, pp. 737-738. 
2
 Hunt-Grubbe, C. The Elementary DNA of Dr Watson. Times. 10-14-2007.  
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areas, until recently no great progress had been made in many others.3 However, 
the discovery of the importance of genes and the development of genetic 
technology has enabled human beings to study the secrets of life at the 
molecular level, and to see glimpses of hope of making greater progress. 
Formerly, the understanding of the constitution of human beings was limited 
largely to what could be seen. However, when science and technology entered 
the molecular era, the understanding of the constitution of human beings at the 
level of DNA opened scientific possibilities while at the same time raising some 
problematic issues.  
1.1.1 What is a Human Gene? 
At the outset, there are some terms which need to be clarified. The official 
document of the Human Genome Project (HGP) defined these terms as following: 
Cells are the fundamental working units of every living system. All the 
instructions needed to direct their activities are contained within the 
chemical DNA (deoxyribonucleic acid).  
DNA from all organisms is made up of the same chemical and physical 
components. The DNA sequence is the particular side-by-side 
arrangement of bases along the DNA strand (e.g., ATTCCGGA). This 
order spells out the exact instructions required to create a particular 
organism with its own unique traits.  
The genome is an organism‘s complete set of DNA. Genomes vary 
widely in size: the smallest known genome for a free-living organism 
(a bacterium) contains about 600,000 DNA base pairs, while human 
and mouse genomes have some 3 billion. Except for mature red blood 
cells, all human cells contain a complete genome.4 
As ‗Nature‘ magazine‘s reporter Helen Pearson said: 
                                         
3
 Although ‗Today, global life expectancy at birth is about 67 years; two centuries ago it was 30 
years or less.‘ (Riley, J. C. 2001, Rising Life Expectancy: A Global History, Cambridge 
University Press, New York), we still cannot say that we have mastered all the secrets of human 
life. 
4
 Genomics and Its Impact on Science and Society, full text can be seen on the official website of 
HGP, available on 
http://www.ornl.gov/sci/techresources/Human_Genome/publicat/primer2001/primer11.pdf, last 
visit on 2010-04-19. 
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In classical genetics, a gene was an abstract concept — a unit of 
inheritance that ferried a characteristic from parent to child. As 
biochemistry came into its own, those characteristics were associated 
with enzymes or proteins, one for each gene. And with the advent of 
molecular biology, genes became real, physical things — sequences of 
DNA which when converted into strands of so-called messenger RNA 
could be used as the basis for building their associated protein piece 
by piece. 5 
Every cell in a human body containing DNA has the full set of instructions 
necessary to create that particular individual.6 These instructions are encoded in 
twenty-three pairs of individual DNA strands which are called chromosomes.7 
These chromosomes carry over 30,000 encoded genes.8 Each gene performs a 
specific function, some may perform several, but the functions of only a small 
amount of genes are currently understood.9  
In general terms, a gene is unit of heredity, ‗a union of genomic sequences 
encoding a coherent set of potentially overlapping functional products‘.10  There 
are three basic features of a gene:  
a) It is a relatively independent unit of heredity. As an information unit, a 
gene can refresh combinations of the genetic make-up of both parents by 
transferring them to offspring. What is more, a gene can instruct, 
influence and even decide creatures‘ traits, such as body structure and 
living habits. 
                                         
5
 Pearson, H. 2006, "What is a Gene?", Nature, vol. 441, pp. 399-401, at 399. 
6
 Mehlman, M. J. & Botkin, J. R. 1998, Access to the Genome: The Challenge to Equality, 
Georgetown University Press, Washington, D.C. 
7
 Ibid. 
8
 The International Human Genome Sequencing Consortium has estimated, based on the rough 
draft of the genome published in February 2001, that there are approximately 30,000 human 
genes. However, this number may be incorrect, as complex cellular processing of genes and 
gene products may result in several possible products from a single gene sequence. See 
International Human Genome Sequencing Consortium 2001, "Initial Sequencing and Analysis of 
the Human Genome", Nature, vol. 409, no. 6822, pp. 860-921. 
9
 See Online Mendelian Inheritance in Man, the full text can be seen on the official website of the 
National Center for Biotechnology Information of the US, available on www.ncbi.nlm.nih.gov, 
last visited on 2008-10-27. 
10
 Gerstein, M. B., Bruce, C., Rozowsky, J. S., Zheng, D., Du, J., Korbel, J. O., Emanuelsson, O., 
Zhang, Z. D., Weissman, S., & Snyder, M. 2007, "What Is a Gene, Post-ENCODE? History and 
Updated Definition", Genome Research, vol. 17, no. 6, pp. 669-681. 
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b) At a molecular level, a gene is a segment of a DNA molecule, the 
sequences of nucleotides (or bases) in genes represent the heredity of 
human beings and other creatures. The information in a gene is encoded 
in the sequence of base groups of DNA. 
c) Genes are specific sequences of bases that encode instructions on how to 
make proteins.11 Gene sequences of DNA, when transferred into strands 
of messenger RNA, could be used as the basis for building their related 
protein piece by piece. The gene could not only transmit all of this 
information through replication, but also could dominate the organism‘s 
character by controlling the process of synthesizing protein, which is 
called ‗gene expression‘. In other words, a gene exerts its physical 
function through directing the production of proteins and RNA molecules. 
1.1.2 What is Genetic Information? 
According to Article 2 (i) of the UNESCO International Declaration on Human 
Genetic Data, human genetic data is ‗the information about heritable 
characteristics of individuals obtained by analysis of nucleic acids or by other 
scientific analysis.‘12 Although the intention of this definition is merely to set out 
the relationship between human genetic information and scientific research, it 
suggests that the real value of the gene is not its physical substance but the 
information carried in it. 
In general, genetic information is the information for making all of the proteins 
required by all organisms. These proteins determine, among other things, how 
the organism looks, how well its body metabolizes food or fights infection, and 
sometimes even how it behaves.13 
Genetic information, as Laurie summarized, has the following features and 
functions: it 
                                         
11
 See supra note 4.  
12
 The International Declaration on Human Genetic Data which was adopted unanimously and by 
acclamation at UNESCO's 32nd General Conference on 16 October 2003.   
13
 ‗About the Human Genome Project‘, it can be seen on the official website of Human Genome 
Project, available on http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml, 
last visited on 2009-02-19. 
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…relates to families and not just individuals; can offer a degree of 
certainty in determining which of those persons is likely to be 
affected by genetic disease; can provide a measure of predictability in 
the assessment of likelihood of ill health in particular individuals from 
an affected group; can reveal secrets about future ill health, even in 
those who are currently well; can help to determine future risks in 
future person.14  
In fact, genetic information is the real research target of all genetic research, 
while the gene is the material carrier of genetic information. Hence, genes and 
genetic information have a close relationship with each other. Since most human 
cells contain two sets of chromosomes 15  which come from both father and 
mother and each chromosome contains an integrated human genome,16 in theory, 
almost every human cell is able to express all human genetic information (one 
example of an exception to the general rule is that of mature red blood cells). 
It has been argued that a gene is ‗a packet of information encoded within the 
DNA molecule‘. 17  However, this argument confuses the gene and genetic 
information. The relationship between genes and genetic information is similar 
to that of a book and the knowledge it contains. The book is the material carrier 
of its knowledge. Therefore, while a gene contains genetic information, this 
does not mean that genetic information is the same thing as the gene itself; the 
gene is matter, but genetic information is intangible. Matter and information are 
different concepts, and this is the fundamental difference between these two 
terms.  
1.1.3 Three Types of Human Genetic Information 
There is a wide range of debate on whether or not human genetic information 
should be a special subject of research and needs to be treated separately from 
                                         
14
 Laurie, G. 2002, Genetic Privacy: A Challenge to Medico-Legal Norms, Cambridge University 
Press, at 104. 
15
 Chromosomes are long strands of DNA containing many genes and are packaged in structures. 
There are approximately 25000 genes in human genome. 
16
 A genome is the entire DNA contained in one cell. The hereditary material in nearly all living 
organisms is deoxyribonucleic acid or DNA. DNA is held in a cellular structure called the 
nucleus. 
17
 Silver, L. M. 1999, "Meaning of Genes and "Genetic Rights"", Jurimetrics, vol. 40, pp. 9-20, at 
11-12. 
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other types of medical information.18 It seems that both sides have their own 
reasonable points, in favour and against doing so. This debate results from the 
fact that human genetic information collected from an individual has abundant 
applications. Different applications would influence the interests of different 
parties, such as individual participants, certain groups or communities, even all 
human beings. 19 It has been argued that the human genetic information carried 
by an individual can be divided into three different types: non-differential 
human genetic information, individual human genetic information and 
community or group/collective human genetic information.20 Each of these three 
types of human genetic information has its own attributes and merits distinctive 
treatment.  
a) Non-differential human genetic information 
Non-differential human genetic information describes the genetic information 
shared by each human being. It has been shown that nearly 60% of human genes 
are isogenies with the fruit fly.21 In addition, the chimpanzee genome is 95% 
identical to the human genome. On average, a typical human protein-coding 
gene differs from its chimpanzee ortholog22 by only two amino acid substitutions; 
nearly one third of human genes have exactly the same protein translation as 
their chimpanzee orthologs. A major difference between the two genomes is 
human chromosome 2, which is equivalent to a fusion product of chimpanzee 
chromosomes 12 and 13.23 The working draft of the Human Genome Project (HGP) 
which was released in 2000 and the complete version published in 2003 reveal 
that these non-differential genes are present in each human individual. In this 
sense, non-differential human genetic information could be viewed as a new 
type of common heritage of mankind.  
                                         
18
 More details of this debate can be seen in Chapter 2. 
19
 Zhou, Q. 2006, "The Legal Status of Human Gene and Genetic Information (Lun Renlei Jiyin ji 
Jiyinxinxi de Falvdiwei)", Science-Technology and Law (in Chinese), vol. 63, pp. 113-117. 
20
 See supra note 19. 
21
 ‗Fruit Fly Gene Success‘, it can be seen on BBC News website, available on 
http://news.bbc.co.uk/1/hi/sci/tech/647139.stm, last visited on 2009-02-19. 
22
 Orthology describes genes in different species that derive from a common ancestor.  
23
 "Human chromosome 2 resulted from a fusion of two ancestral chromosomes that remained 
separate in the chimpanzee lineage" The Chimpanzee Sequencing and Analysis Consortium 
2005, "Initial sequence of the chimpanzee genome and comparison with the human genome", 
Nature, vol. 437, no. 7055, pp. 69-87. 
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The view that a resource can be the common heritage of mankind originated 
from the United Nations Convention on the Law of the Sea and was one of its 
fundamental principles.24 The tenet was established in Articles 136 and 137: 
Article136 Common heritage of mankind: The Area and its resources 
are the common heritage of mankind. 
Article137 Legal status of the Area and its resources: 
1. No State shall claim or exercise sovereignty or sovereign rights over 
any part of the Area or its resources, nor shall any State or natural or 
juridical person appropriate any part thereof. No such claim or 
exercise of sovereignty or sovereign rights nor such appropriation shall 
be recognized. 
2. All rights in the resources of the Area are vested in mankind as a 
whole, on whose behalf the Authority shall act. These resources are 
not subject to alienation. The minerals recovered from the Area, 
however, may only be alienated in accordance with this Part and the 
rules, regulations and procedures of the Authority. 
3. No State or natural or juridical person shall claim, acquire or 
exercise rights with respect to the minerals recovered from the Area 
except in accordance with this Part. Otherwise, no such claim, 
acquisition or exercise of such rights shall be recognized.25 
At present, the scope of this principle has gone beyond the ocean and extended 
to particular areas and related natural resources, such as outer space and the 
Antarctic.26 
Each human being only has one genome which contains about 25,000 genes, and 
99.8% of human genetic information is entirely uniform. It has been selected and 
                                         
24
 The United Nations Convention on the Law of the Sea (UNCLOS), also called the Law of the Sea 
Convention or the Law of the Sea Treaty is the international agreement that resulted from the 
third United Nations Conference on the Law of the Sea (UNCLOS III), which took place from 
1973 through 1982. The Law of the Sea Convention defines the rights and responsibilities of 
nations in their use of the world's oceans, establishing guidelines for businesses, the 
environment, and the management of marine natural resources. The Convention concluded in 
1982 replaced four 1958 treaties. UNCLOS came into force in 1994; a year after Guyana 
became the 60th state to sign the treaty. To date 157 countries and the European Community 
have joined in the Convention. However, it is now regarded as a codification of the customary 
international law on the issue. 
25
 United Nations Convention on the Law of the Sea, it can be seen on the official website of UN, 
available on http://www.un.org/Depts/los/convention_agreements/texts/unclos/unclos_e.pdf, 
Article136 and 137, last visited 2009-03-26. 
26
 Porras, D. A. 2006, "The "Common Heritage" of Outer Space: Equal Benefits for Most of 
Mankind", California Western International Law Journal, vol. 37, no. 1, pp. 143-176. 
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evolved for thousands of years; hence, it is a gift from nature, like the natural 
resources of particular areas, such as outer space and the Antarctic. Thus, it is 
suggested that non-differential human genetic information should be a new type 
of common heritage of mankind. Neither states nor individuals could claim a 
proprietary right or sovereignty over non-differential human genetic information. 
Although enormous sums of human, financial and material resources have been 
spent on attempting to understand the 99.8% of non-differential human genetic 
information, and this research is potentially of great medical and commercial 
value, all mankind has a right to use it in peace and share benefit from its use.  
b) Individual human genetic information 
0.2% of human genetic information dominates the diversity of approximately 6 
billion human beings, such as height, weight, colour of eyes, hair and skin, 
appearance, character and even the possibility of suffering from certain diseases. 
This kind of information is individual in nature. It can be used in forensic 
databases, relationship testing and genetic research on certain diseases.27 Some 
biobanks, for example those established in Estonia (Estonian Genome Project)28, 
Iceland (Iceland Health Centre Database)29 and the UK (U.K. Biobank)30 aim to 
collect this kind of genetic information.  
Individual human genetic information which contains high specificity has one to 
one correspondence to a specific human being, except identical siblings. 
Accordingly, except for such siblings, individual human genetic information 
directly decides each individual‘s unique existence in the world. Although 
individual human genetic information has huge economic and social value, since 
it can be used in genetic diagnosis and therapy as well as to identify individuals, 
it is a type of crucial personal information. In some countries, such as the US, 
                                         
27
 Richards, M. 2001, "How Distinctive is Genetic Information?", Studies in History and Philosophy 
of Science Part C: Biological and Biomedical Sciences, vol. 32, no. 4, pp. 663-687, at 674-677. 
28
 Tzortzis, A., ―Estonia Looks to Make Mark with DNA Data,‖ Boston Globe, August 19, 2003 at E1. 
29
 Adalsteinsson, R. 2004, "Human Genetic Databases and Liberty", The Juridical Review, no. 1, 
pp. 65-74. 
30
 Winikoff, D., ―Partnership in U.K. Biobank: A Third Way For Genomic Property?‖ Journal of Law, 
Medicine & Ethics 35, no. 3 (2007): 440-456. 
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personal information is undoubtedly the subject of the right of privacy. 31 
Accordingly, the subject has the right to access, collect and obtain the 
information, keep the information strictly confidential, as well as decide on the 
use of the information. Identification of individual human genetic information 
may lead to violations of privacy, especially in the context of the possibility of 
suffering from certain diseases. For example, if susceptibility becomes known to 
employers or insurance companies, it may lead to discrimination.32 Thus, the 
effective protection of individual human genetic information has become a new 
challenge in the regulation of privacy. 
If individual human genetic information is regarded as being subject to the right 
of privacy, individual human genetic information ‗belongs‘ to the individual who 
is the source of the information and as a result, access to it should be controlled 
by that individual.  
c) Community or Group/Collective Human Genetic Information 
Community or group/collective human genetic information is a useful research 
tool to explore variations that could lead to knowledge about genetic disorders 
and possible cures, as well as the origin and migration patterns of peoples.33 A 
group of people who live together for a long period of time in a certain area 
seem more likely to have a similar genetic make-up, especially in isolated areas, 
because of a number of factors, such as sharing the same habitat, similar life 
style and inter-marriage. Moreover, the possibility of recessive traits in such 
groups would be greater than in other populations. For instance, 
Laken and colleagues…. used anonymized samples from a Tay-Sachs 
data bank in their search for the frequency in Ashkenazi Jews of a 
particular mutation in a gene predisposing to colon cancer (I1307K in 
the APC gene). They found that the mutation was present in 6.1% of 
                                         
31
 Annas, G. J. 1999, "Genetic Privacy: There Ought to be a Law", Texas Review of Law and 
Politics, vol. 4, pp. 7-15. 
32
 See Spaak, T. 2006, "Genetic Discrimination", Minnesota Journal of Law, Science & Technology, 
vol. 7, pp. 639-655. Also see Hellman, D. 2003, "What Make Genetic Discrimination 
exceptional?", American Journal of Law and Medicine, vol. 29, pp. 77-116. Also see Jungreis, R. 
2007, "Fearing the Fear Itself: The Proposed Genetic Information Nondiscrimination Act of 2005 
and Public Fears about Genetic Information", Journal of Law and Policy, vol. 15, pp. 221-247. 
33
 McGregor, J. L. 2007, "Population Genomics and Research Ethics with Socially Identifiable 
Groups", Journal of Law, Medicine and Ethics, vol. 35, pp. 356-370. 
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the Jews in the sample and none of the non-Jews. The authors noted 
with understandable excitement that this is the commonest cancer-
associated mutation in a specific population yet described.34 
Community or group/collective human genetic information reflects the influence 
of a long period of history, nature and lifestyle. This kind of genetic information, 
which is common to certain populations, communities or groups of people and 
contains information about heritability, can be studied and analyzed using a 
large number of samples from these communities and groups. 35  It can be 
suggested that in the same way that all human beings have collective interests 
in non-differential human genetic information, although it is carried by 
individuals, certain communities or groups also could have collective interests in 
community or group collective human genetic information. Since collective 
human genetic information is the research target of human population genetic 
research, I will argue that the interests of groups or communities should be 
considered carefully in HPGR. 
1.2 Human Population Genetic Research (HPGR) 
With the development of genetic science and technology, research on the human 
genome and genetic information is the new ‗hotspot‘ of biomedical research. 
However, it also leads to ethical and legal concerns concerning human subject 
protection. 
1.2.1 The Significance of Human Population Genetic Research 
HPGR focuses on human genetic information at a group level. It is also 
sometimes called ‗population-based genetic research/study‘ or ‗population 
genomic research/study‘. There are two different definitions of HPGR: a general 
one and a narrow one.  
                                         
34
 Weijer, C. 1999, "Protecting Communities in Research: Philosophical and Pragmatic Challenges", 
Cambridge Quarterly of Healthcare Ethics, vol. 8, pp. 501-513, at 502. 
35
 There was an existing example that Harvard‘s School of Public Health has selected over 6 
millions of people and brought back 16400 blood samples of asthma patients in name of 
therapy. ‗Harvard Gene Study in China Is Questioned‘ can be seen on the website of Los 
Angeles Times, available on http://articles.latimes.com/2002/mar/30/news/mn-35514, last 
visited on 2009-02-23.  
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General HPGR  is defined as ‗….a study which aims at understanding the nature 
and extent of genetic variation among a population or individuals within a group 
or between individuals across different groups.‘36 To be precise, the research 
object of general HPGR is the first type of genetic information mentioned above, 
which is non-differential human genetic information that is shared by all human 
beings.  
At present, the most influential general human population genetic research is 
the Human Genome Project (HGP), which ‗refers to the international 13-year 
effort, formally begun in October 1990 and completed in 2003, to discover all 
the estimated 20,000-25,000 human genes and make them accessible for further 
biological study. Another project goal was to determine the complete sequence 
of the 3 billion DNA subunits (bases in the human genome).‘37 The UK House of 
Commons Science and Technology Committee Report on Human Genetics 
outlined the Project‘s possible outcomes in the following way: 
- better understanding of human illness and the role of genetic 
influences in a great many conditions including psychiatric and 
neurological disorders; 
- quicker and cheaper diagnoses of common diseases; 
- better understanding of the biochemical or physiological 
mechanisms involved in genetic disease: focusing on the mechanism 
involved may bring; 
- improved techniques in the design of drugs to produce chemicals 
that can fit precisely with molecules implicated in disease 
(pharmacogenomics); 
- gene therapy; 
- germ-line therapy.38 
                                         
36
 This definition stems from United Nations Educational, Scientific and Cultural Organization‘s 
―Bioethics and Human Population Genetics Research (1995)‖. 
37
 See supra note 13. 
38
 UK House of Commons Science and Technology Committee, Human Genetics: The Science and 
its Consequences, Third Report (London, HMSO, 6 July 1995), pp. 31-51, paras. 65-124. 
Quoted from Laurie, G. T. 2002, Genetic Privacy: A Challenge to Medico-Legal Norms, 
Cambridge University Press, at 87.  
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Hence, the potential benefits of the HGP are numerous and significant. 
Connecting the DNA sequences of individual genes within the human genome to 
the various diseases and traits for which they encode will require thousands, 
even millions, of individual research subjects. Therefore, this research relies on 
the large-scale collection of genetic, genealogical and medical data from many 
individuals.39 Meanwhile, the research spawned a range of concerns, regarding 
human dignity,40 privacy,41 autonomy,42 patent,43 and discrimination.44 
The narrow definition of HPGR focuses on community or group/collective human 
genetic information, such as the Human Genome Diversity Project (HGDP). 45 
According to international consensus, population genetic research aims to 
understand the nature and extent of genetic variation among a population or 
individuals within a group or between individuals across different groups.46  This 
is the common understanding of human population genetic research and is the 
aspect that will be considered in this thesis. This type of HPGR focuses on a 
certain population, normally an isolated one. Studies such as the Human Genome 
Diversity Project belong to this type of HPGR. The research object of this kind of 
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  Greely, H. T. 1999, "Iceland's Plan for Genomics Research: Facts and Implications", Jurimetrics, 
vol. 40, no. 2, pp. 153-192, at 157. 
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 See Brownsword, R. 2003, "An Interest in Human Dignity as the Basis for Genomic Torts", 
Washburn Law Journal, vol. 42, pp. 413-487. Also see Caulfield, T. & Brownsword, R. 2006, 
"Human Dignity: A Guide to Policy Making in the Biotechnology Era?", Nature Reviews: 
Genetics, vol. 7, pp. 72-76. 
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 See Ginsburg, D. H. 1999, "Genetics and Privacy", Texas Review of Law and Politics, vol. 4, pp. 
17-23. Also See Laurie, G. T. 2002, Genetic Privacy: A Challenge to Medico-Legal Norms, 
Cambridge University Press. 
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 See Smith, M. J. 2001, "Population-based Genetic Studies: Informed Consent and 
Confidentiality", Santa Clara Computer and High Technology Law Journal, vol. 18, pp. 57-93. 
Also see Lawton, A. 1997, "Regulating Genetic Destiny: A Comparative Study of Legal 
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418. 
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 See Gold, E. R. & Caulfield, T. A. 2003, Human Genetic Inventions, Patenting and Human Rights, 
Health Law Institute of University of Alberta.  
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 See Spaak, T. 2006, "Genetic Discrimination", Minnesota Journal of Law, Science & Technology, 
vol. 7, pp. 639-655. Also see Hellman, D. 2003, "What Make Genetic Discrimination 
exceptional?", American Journal of Law and Medicine, vol. 29, pp. 77-116. Also see Jungreis, R. 
2007, "Fearing the Fear Itself: The Proposed Genetic Information Nondiscrimination Act of 2005 
and Public Fears about Genetic Information", Journal of Law and Policy, vol. 15, pp. 221-247. 
45
 The Human Genome Diversity Project (HGDP) was started by Stanford University's Morrison 
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‗population-based genetic research/study‘ or ‗population genomic research/study‘. 
Chapter 1 
Introduction  13 
 
HPGR is the third type of genetic information referred to above; that is, 
community or group collective human genetic information that is able to 
determine variation that could lead to knowledge about genetic disorders and 
possible cures, as well as the origin and migration patterns of peoples. In other 
word, unlike general HPGR, which emphasises the basic genetic equality of 
humans, the narrow HPGR project is directed at discovering DNA polymorphisms, 
emphasizing the genetic difference between human groups.47  
For example, the Human Genome Diversity Project, proposed in 1991, is a 
collaborative research project that is being developed on a global basis under 
the auspices of the Human Genome Organisation. The ‗Summary Document of 
the Human Genome Diversity Project‘, which is the official report of the HGDP 
International Planning Workshop, describes the project as follows: 
The overall goal of the project is to arrive at a much more precise 
definition of the origins of different world populations by integrating 
genetic knowledge, derived by applying the new techniques for 
studying genes, with knowledge of history, anthropology and language. 
More specifically the aims are: To investigate the variation occurring 
in the human genome by studying samples collected from populations 
that are representative of all of the world‘s peoples, and, ultimately, 
to create a resource for the benefit of all humanity and for the 
scientific community worldwide. The resource will exist as a 
collection of biological samples that represents the genetic variation 
in human populations worldwide and also as an open, long-term, 
genetic and statistical database on variation in the human species 
that will accumulate as the biological samples are studied by 
scientists from around the world. 48 
The HGDP, which targets genes from certain populations, especially isolated and 
indigenous ones which are unusually homogenous, made genetic and medical 
research easier and genes from such populations were considered valuable. In 
1991, one of HGDP's initiators, Cavalli-Sforza, highlighted the importance of 
genetic research on these populations: 
                                         
47
 Sleeboom-Faulkner, M. 2006, "How to Define a Population: Cultural Politics and Population 
Genetics in the People's Republic of China and the Republic of China", BioSocieties, vol. 1, pp. 
399-419, at 401-402. 
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 Summary Document of Human Genome Diversity Project, full text can be seen on the official 
website of HGDP, available on http://www.stanford.edu/group/morrinst/hgdp/summary93.html, 
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Isolated human populations contain much more informative genetic 
records than more recent, urban ones. Such isolated human 
populations are being rapidly merged with their neighbors, however, 
destroying irrevocably the information needed to reconstruct our 
evolutionary history. Population growth, famine, war, and 
improvements in transportation and communication are encroaching 
on once stable populations. It would be tragically ironic if, during the 
same decade that biological tools for understanding our species were 
created, major opportunities for applying them were squandered.49 
The ‗Summary Document of Human Genome Diversity Project‘ describes the 
values of the HGDP as follows: 
1 The main value of the HGD Project lies in its enormous potential for 
illuminating our understanding of human history and identity. 2 The 
resource created by the HGD Project will also provide valuable 
information on the role played by genetic factors in the predisposition 
or resistance to disease. 3 The HGD Project will bring together people 
from many countries and disciplines. The work of geneticists will be 
linked in an unprecedented way with that of anthropologists, 
archaeologists, biologists, linguists and historians, creating a unique 
bridge between science and the humanities. 4 By leading to a greater 
understanding of the nature of differences between individuals and 
between human populations, the HGD Project will help to combat the 
widespread popular fear and ignorance of human genetics and will 
make a significant contribution to the elimination of racism.50 
Therefore, the HGDP has become an important type of human genetic research 
which may result in great benefits.  
1.2.2 Concerns about Human Population Genetic Research 
HPGR on target groups on the one hand ‗can generate valuable knowledge about 
genetic disorders, possible cures, and the origin and migration patterns of 
distinctive peoples‘.51 On the other hand, it also may ‗pose distinctive risks and 
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  Tsosie, R. & McGregor, J. L. 2007, "Genome Justice: Genetics and Group Rights", Journal of 
Law, Medicine & Ethics, vol. 35, no. 3, pp. 352. 
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disadvantages for targeted groups and may even resurrect now-discredited 
―scientific‖ theories of race and human capacity‘52. 
It has therefore inspired a debate between proponents who argue that research 
on certain groups, especially isolated groups, should be vigorously advocated to 
gain more knowledge about the origins of human life,53 and opponents of such 
research, who argue that results of such research could be seen as ‗scientific‘ 
proof to support several types of discrimination and which may pose significant 
risks for the target groups.54 
In the context of human population genetic research, the real research target is 
not individual human genetic information, but community or group collective 
human genetic information. Nevertheless, this type of genetic information must 
be sourced from individual members of a particular group/community. Not only 
does a member of the group/community have a personal interest in the use of 
the information resulting from his or her involvement, so too does the 
group/community as a whole. This is entirely different from the traditional 
Western approach to the control of information, which generally vests in the 
person to whom the information belongs, or to whom it relates.55 The traditional 
core value of Western ethics and law has been ‗the rights of the individual to 
determine for herself the course of her life, with minimal interference by 
others.‘56 However, community or group collective human genetic information 
relates not only to the person from whom it is derived, but also to the whole 
community/group.  
As McGregor has said, ‗given the public‘s view about the power of genetics, 
genetic research has many risks associated with it‘. 57  She argued that the 
disclosure of negative information or research results of HPGR could lead to risks 
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of harm to the group as a whole both externally and internally.58 While these 
concepts of external and internal harm will be explored in greater detail later in 
this work, for the moment it can be noted that external harms may arise where 
there is the possibility of exposing a community or group to stereotyping and/or 
stigmatization, including damaging effects on employment and insurance 
opportunities. It has been argued that HPGR may also lead to potential internal 
harms to target group, which would include effects upon group members‘ 
perceptions of the group. For example, Tsosie identified ‗cultural harms‘ as the 
violation of groups‘ rights to their own culture in the context of HPGR.59  
Genetic research which focuses on population groups in the Western World has 
raised concerns about protection of group rights or community rights. In 1990s, a 
research project on the genetics of cancer in Ashkenazi Jews illustrated the 
problem well: 
Streuwing and colleagues reported work on the frequency in Ashkenazi 
Jews of one particular mutation (185delAG) in the BRCA1 gene 
associated with a high risk of developing breast and ovarian cancer. 
Samples for the project were collected from databanks established for 
Tay-Sachs disease and cystic fibrosis screening. Since identifying 
information was removed from all samples, the NIH Office of Human 
Subjects Review did not require individual informed consent. The 
investigators found that 0.9% of Ashkenazi Jews carry the mutation, a 
much higher rate than in the general population.60 
In this project, all of the DNA samples were collected without any personal 
identifying information, which is to say that the DNA samples were analyzed 
anonymously. Thus, except for any physical harm which might be caused by the 
collection procedures, there were no direct risks to individuals who participated 
in these projects, even in respect of discrimination or stigmatization. However, 
the community may be put at risk. The results of these studies could generate a 
substantial negative influence on the whole community of Ashkenazi Jews, and 
have repercussions not only for individuals whose genetic information was used 
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but also for those whose personal information was not used. As Lehrman noted 
with concern: 
Such findings, which have already led to Jewish groups being targeted 
as a potential market for commercial genetic tests, could create the 
perception that Jewish people are unusually susceptible to 
disease. . . . As a result . . . anyone with a Jewish-sounding name 
could face discrimination in insurance and employment as companies 
struggle to keep down health-care costs.61 
Due to the possibility of discrimination, US Jewish leaders asked the National 
Human Genome Research Institute to discuss developing guidelines for the 
conduct of genetic research on Ashkenazi Jews.62 Another example is that the 
Nuu-chah-nulth people of Vancouver Island, Canada, were shocked to learn that 
the genetic samples they had given to a researcher in the early 1980s to discover 
the genetic cause of rheumatoid arthritis were shared with many researchers 
and used for purposes beyond those to which the tribe had consented.63 The 
research uncovered the spread of lymphotropic viruses by intravenous drug use. 
That discovery imposed risks on the group as a whole, stigmatizing the group and 
altering the perception of the group about itself.  
Thus, although human genetic information is not entirely different from other 
types of information in respect of human beings, in the context of HPGR, 
community or group/collective human genetic information is arguably unique, 
and the interests of the community/group require special consideration in 
bioethics and legal regulation. The uniqueness of community or group collective 
human genetic information is that it can be gained from individual members, but 
in conjunction with results obtained from others may reveal information about a 
particular group/community. The idea of the uniqueness of genetic information, 
whether it can be regarded as ‗exceptional‘ and requiring special consideration 
as opposed to other kinds of information that can be acquired from medical 
history or tests, will be explored in more detail later in the thesis. 
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1.2.3 The Inadequacy of Applying Current Western Dominant 
Research Ethics to Human Population Genetic Research 
(HPGR) 
In general terms, the fundamental aims of ethics are to achieve two objectives: 
to tell us how we ought to act in a given situation, and to provide us with strong 
reasons for doing so.64 Research ethics is ‗basically about means of ensuring that 
vulnerable people are protected from exploitation and other forms of harm.‘65 
The contemporary focus on ethics in research came about because of the human 
experiments on prisoners of war and its own citizens conducted by Nazi Germany 
and Japan during World War II.66 Following World War II, the Nuremberg Code 
required that ‗the voluntary consent of the human subject is absolutely 
essential.‘67 The World Medical Association‘s Declaration of Helsinki noted that 
clinical research could be conducted only when the ‗risks involved have been 
adequately assessed and can be satisfactorily managed. Physicians must 
immediately stop a study when the risks are found to outweigh the potential 
benefits or when there is conclusive proof of positive and beneficial results.‘68 
Further, in the US, the Ethical Principles and Guidelines for the Protection of 
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Human Subjects of Research (Belmont Report)69 articulate guidelines for human 
subject research. The basic principles, such as respect for persons, beneficence, 
and justice, have been established and widely accepted in Western countries. 
However, as McGregor has said: 
These regulations and codes based their ethical principles on respect 
for persons, beneficence, and justice. The principle of respect for 
persons translates into respect for individual autonomy (determining 
one's life plan in terms of one's own values and beliefs), respect for 
privacy (access to a person's private sphere), and respect for 
confidentiality (not divulging such privileged knowledge). The 
principle of respect also protects persons with diminished autonomy 
due to age, illness, mental disability, or particular circumstances that 
affect one's autonomy. The most direct implementation of the 
principle seeks and secures informed consent to conduct research. 
The principle of beneficence focuses on whether the benefits of the 
research outweigh the risks. Questions of risks are traditionally 
directed to risks to the individual research participant and the benefit 
for humanity generally. And the principle of justice requires at least 
that the selection of subjects is equitable, and questions, for example, 
why a certain group or population is being targeted for research. 
Questions of justice should also include that the benefits of research 
flow to those who take the risks of research, that is, that there be 
equitable benefit sharing.70 
At a practical level, ‗respect for persons‘ is secured through the requirement for 
individual informed consent. The most concise definition of informed consent to 
take part in research is ‗a decision to participate in research made by a 
competent individual who has received the necessary information; has 
adequately understood the information; and after considering the information, 
has arrived at a decision without having been subjected to coercion, undue 
influence, inducement or intimidation.‘ 71  There are four basic elements of 
informed consent that have been developed since the Nuremberg trials: a) 
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Capacity to consent; b) Full disclosure of relevant information; c) Adequate 
comprehension of the information by the participant; d) A voluntary decision to 
participate and the right to withdraw from participation at any stage without 
prejudice to the participant. Participant withdrawal should be accepted and 
withdrawing participants should not be expected to give any reasons for their 
decision.72 
However, HPGR seems to potentially demand an exception to the common 
reliance on the sufficiency of individual informed consent. Genetic information 
not only discloses information about the human subjects concerned, but also 
discloses genetic information about her/his relatives, and even certain groups 
and their members. Thus, the impact of genetic research is complicated by the 
fact that genetic information may be shared among members of families, ethnic 
or racial communities, and other groups with a distinctive genetic inheritance. 
This not only creates special risks for individuals but also widens the scope of 
people who may be exposed to risk and who must be considered as involved in 
the research. The complication will be more serious in HPGR, because HPGR may 
also lead to potential risks of harm to specific groups. It seems reasonable to 
believe that an individualistic autonomy model, focused on direct risks to the 
subject of research, is ill-suited to the shared nature of group collective genetic 
information, which is the research target of HPGR. Instead it will be suggested 
that another approach to the understanding of autonomy: the relational 
autonomy model is more appropriate. This model highlights the need to 
recognise that an individual exists in a social context, and his or her choices may 
thus be affected by concerns other than personal ones. It will be explored in 
more detail later in the thesis. 
Therefore, it is necessary to go on to consider the extent to which the target 
groups/communities of HPGR and their members are exposed to risks of harm 
from participation in this type of research, and the kind of risks needs to be 
identified. There will also be an evaluation of whether the current Western 
ethical and legal frameworks on research involving human subjects, which are 
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dominated by individualism, can provide adequate protections for target 
groups/communities in HPGR.  
1.3 HPGR in Developing Countries 
HPGR, like the HGDP, is interested in sampling populations to study how human 
groups and individual genetic diversity have grown and aims to identify the 
diversity of the human genome. Ethnic minorities and isolated groups in rural 
areas of developing countries, such as the PRC, would be the ideal target groups 
in HPGR, for following reasons: (1) members of these groups are relatively 
homogeneous with respect to ethnic background, environment, and lifestyle; (2) 
the groups have existed for several thousands of years with a stable resident 
population; (3) the population is large enough to ensure the availability of a 
sufficient number of potential research participants.  
However, ethnic minorities and isolated rural groups in developing countries also 
have features which may lead to concerns about protecting their interests in 
HPGR. For example, On 20 December 2000, Washington Post staff writers John 
Pomfret and Deborah Nelson published an article ‗In Rural China, a Genetic 
Mother Lode.‘ 73 It was a story that reported that a drug company-supported 
research program involving Harvard University researchers and six Chinese 
medical centres were intending to sample the blood and genes of 200 million 
Chinese people in rural isolated areas to conduct genetic research; in addition, 
these resources would be incorporated into foreign products without bringing 
any benefit to the Chinese people who furnished the genetic resources. Harvard 
Provost Fineberg said that ‗[w]e were very mindful of having the same [ethical] 
standards applied to them as in the US every effort was made to assure that was 
the case.‘74 However, this example highlights a question increasingly asked by 
legal professionals and medical ethicists as developed countries‘ academic and 
corporate researchers turn to developing countries to find large amounts of 
human research materials to conduct HPGR: do these standards provide 
adequate protections for participants and groups in HPGR? 
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Target groups of HPGR may be vulnerable because of their members‘ frequently 
low educational level, lack of economic and social resources, difficulties in 
correct understanding of the risks of HPGR or the possibility of undue 
inducement to take part in research. These common characteristics arguably 
make them more likely to accept risks that are either not understood or 
appreciated, or that are unjust. Meanwhile, the researchers or research 
institutions involved in HPGR, who are mostly research institutions or companies 
from developed countries, have the potential to take unfair advantage of their 
superior economic and social resources by offering target groups unfair benefits 
in exchanging for their participation. Furthermore, the absence of effective and 
adequate legal regulations and ethical guidelines in most developing countries, 
as well as poor law enforcement, also exacerbates the vulnerability of target 
groups in HPGR.  
Therefore, the vulnerability of target groups in HPGR in developing countries 
should be addressed in more detail and depth. In particular, it is essential to 
evaluate whether or not the dominant (Western) underpinnings of the ethics of 
research are sufficient to eliminate or reasonably reduce the vulnerability of 
target groups and provide adequate protections for them in HPGR in developing 
countries, such as the PRC. In addition, some target groups from rural areas of 
developing countries have their own cultural sensitivities concerning decision-
making patterns which will also be relevant to this evaluation.  This too may 
mandate a reconsideration of the applicability and practice of HPGR projects 
and processes. 
The People‘s Republic of China is a good model on which to base an analysis of 
whether or not target populations in HPGR are adequately protected by 
contemporary legal and ethical regulations of human subject research. The 
Chinese population comprises one-fifth of the human species. The Chinese 
government officially recognizes 56 ethnic groups, one of which is the Han 
majority (1 billion and 100 million people), and the other 55 are ethnic 
minorities (totalling about 100 million).75 China contains rich genetic resources in 
isolated areas which have idiographic cultures. At the same time, the PRC is the 
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only developing country participating in the HGP. Accordingly, a number of 
developed countries and their research organizations desire to do genomics 
research in China or undertake collaborative research with Chinese research 
organizations in this area. In 1996, experts warned that China faces the prospect 
that the genes of hundreds of millions of its people may become the priceless 
resources of foreign pharmaceutical companies.76  
As mentioned above in the reference to the Harvard case, these researchers will 
generally be expected to have met the ethical and legal requirements for 
conducting their research in their country of origin (generally developed 
countries). However, the PRC, has a thoroughly different legal and cultural 
background from those developed countries, which leads to the need to consider 
whether or not existing developed world legal and ethical frameworks provide 
these research participants with adequate levels of protection and are sensitive 
to cultural concerns. The legal regulation of HPGR in China, such as it is, 
including ‗Interim Measures for the Administration of Human Genetic Resources 
1998‘77 and ‗Ethical guidelines for human embryonic stem cell research 2003‘,78 
is – as will be seen - copied almost word for word from Western legal and ethical 
frameworks, which means that these regulations are neither designed to provide 
protection to target groups in biomedical research, nor consider the particular 
position and cultural sensitivities of the populations concerned.  
The PRC has a unique cultural and historical tradition. China is a country with a 
history as long as the history of human beings themselves, and is also a country 
with strong cultural traditions. The largest group, the Han, make up over 92% of 
China‘s vast population, and the Han civilization is the dominant culture in China. 
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Meanwhile, the other 55 ethnic minorities maintain their own rich traditions and 
customs.  It has been said that:  
From the dawn of time, China‘s history is a story of an immense land 
with several diverse tribes. It is also one of migrations and conflict, 
and separation and fusion of cultures. The product of the 
intermingling of many tribes, the Han people were among the first to 
settle down and develop an agrarian society… Over a 2,000 year 
period, a large number of invaders breached the Great Wall and 
poured into the Chinese heartland. The Huns, the Mongols, and 
Manchurians all came -- and unlike the plunder and destruction 
characterized by the barbarian invasions of Rome, these peoples 
admired what they saw, leading them to stay and assimilate.79 
The fact that the PRC has its own range of cultural and ethical traditions makes 
it more difficult to adopt Western individualised ethical and legal frameworks in 
HPGR. For example, in China‘s traditional culture, the notion of respect for an 
individual‘s right to self-determination is not prominent. In fact, the Confucian 
concept of relational personhood challenges the assumption that the patient 
alone should be given the diagnosis and prognosis and the opportunity to make 
his or her own medical decisions. Social and moral meaning rests in 
interdependence, which overrides self-determination. Consequently, many 
Chinese people may give the family or community the right to receive and 
disclose information, to make decisions and to co-ordinate patient care, even 
when they themselves are competent.80 In contrast, privacy rights and individual 
autonomy are the starting points of the protection system of Western countries. 
In an article on Chinese genetics and ethics by Qiu Ren-zong, one of the most 
well-known bioethicists in China, it is claimed that in traditional medicine in 
general, medicine is taken as the art of humaneness (yi ben ren shu). This means 
that the doctor loves people, cares for people and does well for people. In his 
view, the essential core relationship between patient and doctor is not the same 
as in Western countries; rather, it is based in absolute trust. For example, Qiu 
says: 
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Doctors who practice medicine in China have the capacity to decide 
the life or death of a patient, so they bear a very heavy responsibility. 
Traditional China is a patriarchal society in which paternalism is very 
strong in social life. …In the encounter between physician and patient, 
medical decisions are made by the physician, and the doctor‘s opinion 
is directive. Although there has been a great change in modern China, 
and the paternalism in medicine has been considerably weakened, it 
still prevails.81 
However, most international conventions and ethical guidelines for human 
subject research are based on the principles of individual autonomy, 
beneficence, and justice. Considering the special situation in China, patients‘ 
undoubted trust in doctors and the emphasis on family and group/community 
over individual interests can cause problems in terms of medical research which 
may extend to HPGR.  
In addition, in the PRC, 25% of the population is illiterate or semi-literate. The 
majority of these people are distributed in the isolated rural areas which are 
attractive targets of HPGR.82 As was reported in the Harvard story, those target 
people, whose lives were extremely poor and who had scarcely any medical care, 
were told that if they participated there would be free medical care - so of 
course most people volunteered to participate. 83  Even had there been an 
introduction to the aims and anticipated achievements of this research, which 
‗adhered to the principle of informed consent‘, this would be of arguable value 
in such cases since ‗many couldn‘t read, and few could have guessed at the 
tangle of scientific and business dreams that lay behind the project.‘84  
For these reasons, this thesis will use the PRC as an example to analyze how to 
build new legal and ethical frameworks on biomedical research involving human 
subjects, with special reference to the protection of vulnerable target groups 
and consideration of the specific Chinese bioethical background and cultural 
sensitivities. 
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The proposed alternative ethical and legal frameworks for biomedical research 
will be designed to allow the ethical conduct of human population genetic 
research which does not harm the interests of vulnerable target groups and 
individual participants, based on the specific bioethical background and cultural 
sensitivity of a developing country.  
In summary, human genetic research has come a long way, but some aspects of 
it remain controversial. During the past 20 years, alongside the exploration of 
human genetic information, debates have focused on how to regulate genetic 
research and use genetic technology. 85  Human population genetic research 
creates additional dilemmas that are also significant and urgent, especially in 
developing countries.  
1.4 Hypothesis of the Thesis 
Target groups of HPGR are almost always ethnic minorities or isolated groups in 
rural areas of developing countries. These groups have not only objective 
characteristics which distinguish them from other groups, such as history, 
geography, ethnicity, economics, language and religion, but also may have 
inherent values which lead to the group and its members having a self-
perception of the group‘s distinctiveness.  Further, individual members of the 
group may strongly identify themselves with the group, and particularly with its 
common spiritual tradition, historical narratives, or traditional beliefs. They may 
also have their own well-developed cultural traditions, such as group collective 
decision-making. Meanwhile, the researchers in HPGR are almost always from 
Western developed countries, who are outsiders of target groups.  The personal 
and cultural forces that link members of groups to each other and to their 
traditions, are of great importance to both the individual and to the group itself.  
These traditions are worthy of respect and protection, yet risk being overlooked, 
ignored or disrespected by researchers from a different tradition. 
This thesis intends to examine current ethical and legal frameworks for research 
involving human subjects in HPGR, particularly HPGR in developing countries, 
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specifically in China. Therefore, it will argue that the interests of group in this 
kind of research should be recognised as being worthy of protection and that this 
is not available using the Western ethical and legal regulations already in 
existence. It aims to propose a model that will offer additional protections to 
groups in HPGR. 
This thesis is concerned with two aspects of ethical and legal regulations on 
HPGR. The first relates to an explanation as to why current ethical and legal 
regulations on human subject protection cannot provide adequate protection to 
target groups and their members in HPGR. The second element is the 
vulnerability of target groups in HPGR in developing countries and the additional 
protections they need. This will require consideration of how and why HPGR may 
pose risks of harm to both target groups and their members. Having examined 
these issues, I will then consider how ethical and legal frameworks can be 
proposed in developing countries, such as the PRC, in terms of HPGR. 
This thesis consists of five chapters, including an Introduction and Conclusion. In 
Chapter 2 of this thesis, the risks of harm of human population genetic research 
(HPGR) will be identified and an analysis of the deficiencies of the current 
ethical and legal approaches to human subject protection for HPGR will be 
undertaken. This chapter will address the role and general rules of consent in 
the medical context, as well as the specific rules of consent to medical research 
involving human subjects, including ethical and professional guidance and legal 
principles. It will then address the risk-benefit distinctions between therapeutic 
research and non-therapeutic research, and introduce the legal regulations and 
cases on the protection of the well-being of human subjects from an 
international perspective. Subsequently, it will argue that genetic research 
raises its own concerns in respect of research ethics and explain the uniqueness 
of the types of harm caused by genetic research.  It will clarify that in HPGR it is 
not only an individual but also a population/group that may be at risk of harm, 
such as psychological harms including shame or humiliation; loss of opportunities 
and other economic setbacks or loss of insurance or insurability (possibly 
resulting from stereotyping or stigmatising a group as a whole). Further, this 
chapter will point out that group/community members may suffer harm without 
the opportunity of knowing the risks of harm in advance and being able to make 
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decisions as to whether or not to accept them. In addition, contemporary 
Western legal systems and regulations depend on philosophical statements that 
identify individual rights as the appropriate foundation for the protection of 
human beings. For instance, in the context of medical law, one prevalent 
principle is ‗respect for persons‘, which aims to protect an individual‘s 
autonomy through practical measures like the requirement for legally valid 
consent to treatment. 86  Furthermore, traditional investigators, Institutional 
Review Boards (IRBs) or Research Ethics Committees (RECs) ordinarily pay 
attention to the risks of harm to the individual participant. The ethical basis of 
this framework is concern for the individual rather than for groups or particular 
populations.87 Thus, some scholars suggest that since the current Western legal 
system is ‗rooted in natural rights theories, social contract theories, Kantian 
notions of the individual, and other philosophical antecedents, it is generally 
assumed by liberal democratic governments that legally cognizable human rights 
are individual rights, which stand against the potential tyranny of government‘.88 
Therefore, it will be argued that at least some of the traditional Western 
approaches to research are unsuited to this specific kind of research and are 
particularly inadequate in developing countries, such as China, although some 
essential rules need to be followed, such as the provision of adequate 
information when seeking consent. 
Chapter 3 will make the case for the protection of groups as potentially 
vulnerable populations in HPGR. Since HPGR aims to identify specific aspects of 
the diversity of the human genome, target groups are mostly ethnic minorities or 
isolated groups in rural areas of developing countries. This chapter will suggest 
that these groups are vulnerable to three types of vulnerability: consent-based, 
risk-based, and justice-based. According to these concerns, target groups in 
HPGR may be vulnerable by virtue of a low education level, lack of economic 
and social resources, failure to recognise cultural sensitivities and the absence 
of effective and adequate legal regulations and ethical guidelines in most 
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developing countries. Although in respect of international law, there has been 
some discussion of group rights and some attempts to recognise and protect 
them, such as The Convention on the Prevention and Punishment of the Crime of 
Genocide,89 these declarations are usually aimed at civil and political rights. 
Group/community protection in the area of biomedical research has not been 
given much attention in general, beyond the protection of such groups as 
children and mentally incapacitated adults.90 However, it will be argued that the 
target group and its members need to be protected by specific legal and ethical 
regulations. Thereafter, it will analyze current regulations on vulnerable group 
protection and attempt to provide revised guidelines to protect groups in 
population genetic research. 
Chapter 4 will focus on issues specifically in the PRC. It begins with a brief 
introduction to the Chinese legal system. It will then explore the 
implementation of the current legal framework in respect of human subject 
research protections in HPGR. This is critically reviewed since it is necessary to 
explain the problems of existing Chinese regulation in this area. It will then 
explain the current practices of HPGR in the PRC, while also exploring the 
bioethical background of the PRC and identifying its special characteristics. 
Finally, this chapter will address the specific situation of ethnic minorities and 
isolated groups in rural areas in the PRC, including their cultural sensitivities and 
contemporary legal protections. It will be argued that in order to protect target 
group in HPGR in the PRC, neither can Western standards be merely transplanted 
into China directly, nor are current Chinese legal regulations adequate. Rather, 
a new construct which considers both group vulnerability and specific cultural 
sensitivities is needed. 
In Chapter 5, it will be concluded that the only way of adequately protecting 
target groups in HPGR in developing countries is to construct a tailored ethical 
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and legal framework. The proposals that will be put forward for regulation of 
HPGR in the PRC will highlight the issues of group protection, with reference to 
international ethical guidelines and the legal regulations of other countries, 
taking into account the specific cultural sensitivities of the PRC. The proposed 
solution will be helpful in improving the ethical conduct of biomedical research 
involving human subjects, as well as vulnerable group protection in the PRC. This 
alternative model could also be a valuable guide as to how to provide adequate 
protections for target groups in HPGR in other developing countries, which have 
similar issues to those that will be highlighted in the PRC. Recommendations will 
be made as how such a construct might be developed. I will suggest that group 
protection should be highlighted in ethical and legal frameworks on biomedical 
research, specifically in terms of HPGR. The main bases for this derive from (1) 
the need to take group interests and cultural sensitivities into account, by 
adopting a model of relational autonomy, enhancing researchers‘ responsibilities 
and requiring ethical review of group interests; (2) the need to respect the role 
of developing countries and their own legal and ethical regulations which fit into 
their specific social, economic and cultural context.  
Chapter 2 Harms of Human Population Genetic 
Research 
2.1 Consent and Human Subject Protection 
While most discussions about the ethics of biomedical research involving human 
subjects agree that there is a need for it to take place, they also accept the 
significance of protection for human subjects to ensure their well-being and to 
avoid abuse and exploitation. 1  The requirements of consent, based on the 
principle of respect for autonomy, have become central measures for the 
protection of human subjects in Western bioethics and law. These requirements 
have been developed in the medical treatment context and subsequently applied 
to medical research, although their application even here is not always 
straightforward. Their applicability to genetic research, and more specifically 
HPGR, raises additional problems which will be explored in this and subsequent 
chapters. However, before turning to this particular situation it is necessary to 
consider how the role of autonomy and the general rules of consent in the 
Western medical context have been approached. This chapter will also introduce 
the concept of relational autonomy as a challenge to a highly individualised 
concept of autonomy. The significance of this challenge is in its invitation to 
consider the social context of even individual decision-making.  This will become 
relevant when discussing the potential for collective harm to target groups in 
HPGR, highlighting the need for an enriched understanding of the requirements 
for individual decision-making when people are asked to participate in such 
research. 
2.1.1 Individual Autonomy and Relational Autonomy  
I wish my life and decisions to depend on myself, not on external 
forces of whatever kind. I wish to be the instrument of my own, not of 
other men‘s acts of will. I wish to be a subject, not an object; to be 
moved by reasons, by conscious purposes, which are my own, not by 
causes which affect me, as it were, from outside. I wish to be 
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somebody, not anybody; a doer – deciding not being decided for, self-
directed and not acted upon by external nature or by other men … I 
wish, above all, to be conscious of myself as a thinking, willing, active 
being, bearing responsibility for his choices and able to explain them 
by reference to his own ideas and purposes.2 
Such statements are at the core of Western moral and ethical history, and 
emphasize and justify the concepts of free choice, self-determination and 
individual autonomy. For example, Mill argued that the individuality of human 
beings should be respected by allowing them to make free choices, unless their 
actions would cause significant harm to others.3 Kant highlighted the significance 
of free choice and personal autonomy by stating that a person should be an end 
in himself and should never be used solely as a means to an end.4 Dworkin also 
emphasized the importance of individual autonomy: ‗What makes an individual 
the particular person he is his life-plan, his projects. In pursuing his autonomy, 
one shapes one‘s life, one constructs its meaning. The autonomous person gives 
meaning to his life.‘5 Of particular interest to this thesis is that in the context of 
research on human subjects, he further argued for the importance of individual 
autonomy: ‗one‘s body is irreplaceable and inescapable … In addition because 
my body is me, failure to respect my wishes concerning my body is a particularly 
insulting denial of autonomy.‘6  
Consequently, in both Western medical and research ethics, there exists a strong 
moral conviction, grounded on notions of human dignity and respect for 
individual autonomy, that every individual has a prima facie right to self-
determination with respect to his or her body. Thus, in the context of medical 
ethics, autonomy and consent are central concepts.7 
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The term ‗autonomy‘, stems from the Greek words autos (self) and nomos (rule), 
literally meaning is self-rule or self-governance.8 The original use of the concept 
of autonomy was to describe the self-rule or self-governance of independent 
city-states.9 Since then its use has been expanded to cover the individual. There 
are, however, various definitions of personal autonomy, as well as different 
senses in which autonomy may be used. For example, autonomy can be seen as 
‗the capacity to think, decide, and act on the basis of such thought and decision 
freely and independently and without… let or hindrance,‘10 and be employed to 
refer to an individual‘s capacity to ‗think, decide and act.‘11 Autonomy may 
further refer to a way of living one‘s life, with autonomy being seen as a virtue 
rather than a simple ability. 12  Alternatively, according to two of the main 
proponents of the dominant conception of autonomy in a medical context, 
Beauchamp and Childress, autonomy is the ‗personal rule of the self that is free 
from both controlling interferences by others and from personal limitations that 
prevent meaningful choice.‘ 13  On this view, the subject of autonomy is an 
individual person who ‗freely acts in accordance with a self-chosen plan,‘14 and 
to respect the autonomy of individuals is to ‗acknowledge their right to hold 
views, to make choices, and to take actions based on their personal values and 
beliefs.‘15 This principle has been seen as the moral and ethical basis of the need 
for consent to medical treatment and is also widely accepted as the dominant 
rule to prevent harms to human subjects of research.16  
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However, from the late 1980s, some communitarian philosophers and feminists 
began to criticize the dominance of an over-individualised concept of autonomy, 
and especially Beauchamp‘s and Childress‘s approach to the principle of respect 
for personal autonomy in bioethics.  
This criticism argues that autonomy described in this way presupposes an 
individual with no social context. It also overstates the presumption about the 
way in which the individual makes his or her own decisions, as being 
uninfluenced by others. For example, communitarian philosophers argued that 
‗self-determination presupposes the existence of a community from which an 
individual derives many of his or her values.‘17 They stress that the principle of 
respect for persons must reflect the fact that the individual is situated within a 
particular community. Miller summarizes this argument as follows: 
First, the socialization process determines, or shapes, the values and 
preferences of individuals; hence, the idea of autonomously chosen 
values is factually incorrect. Second, an individual‘s actions, desires, 
and objectives are comprehensible only within the context of social 
conventions and institutions.… Third, the view that an autonomous 
individual chooses his or her own values, preferences, and desires 
presupposes a self that does the choosing. This self will have to have a 
core of values with which to choose, in which case either there are 
values not autonomously chosen, or it is inexplicable how individuals 
come to have a set of values.18 
In addition, feminist theorists have challenged the concept of individual 
autonomy because of its lack of attention to human relationships; to the 
‗relational nature of human life.‘ 19 There are two major concerns which are 
raised by feminists: (1) the conception of persons which is dominant in the 
theory of autonomy, is typically believed to be false; they charge that the 
theory overemphasizes people‘s independence and deference to rationality in 
decision making. They argue that people sometimes act contrary to their best 
interests, which undermines the liberal understanding of an autonomous 
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person.20 (2) The kind of autonomy espoused by the dominant theory has also 
been questioned, especially since it relies on an ideal of personhood that 
feminists generally believe to be ‗both unrealistic and pernicious.‘ 21  They 
believe that people can be harmed by demands to meet the ideal of 
independence and the implicit definition of persons in medical practice. For 
example, Wendell argues that this view of personhood could ‗turn against people 
with disabilities as unrealistic demands that they achieve goals deemed 
appropriate by others or as excuses for refusing to provide necessary services.‘22 
Beauchamp and Childress have responded to this criticism in their most recent 
edition of Principle of Biomedical Ethics as follows: 
Some feminists have sought to affirm autonomy but to interpret it 
through relationship. These conceptions of ‗relational autonomy‘ 
derive from the conviction that persons‘ identities are shaped though 
social relationships and complex intersecting social determinants, 
such as race, class, gender, ethnicity, and authority structures. These 
accounts see persons as interdependent, but they also caution that 
‗oppressive socialization and oppressive social relationships‘ can 
impair autonomy… Such a relational conception of autonomy is 
illuminating and defensible as long as it does not neglect or obscure 
the main features of autonomy that we analyze in this chapter.23 
Hence, Beauchamp and Childress believe that feminist writers have 
misunderstood their theory, but arguably they have failed to appreciate the 
nature of this criticism. Feminists‘ real criticism focuses on the foundation of 
their theoretical position, which is the presupposed definition of a person. Ells 
explained this as follows: 
B&C's [Beauchamp and Childress‘s] feminist critics believe that the 
liberal view of personhood is unacceptable as an ‗ideal‘ on at least 
two grounds. First, the factual ground: persons simply are not, and 
cannot be, the sort of beings that the ideal in the dominant 
conception of autonomy requires… Second, the consequentialist 
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ground: the imposition of such an ideal by the dominant conception of 
autonomy can be harmful.24 
Thus, the feminists cited believe that persons are always and necessarily socially 
situated, which means that they are always and necessarily in relationships with 
others. Their alternative conception of autonomy, which emphasizes the 
limitations of Beauchamp and Childress‘s conception, is ‗grounded on this 
relational conception of persons as involving the competent exercising of skills, 
derived and constrained by social circumstances, that facilitate self-direction.‘25  
Although the feminists‘ accounts of relational autonomy are varying, 26  these 
alternative conceptions of autonomy have several advantages. Firstly, they 
provide a richer and more socially contextualised conception of persons. In some 
situations of medical treatment it is not likely that people can make 
independent and autonomous decisions. For example, a patient may suffer from 
a serious disease which influences her/his capability to make decisions 
independently. Even if the disease is not so serious as to influence her/his 
capacity to exercise independent decision making, she/he might also be scared 
by the disease, and be vulnerable, weak and not in control of the situation. In 
these situations, individualistic autonomy often leaves the patient in a helpless 
situation when her/his social relationships are excluded, and as a result the 
patient often cannot actually make independent and rational decisions and 
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would be more likely to ‗fall prey to the implicit manipulation of medical 
professionals.‘ 27  Dodds even argued that individualistic autonomy in medical 
decisions is inapplicable, since ‗many of the important, but by no means unusual, 
health-care decisions that individuals, friends, and families make are far 
removed from the cool, reflective, clear-headed decision making that is the 
paradigm of this view of autonomy.‘28  
Secondly, they extend the responsibility for choices to society, since society 
contributes to the development of the necessary skills for choice. Autonomy 
should be understood on the basis of an institutional and cultural background. So 
an account of autonomy cannot be totally individualistic but should recognize 
that the individual is situated in a large number of social practices, 
commitments and relations to other people. In practice, there may be certain 
cultural norms that make it likely that individuals would wish to seek or rely on 
family or even community views in their decision-making process. For example, 
in traditional Chinese society, ‗the family is based on an extended or clan 
structure and plays a central role in an individual‘s life… Consequently, many 
Chinese patients may give the family or community the right to receive and 
disclose information, to make decisions, and to co-ordinate patient care, even 
when they themselves are competent.‘ 29  Under a model of individualistic 
autonomy, reliance on family or community views may be considered to place a 
person at the mercy of undue influence, which would hamper the exercise of 
individual autonomy. Under a model of relational autonomy, this seeking or 
relying on outside opinion is not viewed as undue influence, but as reasonable 
involvement of relevant parties and also permits consideration of the interests 
of other people who might be influenced by the decision.  
Thirdly, feminists make it clear that a new understanding of respect for 
autonomy requires ‗anticipation by others of what is needed to make the choice 
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in question and facilitating that choice accordingly.‘30 Individualistic autonomy is 
the result of an abstract universalism that does not take into account the daily 
reality of human life. However, in daily reality, the individual is always situated 
in a multiplicity of contexts and life situations where dependency on others is 
very important. The narrative structure of personal identity and of the 
experiences of the individual, which are based on relational autonomy, show 
that decision-making should always be regarded as the result of the interactions 
of the individual with the social context.  
Therefore, the critiques made by communitarian philosophers and feminists of 
individual autonomy are positive challenges to the dominant interpretation of 
the principle of respect for individual autonomy. No matter what kind of 
relationship they suggest as a model, they recognize that the individual is not an 
entirely independent entity, but a person who is grounded in important and 
close social relationships. In other words, when individuals make decisions, they 
are not in a vacuum, but are always influenced by interactions between 
themselves and others, and make decisions not only based on their own interests 
but also how this decision will affect other people relevant to them. An 
individual may wish to take into account information on how her/his decision 
may affect others who are important to her/him. Just as individualistic 
autonomy cannot account for the interests of other relevant parties, it also 
cannot adequately take account of context. Indeed, in certain contexts, such as 
HPGR, simply to ensure that the individual research participant has been able to 
exercise autonomy based on their own interests would fail to take into account 
the interests of other group members. The shared nature of group collective 
genetic information means that HPGR on some members of the group potentially 
affects other members of the group who did not consent to participating in the 
research, even the whole target group/community. In addition, in some cultures, 
when the decision would be relevant to the interests of both the group and the 
individual, individuals may wish to consider and respect the interests of the 
group as having priority, rather than making the decision only based on their 
personal interests. Therefore, I argue that in the context of HPGR, the relational 
autonomy model would be more appropriate. Before making a decision to 
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participate, an individual would need to be enabled to take into account 
information on the potential influence of her/his decision on others relevant to 
him who might be affected by the decision. The exact concerns raised by 
adopting an individualised informed consent model, rather than the proposed 
relational autonomy model, will be discussed in more detail in following sections.  
2.1.2 The Role of Autonomy and Consent in the Western Medical 
Context 
While there are some challenges to the meaning of the principle of autonomy 
from the philosophical or ethical perspective, the core concept of respect for 
individual autonomy is still dominant in the Western medical context. Respect 
for individual autonomy indicates that an individual who has the capacity to 
make the decision for him or herself should be permitted to do so without 
inappropriate external pressure, and that this decision should be respected. 
Meanwhile, it also implies that no-one has the authority to conduct any 
intervention upon such people‘s bodies without their consent. Under this 
principle, when considered in a medical context, consent can be defined as the 
‗autonomous authorization of a medical intervention or of participation in 
research.‘31 Ideally, patients or research participants have the right to make 
choices about their medical care or research participation and to be provided 
with all available information relevant to such decisions. A person must do more 
than express agreement or comply with a proposal. He or she must authorize it 
through an act of informed and voluntary consent. Consent occurs if and only if a 
patient or research subject, with substantial understanding, and in the absence 
of substantial control by others, intentionally authorizes a physician or 
researcher to do something.32 
The consent discussed above is being described at the ethical level. There is 
another way of looking at consent – one that refers to the rules of consent that 
determine legally or institutionally valid consent. A legally valid consent may not 
be exactly the same as autonomous authorization within an ethical framework; 
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rather, it is a valid authorization within the framework of legal regulations. 
Sometimes, a morally or ethically valid consent is not a legally valid one. For 
example, different countries have various legal ages of consent to surgery. If the 
legal age of consent is twenty in a certain country, although an average 
individual, aged nineteen is capable of understanding relevant information and 
making an autonomous choice to agree to it, this choice cannot be seen as a 
legally valid consent. Nonetheless, it could be argued to be a substantially 
autonomous authorization. Thus, a legally valid consent is a sufficiently 
autonomous authorization under the operative legal regulations. Current legal 
rules and ethical guidelines concerning medical treatment and biomedical 
research are all based on this meaning of consent; that is, a legally valid 
autonomous authorization from a patient or a participant to certain medical 
interventions or research. Consent, when discussed further in this thesis, refers 
to legally valid consent. 
The principles of autonomy and consent are inherent in the civil and political 
rights and freedoms protected by international human rights law, such as the 
European Convention for the Protection of Human Rights and Fundamental 
Freedoms (ECHR)33 and the International Covenant on Civil and Political Rights 
(ICCPR),34 domestic law, such as the Human Rights Act 199835 and pre-existing 
common law in the UK.  
At the level of international human rights law, these principles are expressed in 
both implicit and explicit ways. The ECHR protects a person‘s freedom to 
determine how to live her/his own life through a number of articles including 
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freedom of expression and religion, the right to life and liberty of the person 
and respect for private life, which all provide for respect for individual 
autonomy.  In addition, although Article 3 of the ECHR which prohibits ‗torture 
or inhuman or degrading treatment or punishment‘36 does not directly refer to 
medical treatment, the European Commission of Human Rights pointed out in X v 
Denmark that ‗medical treatment of an experimental character and without the 
consent of the person involved may under certain circumstances be regarded as 
prohibited by Article 3.‘37 What is more, Article 7 of the ICCPR, which is the 
equivalent article of Article 3 of the ECHR, noted specifically that ‗In particular, 
no-one shall be subjected without his free consent to medical or scientific 
experimentation.‘38 
At the level of UK domestic law, common law also explicitly includes the need 
for consent in the medical context. For example, in the case of Re T, all three 
judges in the Court of Appeal supported patient autonomy. They noted that: 
[Lord Donaldson MR]: An adult patient who, like Miss T., suffers from 
no mental incapacity has an absolute right to choose whether to 
consent to medical treatment, to refuse it or to choose one rather 
than another of the treatments being offered.… This right of choice is 
not limited to decisions which others might regard as sensible. It 
exists notwithstanding that the reasons for making the choice are 
rational, irrational, unknown or even non-existent.39 
[Butler-Sloss LJ]: A man or woman of full age and sound understanding 
may choose to reject medical advice and medical or surgical 
treatment either partially or in its entirety. A decision to refuse 
medical treatment by a patient capable of making the decision does 
not have to be sensible, rational or well-considered…40 
[Staughton LJ]: An adult whose mental capacity is unimpaired has the 
right to decide for herself whether she will or will not receive medical 
or surgical treatment, even in circumstances where she is likely or 
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even certain to die in the absence of treatment. Thus far the law is 
clear.41 
Furthermore, in the case of Airedale NHS Trust v Bland, the House of Lords 
affirmed the principles of autonomy and consent as following: 
… it is established that the principle of self-determination requires 
that respect must be given to the wishes of the patient, so that if an 
adult patient of sound mind refuses, however unreasonably, to 
consent to treatment or care by which his life would or might be 
prolonged, the doctors responsible for his care must give effect to his 
wishes, even though they do not consider it to be in his best interests 
to do so…42 
In the case of St George’s Healthcare NHS Trust v SR. v Collins Ex p. S, the Court 
of Appeal considered and re-stated the principle as follows: 
…how can a forced invasion of a competent adult‘s body against her 
will even for the most laudable of motives (the preservation of life) 
be ordered without irremediably damaging the principle of self-
determination? When human life is at stake the pressure to provide an 
affirmative answer authorising unwanted medical intervention is very 
powerful. Nevertheless the autonomy of each individual requires 
continuing protection even, perhaps particularly, when the motive for 
interfering with it is readily understandable, and indeed to many 
would appear commendable…43 
These statements clearly addressed the significance of individual autonomy in 
the medical context and illustrated recognition of the need for consent by 
English courts. Since the rules of consent in relation to medical research are 
similar to those regulating medical treatment, in the next section, the general 
rules of legally valid consent to treatment will be addressed in more detail. 
2.1.3 General Rules of Medical Consent 
Aside from the ethical need for consent, there is also a need to consider the 
legal purpose of consent. Generally speaking, most forms of medical treatments 
involve physical interventions on the patient, even if only an initial examination 
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and tests. A legally valid consent relieves healthcare professionals of liability for 
battery, trespass or assault under the laws of both crime and tort.44 However, in 
the criminal setting, victims generally cannot give a legally valid consent to 
bodily harm. This was made clear in the case of R v Brown, in which the court 
held that the consent of men to sado-masochistic sexual activities was not 
capable of obviating the criminal liability of the actors. 45  Therefore, if a 
patient‘s consent is capable of protecting healthcare professionals from 
prosecutions for medical interventions involving actual bodily harm, medical 
interventions must be seen as an exception to the general criminal law. This has 
been accepted by UK courts. For example, in R v Brown, Lord Templeman noted 
that ‗[S]urgery involves intentional violence resulting in actual or sometimes 
serious bodily harm but surgery is a lawful activity.‘46 In Airedale NHS Trust v 
Bland Lord Mustill said that:  
…bodily invasions in the course of proper medical treatment stand 
completely outside the criminal law. The reason why the consent of 
the patient is so important is not that it furnishes a defence in itself, 
but because it is usually essential to the propriety of medical 
treatment.47 
These statements point out that appropriate surgery has its own justification as 
an exception to the general criminal law. This means that normal medical 
procedures performed to an appropriate standard with the patient‘s consent will 
not be criminal offences. 
In the non-criminal setting, medical intervention without legally valid consent 
can be seen as battery (assault in Scotland) or negligence. A battery occurs when 
there is any touching without a legally valid consent. Early case law in the US, 
such as Mohr v. Williams,48 accepted that no matter whether or not the touching 
is hostile, a battery has been constituted by touching without legally valid 
consent from the patient. In this case, an ear specialist, Williams, performed 
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surgery on Mohr‘s right ear with her consent. After Williams began performing 
the operation he decided that Mohr‘s left ear rather than her right ear required 
surgery. Although the condition was not life threatening. Williams operated 
successfully on the left ear without having received permission from Mohr. Mohr 
sued in battery and was successful. The court held that the physician should 
have obtained the consent of the patient before operating on the other ear. 
However, in the case of Wilson v Pringle49 in the UK, the Court of Appeal held 
that in order to constitute a battery, the touching must be ‗hostile‘. The main 
consideration is that there is generally acceptable physical touching in ordinary 
life, such as physical touching in crowded stores. In the medical context, since 
healthcare professionals‘ intention in providing medical treatment is almost 
always to benefit their patients, it could be argued that healthcare 
professionals‘ actions cannot be seen as battery under the ‗hostile‘ touching 
condition, although this point has not been considered by UK courts. In some 
cases where health care professionals have been successfully sued for battery, 
they had conducted unnecessary treatment. For example, in the UK case, 
Appleton v Garrett,50 the judge held that the dentist, Garrett, in order to gain 
personal profit, deliberately conducted unnecessary treatment on Appleton, 
while deliberately misleading Appleton that the treatment was necessary, since 
he knew that otherwise Appleton would not have consented to it. The consent 
Appleton had provided was not, therefore, based on the truth about the need 
for treatment and was accordingly not a legally valid consent. The court found 
Garrett liable in battery. 
However, there are some medical treatments which do not require physical 
touching, such as when a doctor prescribes a drug. Given that the essence of 
battery is physical touching, battery is not an appropriate legal action in these 
cases if they take place without legally valid consent. In addition, there are 
some cases where the patient has given her/his consent to a certain medical 
intervention, but the process of obtaining consent is flawed to some extent, 
such as where the risks of this medical intervention have not been disclosed 
completely or adequately. In these cases, negligence would be the only available 
legal avenue for redress. The differences between the actions of battery and 
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negligence were stated clearly in the UK case of Chatterton v Gerson51 which 
will be considered further below. Generally, if a person is competent and 
consent is given voluntarily, then once a person has given consent in the 
knowledge of the broad nature of the intervention, they have given a legally 
valid consent. Thus, if there has been inadequate information disclosure about 
risks, the consent is still legally valid, so there can be no action for battery, but 
the person performing the intervention may be able to be sued for negligence. 
The essential elements of a legally valid consent that will avoid liability for both 
battery and negligence on the part of the person performing medical procedures 
can be summarized as follows: competence, adequate information disclosure 
and voluntariness. 
(1) Competence: this term means the ability to perform a task. In the context 
of medical decisions, competence is the capacity that a patient must 
understand both the information presented and its relevance, and the 
reasonably foreseeable consequences of her/his decision, as well as to 
make a choice on this decision. Faden and Beauchamp argued that the 
function of a competence judgement is to ‗distinguish persons from whom 
consent should be solicited from those from whom consent need not or 
should not be solicited.‘52 
There are two requirements for competence: 1) the capacity to 
understand relevant information and the potential risks of harm; 2) the 
capacity to make the decision as to whether or not to authorize a certain 
medical intervention. This capacity includes physical, psychological and 
legal requirements. Thus, consent must be given by a person who is 
deemed to be legally capable of consenting. The Mental Capacity Act 
2005,53 which applies in England and Wales, noted that a person cannot be 
seen as competent to make decisions for herself/himself if s/he is unable: 
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(a) to understand the information relevant to the decision, 
(b) to retain that information, 
(c) to use or weigh that information as part of the process of 
making the decision, or 
(d) to communicate his decision (whether by talking, using 
sign language or any other means).54 
Although there is a presumption that an adult is competent,55 in practice, 
most judgements on competence can only be made in specific situations. 
A person can be capable of performing some tasks at one time, such as 
making decisions about proposed medical treatment, while not capable of 
accomplishing the same tasks at another time.56 For example, in a UK case, 
Re T, Lord Donaldson MR highlighted the complexity of making a 
judgement on capacity as follows: 
Doctors faced with a refusal of consent have to give very 
careful and detailed consideration to the patient's capacity to 
decide at the time when the decision was made. It may not be 
the simple case of the patient having no capacity because, for 
example, at that time he had hallucinations. It may be the 
more difficult case of a temporarily reduced capacity at the 
time when his decision was made. What matters is that the 
doctors should consider whether at that time he had a 
capacity which was commensurate with the gravity of the 
decision which he purported to make. The more serious the 
decision, the greater the capacity required.57 
Thus, competence cannot be evaluated without knowledge of the exact 
situation. Generally, in respect of medical interventions, the following 
requirements are essential to competence: capacity to understand the 
proposed interventions; capacity to weigh its risks and benefits; and 
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capacity to make an autonomous decision based on relevant knowledge 
and information.58 
(2) Adequate Information Disclosure: this refers to the duty of the clinician to 
inform the patient of the nature of the proposed procedures and provide 
information relevant to the medical intervention, before seeking consent. 
The European Convention on Human Rights and Biomedicine (ECHRB)59 
highlights that a patient should be given ‗appropriate information as to 
the purpose and nature of the intervention as well as on its consequences 
and risks.‘60 The Explanatory Report on the ECHRB61 emphasized that the 
information provided: 
…must be sufficiently clear and suitably worded for the person 
who is to undergo the intervention. The patient must be put 
in a position, through the use of terms he or she can 
understand, to weigh up the necessity or usefulness of the aim 
and methods of the intervention against its risks and the 
discomfort or pain it will cause. 62 
The disclosure of relevant information is essential to the rules of consent, 
because adequate relevant information is the basis for the patient to 
make autonomous choices.63 Ethically, if patients have a right to make 
decisions about proposed procedures, they must also have the right to be 
told what they need to know in order to make an informed assessment 
before deciding what to do. Thus, if they do not know all of the relevant 
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information, their decision to give or refuse consent is problematic. 
Therefore, information disclosure is vital in the medical consent. 
Having noted the significance of information disclosure to consent, it is 
necessary to address the legal standard for information disclosure. The 
general principle of information disclosure in UK law was set out in 
Chatterton v Gerson by Bristow J who said that  
In my judgment once the patient is informed in broad terms of 
the nature of the procedure which is intended, and gives her 
consent, that consent is real, and the cause of the action on 
which to base a claim for failure to go into risks and 
implications is negligence, not trespass. Of course if 
information is withheld in bad faith, the consent will be 
vitiated by fraud. Of course if by some accident, as in a case 
in the 1940‘s in the Salford Hundred Court where a boy was 
admitted to hospital for tonsilectomy and due to 
administrative error was circumcised instead, trespass would 
be the appropriate cause of action against the doctor, though 
he was as much the victim of the error as the boy. But in my 
judgment it would be very much against the interests of 
justice if actions which are really based on a failure by the 
doctor to perform his duty adequately to inform were pleaded 
in trespass. 64 
This principle was approved by a further two cases: Hills v Potter65 and 
Sidaway v Bethlem Royal Hospital Governors.66 It creates two different 
levels of information disclosure one to avoid liability for battery, the 
other to avoid liability for negligence.  This approach has been criticized 
for several reasons, such as that it ‗reduces the role of battery in English 
law,‘ 67  it ‗excludes other relevant information such as alternative 
treatment, benefits of the proposed treatment and advice on the 
underlying ailment‘,68 and that there is ‗no inherent difference between 
information as to the nature of a procedure and the information as to its 
risks and consequences.‘69 Nevertheless, the current law is that once the 
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broad nature of the procedure has been disclosed to the patient, 
negligence is the only possible legal claim. Thus, the specific level of 
information disclosure under the current law of negligence needs to be 
explored. There are several options that could be considered when setting 
a legal standard.  
The subjective standard of disclosure focuses on what is of specific 
interest to a particular individual. The justification for this standard was 
provided by Justice Stanley Mosk in the US case Cobb v Grant70: 
A medical doctor, being the expert, appreciates the risks 
inherent in the procedure he is prescribing, the risks of a 
decision not to undergo the treatment, and the probability of 
a successful outcome of the treatment. But once this 
information has been disclosed, that aspect of the doctor‘s 
expert function has been performed. The weighing of these 
risks against the individual subjective fears and hopes of the 
patient is not an expert skill. Such evaluation and decision is a 
non-medical judgment reserved to the patient alone.71 
The subjective standard requires the discovery of the interests of each 
particular patient and the use of this information as a part of disclosure, 
so it is potentially time-consuming. Given the limited time in medical 
practice available to make disclosure, although this approach is probably 
the standard which can provide a person with the maximum information 
s/he needs to make an autonomous choice, it would be extremely 
difficult to meet. Therefore, generally, there are two further alternative 
standards of information disclosure regarding medical interventions that 
could be required by law: a prudent patient standard (reasonable patient 
standard) and a prudent doctor (professional practice) standard. 
Under the prudent patient standard, which is applied in some States in 
the US, the law would require doctors to disclose all of the information 
which would be considered relevant by a reasonable patient. This was 
proposed in the US case of Salgo v Leland Stanford Jr. Univ. Bd. of 
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Trustees.72 In this case, a patient, Martin Salgo, awoke paralyzed after 
aortography, having never been informed that such a risk existed. He sued 
the physician for negligence in performance of the procedure and failing 
to warn of the risk of paralysis. The court noted that the physician has the 
duty to disclose ‗any facts which are necessary to form the basis of an 
intelligent consent by the patient to proposed treatment,‘ but that ‗in 
discussing the element of risk a certain amount of discretion must be 
employed consistent with the full disclosure of facts necessary to an 
informed consent.‘73 Thereafter, the standard was developed in another 
influential case, Canterbury v Spence. 74  In this case, the patient 
underwent a laminectomy for serious back pain. After this operation, he 
fell off his hospital bed and then suffered major paralysis. He sued the 
physician claiming that he had not informed him that there was about a 
1% risk of paralysis after a laminectomy. The court said as follows: 
True consent to what happens to one‘s self is the informed 
exercise of a choice, and that entails an opportunity to 
evaluate knowledgeably the options available and the risks 
attendant upon each. The average patient has little or no 
understanding of the medical arts, and ordinarily has only his 
physician to whom he can look for enlightenment with which 
to reach an intelligent decision. From these almost axiomatic 
considerations springs the need, and in turn the requirement, 
of a reasonable divulgence by physician to patient to make 
such a decision possible.75 
This statement made it clear that since the aim of information disclosure 
is to provide relevant information to patients to enable them to make 
decisions about their medical treatment, the disclosure should be able to 
be understood by an average patient who has little or no medical 
knowledge. After this case, the reasonable patient standard has gradually 
been accepted by courts in a number of countries. 76   In the UK, this 
standard was also accepted by Lord Scarman in the landmark UK case of 
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Sidaway v Bethlem Royal Hospital Governors. In this case, Lord Scarman 
noted as follows: 
The doctor‘s duty arises from his patient‘s rights. If one 
considers the scope of the doctor‘s duty by beginning with the 
right of the patient to make his own decision whether he will 
or will not undergo the treatment proposed, the right to be 
informed of significant risk and the doctor‘s corresponding 
duty are easy to understand: for the proper implementation of 
the right requires that the doctor be under a duty to inform 
his patient of the material risks inherent in the treatment.77 
Despite this, however, the other Law Lords held that the question 
whether an omission to warn a patient of inherent risks of proposed 
treatment constituted a breach of a doctor‘s duty of care was to be 
determined by applying the Bolam principle, which is also known as the 
prudent doctor, or professional practice, standard. This principle was 
established in the case of Bolam v Friern Hospital Management 
Committee.78 In this case, the judge set out the principle that a doctor is 
‗not guilty of negligence if he has acted in accordance with a practice 
accepted as proper by a responsible body of medical men skilled in that 
particular art.‘ 79  Thus, in Sidaway the majority did not share Lord 
Scarman‘s view and did not support it. However, it has been considered 
more favourably in Commonwealth jurisdictions. For example, in an 
Australian case, Rogers v Whittaker,80 Whittaker did not disclose to Rogers 
that an operation to correct the sight of her almost blind right eye had 
the potential risk to cause her left eye to lose sight, which would lead to 
total blindness. The High Court of Australia considered both the Sidaway 
case81 and Canterbury v. Spence,82 then applied the reasonable patient 
standard and explained the reasons for doing so as follows: 
The law should recognise that a doctor has a duty to warn a 
patient of a material risk inherent in the proposed treatment; 
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a risk is material if, in the circumstances of the particular 
case, a reasonable person in the patient‘s position, if warned 
of the risk, would be likely to attach significance to it or if 
the medical practitioner is or should reasonably be aware that 
the particular patient, if warned of the risk, would be likely 
to attach significance to it. This duty is subject to the 
therapeutic privilege. 83 
In the UK, however, in the Sidaway case, Lord Diplock gave the Bolam 
principle a wide application as follows: 
…no convincing reason has in my view been advanced before 
your Lordships that would justify treating the Bolam test as 
doing anything less than laying down a principle of English law 
that is comprehensive and applicable to every aspect of the 
duty of care owed by a doctor to his patient in the exercise of 
his healing functions as respects that patient.84 
In addition, Lord Bridge, Lord Keith and Lord Templeman, although 
accepting that the risks of certain medical interventions should be 
evaluated with reference to the specific situation of the patient‘s 
subjective beliefs, fears and hopes, not expert skill, still held that the 
level of disclosure should be decided based on medical evidence, unless ‗a 
patient‘s right to decide whether to consent to the treatment was so 
obvious that no prudent medical man could fail to warn of the risk save in 
emergency or some other sound clinical reason for non-disclosure.‘85 Thus, 
the English courts applied a medical professional practice principle to 
information disclosure. This requires disclosure of information that the 
medical professional, supported by other medical opinion, considers 
relevant. 
However, since Sidaway, the Bolam test has been refined. In the case of 
Bolitho v City and Hackney HA,86 the House of Lords modified the Bolam 
test, although not in the context of information disclosure. Lord Browne-
Wilkinson held: 
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…in my view, the court is not bound to hold that a defendant 
doctor escapes liability for negligent treatment or diagnosis 
just because he leads evidence from a number of medical 
experts who are genuinely of opinion that the defendant's 
treatment or diagnosis accorded with sound medical 
practice.…the court has to be satisfied that the exponents of 
the body of opinion relied upon can demonstrate that such 
opinion has a logical basis. In particular in cases involving, as 
they so often do, the weighing of risks against benefits, the 
judge before accepting a body of opinion as being responsible, 
reasonable or respectable, will need to be satisfied that, in 
forming their views, the experts have directed their minds to 
the question of comparative risks and benefits and have 
reached a defensible conclusion on the matter.87 
This statement showed that the courts still have the right and the duty to 
critically analyse the basis of the expert witnesses‘ evidence to ensure 
that the opinion itself is reasonable, not just that the experts are suitably 
qualified and credible, although Lord Browne-Wilkinson emphasised that 
‗it will very seldom be right for a judge to reach the conclusion that views 
genuinely held by a competent medical expert are unreasonable.‘88  
In addition, in Pearce v United Bristol Healthcare NHS Trust, 89  the 
standard of risk disclosure required to enable the patient to decide 
whether to accept the doctor‘s advice was considered. The consultant 
obstetrician in this case suggested to the patient, who was pregnant and 
had gone past the expected date of delivery and was extremely 
concerned for the safety of her fetus, that the safest course was to allow 
labour to begin naturally, but did not disclose that there was a small (0.1–
0.2 per cent) risk of stillbirth. The risk unfortunately materialised. The 
woman sued the doctor for failure to disclose the risk. Although her claim 
was rejected both at first instance and by the Court of Appeal, Lord Woolf 
MR‘s judgment did argue that: 
…if there is a significant risk which would affect the judgment 
of a reasonable patient, then in the normal course it is the 
responsibility of a doctor to inform the patient of that 
significant risk, if the information is needed so that the 
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patient can determine for him or herself as to what course he 
or she should adopt.90 
This statement appeared to advance the cause of the prudent patient 
standard. This more patient-centred trend has been continued in more 
recent cases. For example, in Wyatt v Curtis,91 Sedley LJ suggested that 
Lord Woolf‘s explanation on Lord Bridge‘s statement in Sidaway on 
whether or not a risk is ‗substantial‘ or ‗grave‘ should be considered from 
the prospective of the patient not the doctor. He noted that 
Lord Woolf‘s formulation refines Lord Bridge‘s test by 
recognising that what is substantial and what is grave are 
questions on which the doctor‘s and the patient‘s perception 
may differ, and in relation to which the doctor must therefore 
have regard to what may be the patient‘s perception. To the 
doctor, a chance in a hundred that the patient‘s chickenpox 
may produce an abnormality in the foetus may well be an 
insubstantial chance, and an abnormality may in any case not 
be grave. To the patient, a new risk which (as I read the 
judge‘s appraisal of the expert evidence) doubles, or at least 
enhances, the background risk of a potentially catastrophic 
abnormality may well be both substantial and grave, or at 
least sufficiently real for her to want to make an informed 
decision about it.92 
In another case, Chester v Afshar,93 Lord Steyn explicitly rejected medical 
paternalism as follows: 
A surgeon owes a legal duty to a patient to warn him or her in 
general terms of possible serious risks involved in the 
procedure. The only qualification is that there may be wholly 
exceptional cases where objectively in the best interests of 
the patient the surgeon may be excused from giving a warning. 
This is, however, irrelevant in the present case. In modern 
law medical paternalism no longer rules and a patient has a 
prima facie right to be informed by a surgeon of a small, but 
well established, risk of serious injury as a result of surgery.94 
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Although Lord Steyn‘s statement did not clearly indicate whether the 
issue of determining if a risk is significant should be decided by the view 
of the patient, his rejection of medical paternalism could be viewed as 
evidence of the trend towards acceptance of a prudent patient standard 
in the UK. In another more recent case, Birch v University College London 
Hospital NHS Foundation Trust,95 the patient, had been warned of the 1% 
risk of stroke of undertaking catheter angiography, but was not informed 
that there was an alternative procedure, a MRI scan, which has no risk of 
stroke. According to expert witnesses on behalf of the defendants, the 
doctor‘s duty was merely to disclose the risks relevant to catheter 
angiography, which had been done properly. However, Mr Justice 
Cranston agreed with Mrs Birch that the prudent doctor standard was not 
logically reasonable in this case. He firmly agreed with Lord Woolf MR‘s 
statement that the doctor‘s duty to inform of ‗significant risks‘ would not 
be discharged until the patient was made aware that fewer or no risks 
were associated with another available treatment. He then argued that 
although expert witnesses insisted the doctor has fulfilled the duty of 
disclosure, the failure to discuss these comparative risks ‗could not be 
described in law as reasonable, responsible or logical.‘ 96  Therefore, 
although the judgment of Sidaway is still not directly overruled, this 
(albeit limited) movement towards the acceptance of a prudent patient 
standard is, therefore, a continuing trend in English law, which may be 
welcomed in its potentially greater respect for patient autonomy. 
(3) Voluntariness: this refers to the patient‘s right to come to a decision 
freely, without undue influence, such as force, coercion or 
manipulation.97 In general, coercion means that ‗one party intentionally 
and successfully influences another by presenting a credible threat of 
unwanted and avoidable harm so severe that the person is unable to resist 
acting to avoid it.‘ 98  Manipulation refers to several forms of undue 
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influence that are neither coercion nor reasonable persuasion.99 At the 
ethical level, voluntariness indicates that an individual can make 
decisions regarding his or her treatment free from overwhelming external 
pressure and is exercising the right to self-determination. However, in 
medical interventions, external influence by those performing them may 
be a factor in the person‘s decision to give consent. For example, a 
patient may refuse to undergo certain medical procedures for reasons of 
fear or false belief, but s/he may agree to undergo this medical 
intervention following persuasion from the physician. In this case, it may 
well be the case that the patient‘s consent is given voluntarily, if this 
influence is not seen as improper, although the physician has externally 
influenced the patient‘s decision. Thus, the boundary of ‗undue 
influence‘ is a significant issue in the evaluation of valid consent and 
should be considered carefully. 
In UK case law, the voluntariness of patient involvement was considered 
in the case of Re T (Adult: Refusal of Medical Treatment).100 In this case, 
Miss T a woman injured in a car accident when 34 weeks pregnant, told 
medical staff that she refused to consent blood transfusion which might 
be necessary following a Caesarean section. She refused blood, after 
being alone with her mother, who was a Jehovah‘s Witness. This faith 
does not accept blood transfusions. After Miss T became unconscious, her 
father and boyfriend applied to the court for assistance. The English Court 
of Appeal held that Miss T‘s mother had apparently influenced the 
decision of the daughter, who was not a Jehovah‘s Witness. The court 
denied the effectiveness of the Miss T‘s refusal of treatment as follows 
…although an adult patient was entitled to refuse consent to 
treatment irrespective of the wisdom of his decision, for such 
a refusal to be effective his doctors had to be satisfied that at 
the time of his refusal his capacity to decide had not been 
diminished by illness or medication or by false assumptions or 
misinformation, that his will had not been overborne by 
another‘s influence and that his decision had been directed to 
the situation in which it had become relevant; that where a 
                                         
99
 See supra note 8, at 133. 
100
 See supra note 39. 
Chapter 2 
Harms in Human Population Genetic Research  57 
 
patient‘s refusal was not effective the doctors were free to 
treat him in accordance with their clinical judgment of his 
best interests…101 
Although the judge in this case failed to define undue influence in any 
detailed manner, this case illustrates the requirement of voluntariness in 
medical consent in English law. 
In summary, if the decision is made by a patient who meets the requirement of 
competence, with adequate information disclosure from her/his medical 
professionals and without any form of undue influence, this consent would be 
seen as a legally valid consent. If people have difficulties in providing voluntary, 
informed consent arising from limitations of decision-making capacity (e.g. 
children), or situational circumstances (e.g. prisoners), or because they are 
especially at risk of exploitation (e.g. some under-valued ethnic minorities), 
they should be seen as vulnerable and additional scrutiny of their decisions or 
other protections would be required. 102  Generally, the requirements and 
standards of medical consent discussed above can be applied to human subjects 
in biomedical research; however, given the existence of some differences 
between medical treatment and research, there are additional specific rules 
concerning consent to take part in research. In the next section, these rules will 
be addressed.  
2.1.4 General Rules of Consent in Medical Research 
It is self-evident that, from the standpoint of promoting the development of 
biomedical science and technology, as well as contributing to human knowledge, 
there is a need for research involving human subjects. In order to translate 
biomedical discoveries into practical medical treatment procedures or products, 
research involving human subjects is a necessary step, which offers the prospect 
of better lives for many people.103 To take this further, some have argued that it 
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is a moral obligation to undertake, support and even to participate in serious 
scientific research.104 For example, Harris proposes that: 
The argument concerning the obligation to participate in research 
should be compelling for anyone who believes there is a moral 
obligation to help others, and/or a moral obligation to be just and do 
one‘s share. Little can be said to those whose morality is so 
impoverished that they do not accept either of these two 
obligations.105 
Research involving human subjects is helpful to scientific development, to the 
benefit of society in general and future patients in particular, so as a member of 
society, Harris considers that every individual should support and participate in 
biomedical research, at least if the research is directed toward preventing 
serious harm or providing significant benefits. Although it is too extreme to 
argue that research is a bigger priority than concern for the welfare and rights of 
human subjects, his argument has identified one important distinction between 
biomedical research and medical treatment. In medical treatment, the 
healthcare professional has a number of clear obligations: to seek to cure the 
patient; to alleviate his or her symptoms and to prevent illness or injury. This 
means that medical treatment is targeted to benefit the patient himself or 
herself. However, in the research context, promoting the human subject‘s well-
being is not the primary focus, which is instead the improvement of the well-
being of society and future patients by the creation of generalizable knowledge. 
Research focuses on benefiting the public as a whole, although it may also 
provide benefits to the research participant. The researcher has an obligation to 
ensure that the research findings are valid and replicable, and this has 
implications for the design and execution of the research.  
Medical research on human subjects in the UK is currently regulated through a 
combination of the principles enunciated in international agreements and 
professional rules and guidance. There is a general assumption that the 
principles of consent to medical treatment form the foundation of consideration 
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of consent to medical research in the UK, but there is little case law on medical 
research. 
There is no legal definition of medical research in the UK,106 (although there is a 
definition of a clinical trial).107 The ‗Supplementary Guidance Good Practice in 
Research and Consent to Research‘,108 the professional guidance provided by the 
General Medical Council (GMC),109 defined medical research as follows:  
Research… refers to an attempt to derive generalisable new 
knowledge. Research aims to find out what is best practice by 
addressing clearly defined questions with systematic and rigorous 
methods. It includes studies that aim to generate hypotheses as well 
as those that aim to test them.110  
This definition indicates that a medical researcher‘s primary aim is to benefit a 
broader population by producing reliable, statistically significant information 
through their medical research, while medical treatment is designed to benefit a 
specific individual, aims to restore the patient‘s health or prevent deterioration. 
The Helsinki Declaration also does not provide an explicit definition of medical 
research, but instead describes it by reference to the purpose of the research:  
The primary purpose of medical research involving human subjects is 
to understand the causes, development and effects of diseases and 
improve preventive, diagnostic and therapeutic interventions 
(methods, procedures and treatments). Even the best current 
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interventions must be evaluated continually through research for their 
safety, effectiveness, efficiency, accessibility and quality. 111 
Similarly, in the US, the Ethical Principles and Guidelines for the Protection of 
Human Subjects of Research (the Belmont Report) 112  also pointed out that 
medical treatment, which aims to provide diagnosis, preventive treatment or 
therapy to particular individuals, encompasses ‗interventions that are designed 
solely to enhance the well-being of an individual patient or client and that have 
a reasonable expectation of success;‘,113 while medical research, which is usually 
described in a formal protocol that sets forth an objective and a set of 
procedures designed to reach that objective, is ‗designed to test a hypothesis, 
permit conclusions to be drawn, and thereby to develop or contribute to 
generalizable knowledge (expressed, for example, in theories, principles, and 
statements of relationships).‘114 
The main consideration of a biomedical research design must be to include a 
research question which should be able to be answered reliably and efficiently, 
sufficient numbers of human subjects must be enrolled in a reasonable period, 
and human subjects must comply with their allocated treatment. In theory then, 
the welfare of individual human subjects may be sacrificed to complete these 
targets when there is conflict. However, if researchers ignore the interests and 
well-being of human subjects, it may lead to unacceptable results, such as the 
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medical experiments conducted by Nazi doctors in German concentration 
camps115 during the Third Reich, and the egregious experimentation undertaken 
in Unit 713116 in China. Therefore, the first basic principle of the Nuremberg 
Code 117  highlighted the importance of human subjects‘ voluntariness; ‗[T]he 
voluntary consent of the human subject is absolutely essential.‘118 The potential 
research participant ‗should be so situated as to be able to exercise free power 
of choice, without the intervention of any element of force, fraud, deceit, 
duress, over-reaching, or other ulterior form of constraint or coercion‘.119 The 
first principle placed the well-being and protection of the individual at the 
centre of research ethics, and highlighted that neither the progress of medical 
science and technology nor potential benefit for society as a whole should be 
the determining factor of the ethics of research involving human beings.  
In addition, compared to medical treatment, biomedical research may expose 
human subjects to a degree of additional risk to that inherent in proven medical 
treatment. In the medical treatment setting, the patient takes the treatment for 
his or her health benefit. In the context of biomedical research, although such 
research could lead to potential benefits to biomedical science and human 
knowledge as a whole, as well as potential benefits to future patients, the direct 
and immediate benefits to participants in biomedical research may be less clear-
cut. In contrast, human subjects may be exposed to a broad array of risks as a 
result of research participation.  
Moreover, uncertainty is one of the main features of biomedical research. No 
matter how much animal and laboratory research has been conducted, the 
                                         
115
 After World War II, a trial of the perpetrators of the Nazi experiments was held in Nuremberg, 
Germany and is reported as United States of America v. Karl Brandt et al, which resulted in 
what has come to be known as the Nuremberg Code.  
116
 Unit 731 was a covert biological and chemical warfare research and development unit of the 
Imperial Japanese Army that undertook lethal human experimentation during the Second Sino-
Japanese War (1937–1945) and World War II. However, because of some political reasons, 
Japan Unit 731 avoided a procedure like the Nuremberg Doctor Trial. 
117 The Nuremberg Code is a set of research ethics principles for human experimentation set as a 
result of the Subsequent Nuremberg Trials at the end of the Second World War. The record of this 
trail can be seen on the official website of the US, available on 
http://www.archives.gov/research/captured-german-records/microfilm/m889.pdf, last visited on 2010-10-
11. 
118
 Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 
10, vol. 2 (Washington, D.C.: US Government Printing Office, 1949), at 181. 
119
 Ibid. 
Chapter 2 
Harms in Human Population Genetic Research  62 
 
effect of biomedical research on human subjects cannot be known. Mason and 
Laurie identify the aim of randomized clinical trials (RCTs) as being ‗to decide 
whether a new drug or other treatment is better than an existing one, or is 
preferable to none at all, the new treatment is given to a group of patients or 
healthy volunteers and not given to a group as similar a group as can be 
obtained.‘120  
Therefore, it may be concluded that since biomedical research involving human 
subjects is a necessary step which may lead to benefits to society as a whole, 
even though it may cause uncertain and additional risks of harm to its 
participants, we should allow it to be conducted.  Nevertheless, we also bear 
responsibility for ensuring that the interests of those who participate in research 
are understood and protected. In other words, it could be suggested that 
biomedical research involving human subjects deserves specific rules, distinct 
from those that apply to medical treatment. 
Currently, there are several international declarations and ethical guidelines on 
research involving human subjects, including: the World Medical Association 
(WMA) Declaration of Helsinki (Helsinki Declaration) 121  which is the most 
important statement of the principles guiding medical research; the 
International Ethical Guidelines for Biomedical Research Involving Human 
Subjects 122  (CIOMS Guidelines) drawn up by the Council for International 
Organisation for Medical Sciences (CIOMS) in collaboration with the World Health 
Organisation (WHO), which sets general standards for the ethical conduct of 
research in countries around world; the Universal Declaration on Bioethics and 
Human Rights 123 , and the Universal Declaration on the Human Genome and 
                                         
120
 Mason, J. K. & Laurie, G. T. 2011, Mason and McCall Smith's Law and Medical Ethics, 8th edn, 
Oxford University Press, at 620. 
121
 See supra note 111. 
122
 International Ethical Guidelines for Biomedical Research Involving Human Subjects was 
prepared by the Council for International Organizations of Medical Sciences (CIOMS) in 
collaboration with the WHO, Geneva, 2002. The full text of CIOMS Guidelines can be seen on 
the official website of World Heath Organization (WHO) on 
http://whqlibdoc.who.int/emro/2004/9290213639_annex2.pdf, last visited on 2010-07-27. 
123
 The Universal Declaration on the Bioethics and Human Rights was adopted by UNESCO's 
General Conference on 19 October 2005. The full text of the Universal Declaration on Bioethics 
and Human Rights can be seen on the official website of UNESCO on 
http://portal.unesco.org/en/ev.php-
URL_ID=31058&URL_DO=DO_TOPIC&URL_SECTION=201.html, last visited on 2010-07-27. 
Chapter 2 
Harms in Human Population Genetic Research  63 
 
Human Rights, 124 both adopted by United Nations Educational, Scientific and 
Cultural Organization (UNESCO). In addition, the European regional convention, 
the Convention for the Protection of Human Rights and Dignity of the Human 
Being with Regard to the Application of Biology and Medicine: Convention on 
Human Rights and Biomedicine (Convention on Human Rights and Biomedicine)125, 
is also an influential document on research involving human subjects. 
According to these international declarations and ethical guidelines, there are 
two basic values that are central to current ethical and legal frameworks on 
biomedical research: the autonomy of the human subject and the well-being of 
the human subject. In order to protect the autonomy and well-being of human 
subjects, there are two critical steps in determining whether biomedical 
research involving them can be conducted in an ethical manner: obtaining 
potential subjects‘ valid consent and assessing risks and potential benefits to 
them. These two steps work at two different levels. At one level, individual 
research subjects should be fully informed about the nature, scope, and risks of 
the research, and consent to participation should be voluntary. At another level, 
existing regulations require researchers to submit proposals for research 
involving human subjects to expert committees, which must judge those 
proposals based on their adherence to current legal regulations and ethical 
guidelines for the protection of human subjects, as well as ensuring the validity 
of the process of information disclosure and consent. 
Similar to the rules of consent in medical treatment, in the biomedical research 
context competence is a precondition of valid consent. However, all of the 
current international declarations and ethical guidelines provide additional rules 
designed to provide protection for vulnerable populations, for example, human 
subjects who are incompetent to give a valid consent. CIOMS Guideline 9 noted 
that  
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When there is ethical and scientific justification to conduct research 
with individuals incapable of giving informed consent, the risk from 
research interventions that do not hold out the prospect of direct 
benefit for the individual subject should be no more likely and not 
greater than the risk attached to routine medical or psychological 
examination of such persons. Slight or minor increases above such risk 
may be permitted when there is an overriding scientific or medical 
rationale for such increases and when an ethical review committee 
has approved them.126 
According to the Helsinki Declaration there are three rules that need to be 
obeyed. Firstly, ‗if the research subject is legally incompetent, then the consent 
has to be given by the legally authorised representative.‘127 Secondly, there are 
other special protections for these vulnerable people, which are that minors and 
incompetents should not be included in research unless the research is necessary 
to promote the health of the population to which they belong, and the research 
could not be performed on legally competent persons instead. If the minor is 
able to understand the research, his or her assent is necessary in addition to the 
consent of the parents.128 Thirdly, if the patient is not able to give consent, for 
example because s/he is unconscious, and in the absence of proxy consent, the 
research should be done only if the condition that prevents the obtaining of 
informed consent is a necessary characteristic of the research population.129 
In the context of biomedical research on competent human subjects, 
voluntariness is another fundamental requirement. As has been pointed out 
above, the first principle of the Nuremberg Code highlighted that the human 
subjects‘ voluntary consent is an essential and absolute requirement for 
biomedical research. It placed the individual human subject as the decisive 
entity in biomedical research. However, this absolute requirement of individual 
informed consent would mean that individuals who cannot provide consent 
would be excluded from participation, which may lead to some negative effects. 
For example, excluding individuals from participation in biomedical research 
might result in losing the opportunity to test new drugs and medical treatments 
which might be relevant to a particular population, such as babies and young 
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children. What is more, these individuals may also be excluded from some 
clinical research which might benefit them as individuals.130 Thus, the absolute 
requirement of consent has been reconsidered by all other international 
declarations and ethical guidelines for biomedical research involving human 
subjects. These declarations all highlight the importance of freedom of choice 
and personal decision-making in informed consent, while allowing individuals 
who are not competent to be included in biomedical research under specific 
strict rules to seek to ensure their well-being is not compromised. 
The main distinction between the general rules of consent for medical treatment 
and medical research is consideration of the extent of necessary information 
disclosure. In comparison with the legal requirements of information disclosure 
in medical treatment,131 ethical declarations, guidelines and limited case law 
indicate that in the context of biomedical research involving human subjects, a 
higher standard of information disclosure is required. Most international 
declarations and conventions on biomedical research have attempted to describe 
the information that needs to be disclosed by researchers. For example, the 
Helsinki Declaration noted that: 
In medical research involving competent human subjects, each 
potential subject must be adequately informed of the aims, methods, 
sources of funding, any possible conflicts of interest, institutional 
affiliations of the researcher, the anticipated benefits and potential 
risks of the study and the discomfort it may entail, and any other 
relevant aspects of the study…. Special attention should be given to 
the specific information needs of individual potential subjects as well 
as to the methods used to deliver the information.132 
The UNESCO Universal Declaration on Bioethics and Human Rights noted the duty 
of disclosure as the following:  
Scientific research should only be carried out with the prior, free and 
informed consent of the person concerned. The information should be 
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adequate, provided in a comprehensible form and should include 
modalities for withdrawal of consent.133 
Similarly, the CIOMS Guidelines, which defined informed consent in the 
biomedical research context as ‗a decision to participate in research, taken by a 
competent individual who has received the necessary information; who has 
adequately understood the information; and who, after considering the 
information, has arrived at a decision without having been subjected to coercion, 
undue influence or inducement, or intimidation,‘134 listed 27 pieces of essential 
information that need to be disclosed to inform the research subject ‗in 
language or another form of communication that the individual can 
understand.‘135  
In addition, the need for a higher standard of information disclosure for medical 
research involving human subjects has also been pointed out in court judgments 
in some countries. For example, in the Canadian case of Halushka v University of 
Saskatchewan,136 the judge noted the requirement of full information disclosure 
in biomedical research and explained this as follows 
The duty imposed upon those engaged in medical research to those 
who offer themselves as subjects for experimentation is at least as 
great as, if not greater than, the duty owed by the ordinary physician 
or surgeon to his patient. The subject of medical experimentation is 
entitled to a full and frank disclosure of all the facts, probabilities 
and opinions which a reasonable man might be expected to consider 
before giving his consent... Failure to make full disclosure may vitiate 
any consent whether impliedly or expressly given; the undisclosed or 
misrepresented facts need not concern matters which directly cause 
the ultimate damage if they are of a nature which might influence the 
judgment upon which the consent is based.137 
Similarly, in another Canadian case, Weiss v Solomon, 138  the judge of the 
Superior Court of Quebec noted that ‗The court must thus conclude that in a 
purely experimental research programme, the doctor must disclose all known 
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risks, including those which are very rare or remote and a fortiori those whose 
consequences would be grave.‘139 However, in the UK, although medical research 
involving human subjects has been addressed by law in the Medicines for Human 
Use (Clinical Trials) Regulations 2004 and the EU Clinical Trials Directive 
2001/20/EC140 through the requirement to inform clinical trial subjects of ‗its 
nature, significance, implications and risks and appropriately documented,‘141 
there is no specific obligation set out concerning the degree or standard of 
information disclosure on the part of researchers. Whether a higher standard of 
information disclosure is required for potential research participants compared 
with patients is therefore uncertain. 
It must also be noted that medical research involving human subjects is a broad 
term that encompasses a wide variety of research. It has been described as 
having two categories: therapeutic research and non- therapeutic research. 
Therapeutic research, which includes most clinical trials, can be distinguished 
from non-therapeutic research in that the former has a possibility of immediate 
benefit to the subjects, whereas the latter has no such intended potential.142 
This distinction has an historical basis, emerging after World War II in order to 
prevent future medical treatment and biomedical research abuses such as those 
committed during the war, under the assumption that research combined with 
patient care could be considered more ethical, as the patient benefited and 
physicians were guided by the patient‘s interests. Therapeutic research may 
benefit the participants as it not only aims to provide scientific knowledge, but 
also aims at healing or improving the participant‘s condition. Non-therapeutic 
research, which can be carried out on both patients and healthy subjects, will in 
all likelihood not be for the benefit of the research participant but for the 
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benefit of others, such as future patients. The participant would need to accept 
the possibility of adverse effects and health risks, but the potential benefits, 
such as findings in connection with a new treatment, will be for others. While 
the Helsinki Declaration dropped the therapeutic/non-therapeutic research 
distinction in its 2008 version, it nonetheless provided separate principles on 
‗clinical research combined with professional care.‘ Section 31 of the 
Declaration states that ‗the physician may combine medical research with 
medical care only to the extent that the research is justified by its potential 
preventive, diagnostic or therapeutic value and if the physician has good reason 
to believe that participation in the research study will not adversely affect the 
health of the patients who serve as research subjects.‘143 As has already been 
pointed out, there may be reasons to require a higher standard of information 
disclosure for medical research than for medical treatment. However, a 
distinction may also be made between therapeutic and non –therapeutic 
research. For example, in the US case of Whitlock v Duke University,144 the court 
took the view that the standard of information disclosure in non-therapeutic 
research is stricter than in therapeutic research. Since the considerations and 
balance of interests are different, the court concluded that the standard of 
consent adopted by the Nuremberg Code required a greater degree of disclosure 
where research is considered non-therapeutic, and found the standard of care 
required for informed consent relating to medical treatment inapplicable to 
determine the responsibility for obtaining consent in a non-therapeutic context. 
In non-therapeutic research, the researcher is under a duty to disclose all risks 
which may reasonably be anticipated and not just the ‗usual and most frequent‘ 
risks. 145  The standard of disclosure in non-therapeutic research requires 
disclosure of ‗the possible effects upon the health and person of the subject.‘146  
In the current medical ethical and legal frameworks, if these general rules of 
consent to medical research are met, any consent offered would be seen as valid 
and respectful of the autonomy of the individual. Apart from the issue of 
consent to participation, the other main concern of ethical and legal frameworks 
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governing medical research is that of an assessment of the risks involved 
compared with the potential benefits. 
2.2 Harms of Research Involving Human Subjects 
2.2.1 Risks of Harm in Medical Research 
A ‗risk-benefit assessment‘ or ‗risk-benefit ratio‘ is a common expression in 
biomedical research involving human subjects. 147  Risk involves both the 
probability and the magnitude of harms to human research subjects, and cannot 
be equated simply with the magnitude of negative outcome, such as serious 
physical injury or death. Under this approach, a proper analysis of risk requires 
consideration of its probability of harm occurring, since a one-in-a-million risk of 
death is likely to be regarded differently to a one-in-ten risk of death.  However, 
magnitude of risk is also significant, so that a risk of death would be viewed 
differently from a risk of minimal physical harm. Human subjects may be 
exposed to a wide spectrum of risks as a result of participation in medical 
research. Weijer divided such risks of harm into four categories: physical, 
psychological, social, and economic.148 He described each type of risk briefly as 
follows: 
Physical risks: The research subject may suffer bodily harm - minor or 
serious, temporary or permanent, immediate or delayed - as a result 
of his or her participation in the study. 
Psychological risks: Study participation may affect the research 
subject‘s perception of self, cause emotional suffering (e.g., anxiety 
or shame), or may induce aberrations in thought or behaviour. 
Social risks: Research findings, or even study participation itself may 
expose subjects to the possibility of insurance or employment 
discrimination, or other forms of social stigmatization. 
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Economic risks: Research subjects may directly or indirectly bear 
financial costs related to research participation.149 
More than one type of risk may occur in a single biomedical research protocol 
involving human subjects. An example provided by Weijer can illustrate this 
clearly. In research into a new drug for people with acutely symptomatic 
schizophrenia, although there are effective drugs for this disease at present, 
patients are randomly assigned to take various types of drug: a new 
antipsychotic drug, a standard drug or a placebo. These human subjects are 
treated in a hospital for a period of time, where they are assessed with a variety 
of psychometric scales.150 In this medical research, since the new drug may have 
serious adverse effects, some of which may even be irreversible, human subjects 
who take the new drug may suffer physical harms, such as continuing 
hallucinations or paranoia, and they may be at increased risk of suicide. Human 
subjects who are assigned to the placebo will be deprived of needed treatment 
for a period of time, which may lead to the deterioration of the disease. 
Meanwhile, although this is rare, participating in this placebo-controlled 
research may also lead to psychological harm, such as emotional suffering 
caused by exacerbation of their disease because of the absence of treatment, 
since human subjects may sometimes believe that they are taking a placebo, no 
matter whether they are in fact taking a real medicine. Due to the existence of 
potential risks of harm caused by randomized trials involving placebos, the 
Helsinki Declaration (as amended) required that placebos should only be used in 
very limited circumstances. It noted in Article 32 that: 
The benefits, risks, burdens and effectiveness of a new intervention 
must be tested against those of the best current proven intervention, 
except in the following circumstances: 
The use of placebo, or no treatment, is acceptable in studies where 
no current proven intervention exists; or 
Where for compelling and scientifically sound methodological reasons 
the use of placebo is necessary to determine the efficacy or safety of 
an intervention and the patients who receive placebo or no treatment 
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will not be subject to any risk of serious or irreversible harm. Extreme 
care must be taken to avoid abuse of this option.151 
Realizing the risks of harm for human subjects in biomedical research, all 
international declarations and conventions, without exception, declare that the 
welfare of human subjects is the first priority. For example, the Helsinki 
Declaration emphasizes this principle several times in the introduction.  Article 3 
states that ‗[I]t is the duty of the physician to promote and safeguard the health 
of patients, including those who are involved in medical research. The 
physician‘s knowledge and conscience are dedicated to the fulfilment of this 
duty.‘152 The Universal Declaration on Bioethics and Human Rights also declares 
the welfare of human subjects as the first priority, and set it as a basic principle 
which has to be respected. In Article 3, it states that ‗[T]he interests and 
welfare of the individual should have priority over the sole interest of science or 
society.‘ 153  The Convention on Human Rights and Biomedicine in Article 2, 
similarly declares that ‗[T]he interests and welfare of the human being shall 
prevail over the sole interest of society or science.‘154 In order to ensure the 
welfare of human subjects, these international declarations and conventions 
require the harm/benefit assessment to weigh the merits of proposed 
biomedical research and the potential impact on the rights, safety, and welfare 
of participants. They clearly state that the risk to participants should be 
justified by the anticipated benefits to them and/or society, through 
risk/benefit assessments which are concerned with the probabilities and 
intensity of possible harm balanced against anticipated benefits. The research 
should be designed so that the researcher or research institution ensures that 
the potential benefits and risks are reasonably evaluated, and risks are 
minimised. The assessment of risks and potential benefits requires a careful 
appraisal of all available relevant data including, in some cases, alternative ways 
of obtaining the benefits sought in the research. For example, Article 16 of the 
Convention on Human Rights and Biomedicine, which provides special regulations 
for the protection of human subjects in scientific research, urges that it should 
be ensured that: 
                                         
151
 See supra note 111. 
152
 Ibid, Article 3. 
153
 See supra note 123. 
154
 See supra note 125. 
Chapter 2 
Harms in Human Population Genetic Research  72 
 
The risks which may be incurred by that person are not 
disproportionate to the potential benefits of the research; the 
research project has been approved by the competent body after 
independent examination of its scientific merit, including assessment 
of the importance of the aim of the research, and multidisciplinary 
review of its ethical acceptability.155 
In addition, the first guideline of the CIOMS Guidelines relates to risk-benefit 
assessment and risk management. It points out that  
The ethical justification of biomedical research involving human 
subjects is the prospect of discovering new ways of benefiting 
people‘s health. Such research can be ethically justifiable only if it is 
carried out in ways that respect and protect, and are fair to, the 
subjects of that research and are morally acceptable within the 
communities in which the research is carried out. Moreover, because 
scientifically invalid research is unethical in that it exposes research 
subjects to risks without possible benefit, investigators and sponsors 
must ensure that proposed studies involving human subjects conform 
to generally accepted scientific principles and are based on adequate 
knowledge of the pertinent scientific literature.156 
This means that when, and only when, biomedical research involving human 
subjects provides adequate respect and protection for their welfare, can it be 
seen as ethically justifiable. Thus, providing adequate respect for, and 
protection of the welfare of, human subjects is also the first priority of the 
CIOMS Guidelines. Guideline 8 also refers to risk-benefit assessment and risk 
management. In general, the guideline requires that the researchers must 
ensure that potential benefits and risks are reasonably balanced and that risks 
are minimized.157 In respect to the different aims of therapeutic research and 
non-therapeutic research, CIOMS Guideline 8 sets distinctive standards on 
benefit-risk assessment in therapeutic research and non-therapeutic research.158 
In therapeutic research, since participants are involved in the expectation that 
it will be at least as advantageous to the individuals concerned as normal 
treatment, the risk must be justified ‗in relation to expected benefits to the 
individual subject.‘ 159  This means that the risks should be less than, or 
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approximately equal to, the risks of existing treatment, while the benefits 
should be better than existing treatment. On the other hand, in non-therapeutic 
research, which aims to gain generalizable knowledge expected to benefit 
society as a whole, risks must be ‗reasonable in relation to the importance of 
the knowledge to be gained.‘160 
Risk assessment also has a legal basis in some countries. For example, the US 
Common Rule 161  requires that risks to human subjects should be minimized. 
Furthermore, risks associated with non-therapeutic research as well as being 
minimized must be ‗reasonable in relation to anticipated benefits, if any, to 
subjects, and the importance of the knowledge that may reasonably be expected 
to result.‘162 Risks associated with therapeutic research must be in relation to 
the ‗benefits of therapies subjects would receive even if not participating in the 
research.‘163 
The example of new drug research for people with acutely symptomatic 
schizophrenia provided above also indicated another type of risk: these 
schizophrenic patients may pose risks to third parties, for instance if their 
behaviour is affected leading them to act violently toward others, such as their 
family. If this research is conducted while they are living in their homes, more 
third parties‘ interests could be exposed to risk of harm, such as neighbours, or 
people who may have daily contact with them.  Despite the possibility that there 
may be third parties who could be adversely affected by the research, under the 
current ethical and legal frameworks of biomedical research, only the consent of 
the human subject is required. The interests of third parties cannot be 
protected by the rule of consent, which is the core principle in both legal and 
ethical frameworks on medical research. Another legal and ethical requirement 
for medical research is protecting the well-being of human subjects, which 
through the assessment of the risks and potential benefits of certain medical 
research is the overriding criterion for deciding whether or not certain research 
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should be conducted. Nevertheless, the interests of third parties may not be 
sufficiently protected by this requirement either. 
Kimmelman analyzed the Tuskegee Syphilis case, 164  in which a study was 
designed to document the natural history of the disease by preventing about 400 
men from obtaining treatment for their late stage syphilis. The men in question 
were told that they were being treated for ‗bad blood‘. Kimmelman illustrated 
that third parties‘ interests were at risk of harm as follows: 
Normally, late-stage syphilis is not contagious. However, two 
circumstances surrounding this study suggest that family members, 
children, and the sexual partners of the male subjects may have been 
at risk of contracting syphilis. First, medical historians have 
speculated that some of the men in the study might not have been in 
the late stage of syphilis. If so, they would have been contagious. 
Second, persons in the early phases of the late stage syphilis are also 
contagious.165 
In this research, relevant information was not provided to the research subjects, 
but it was also not provided to their family members or sexual partners, who 
could have been adversely affected by this research. Under current research 
guidelines, since this type of research would neither collect any information 
from or about persons other than the patients, nor would any other persons be 
asked to undergo any interventions relevant to the research, the researcher does 
not need to obtain consent from or provide any relevant information to persons 
other than the research subjects. 
Furthermore, Resnik and Sharp also list some examples of research that may 
expose third parties to risks of harm as follows: 
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Vaccine research in which subjects are exposed to a biological agent 
that may pose a health hazard to others who come in contact with 
research subjects; studies that involve research interventions in 
settings occupied by multiple individuals such as a home, a school, or 
a community centre; research in settings in which third-party 
occupants may assume privacy, such as a home; research on mental 
illnesses associated with violent behaviour in which changes to 
ongoing treatment programs may present risks to persons living nearby; 
research on a localized environmental hazard that may impact all 
community residents; studies in which lactating women receive 
experimental medication that may be transmissible through nursing. 
166 
In all of these types of research, certain third parties may suffer harm caused by 
the research, but their opinions would not be sought. Although the risks to third 
parties might be considered as part of the review of the effects of the study in 
general, current guidelines and regulations do not explicitly require IRBs/RECs to 
address such risks, and many IRBs/RECs tend to limit their deliberations to issues 
and concerns related to the guidelines and regulations.167 Since IRBs/RECs may 
not have sufficient time or appropriate expertise to assess risks to third parties 
in research, especially given the many demands and pressures of ethical review 
work, without such a requirement, it would be rare to conduct a risk-benefit 
assessment on the interests of third parties. Thus, the interests of third parties 
cannot be protected adequately under current research guidelines and legal 
requirements.  
In summary, expanding knowledge on human health and the causes of disease, 
as well as promoting the development of biomedical science, is important. 
Obtaining the valid consent of human subjects and the assessment of risks and 
potential benefits of research are the two main measures that provide 
protection to human subjects. Nevertheless, some types of biomedical research 
may lead to new challenges to the legal and ethical frameworks of human 
subject protection, a problem that is particularly acute in the case of genetic 
research, which will be considered in the next section. 
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2.2.2 Concerns Raised by Genetic Research 
According to John Harris: 
It is [human] genetics that is beginning to create a new generation of 
acute and subtle dilemmas that will in the new millennium transform 
the ways in which we think of ourselves and of society. It is genetics, 
bringing both a new understanding of what we are and almost daily 
developing new ways of enabling us to influence what we are, that is 
creating a revolution in thought, and not least in ethics.168  
The main thrust of this statement reflects contrasting thinking on the genetic 
revolution.  On the one hand, there is the possibility of benefits that will arise 
from the development of genetic technology. For example, the Guidelines for 
Human Biobanks and Genetic Research Databases (HBGRDs)169 of the Organisation 
for Economic Co-operation and Development (OECD) noted that human genetic 
research ‗analysed in conjunction with personal or health data is particularly 
promising and will be critical to improvements in the prevention, detection, 
diagnosis, treatment, and cure of disease and for the development of new 
products and services.‘170 Another example is the Human Genome Project (HGP), 
which is the most influential genetic research project designed to ‗determine 
the complete sequence of the 3 billion DNA subunits (bases), identify all human 
genes, and make them accessible for further biological study.‘171 The potential 
benefits of the project have been described as follows: 
Technology and resources generated by the Human Genome Project 
and other genomics research are already having a major impact on 
research across the life sciences. The potential for commercial 
development of genomics research presents US industry with a wealth 
of opportunities, and sales of DNA-based products and technologies in 
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the biotechnology industry are projected to exceed $45 billion by 
2009.172 
Given these factors, some public medias asserted that biology has been widely 
predicted to be the foremost science of the 21st century.173 Some current and 
potential applications of genetic research include molecular medicine, energy 
sources and environmental applications, risk assessment, bioarchaeology, 
anthropology, evolution, and human migration, DNA forensics (identification), 
agriculture, livestock breeding, and bioprocessing. 174  This view of genetics 
reflects an optimistic and positive view of human genetic research; namely, that 
it should be promoted and conducted because human genetic research may help 
to unfold the secrets of many human diseases, discover the cures and therapies 
for human suffering, and enrich our knowledge of human origins and evolution.  
On the other hand, there are challenges that may result from human genetic 
research. Genetic science and technology have invoked significant debate on 
ethical and legal concerns. In order to understand the particular concerns raised 
by genetic research, we need to consider the genetic exceptionalism debate and 
its application to the alleged uniqueness of genetic research. 
(1) The Genetic Exceptionalism Debate 
In 1995, Annas, Glantz and Roche published the article ‗Drafting the Genetic 
Privacy Act: Science, Policy and Practical Considerations‘. 175  This article 
generated a huge debate on what has been described as genetic exceptionalism. 
Murray, amongst others, has used this term, borrowing from the earlier term 
‗HIV exceptionalism.‘ 176  In this debate, the target topic is whether genetic 
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information is different in kind from other medical information; and, if so, 
whether this means that genetic information deserves special legal protection. 
Proponents of the special nature of genetic information provide several 
arguments to illustrate it. In an article on genetic privacy, for example, Gostin 
indicated that the analysis of genetic information can identify the most sensitive 
and personal attributes of an individual‘s life. 177  Annas, Glantz and Roche 
maintained that genetic information is unique, and concluded that ‗[t]o the 
extent that we accord special status to our genes and what they reveal, genetic 
information is uniquely powerful and uniquely personal, and thus merits unique 
privacy protection.‘178 They provided three reasons why genetic information is 
‗uniquely private or personal information‘:  
(1) Human genetic information can be seen as the ‗future diary‘ of human 
beings.179 This means that genetic information can predict a human being‘s 
probable health future. In addition, they argued that genetic information 
describes an important proportion of an individual‘s future and may even 
affect the individual‘s view on the possibility of having a future. Moreover, 
genetic information is written in ‗code‘ and in most situations it remains 
stable and can be stored for a long period of time. As molecular biological 
technology advances, more of the code can be uncovered.  As a result, 
sensitive information concerning future health probabilities may be learned 
from gene fragments and genetic information that were stored in the past, 
without the permission of the individual who is, or was, its originator. In 
addition, it has been argued that genetic information not only can predict 
future disease, but also human behaviour. There is, for example, an existing 
area of research concerning behavioural genetics which seeks to understand 
both the genetic and environmental contributions to individual variations in 
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human behaviours.180 According to this research, genes may influence the 
personality and behavioural characteristics of human beings. This may 
suggest that genetic information is different from other medical information.  
(2) Genetic information ‗divulges personal information about one‘s parents, 
siblings and children.‘181 An individual inherits half of his or her  genes from 
each of his or her biological parents, and passes half of  these genes to each 
of his/her biological children. It means that genetic information provides 
information about others in addition to the individual from whom samples 
were taken. This does not stop at the door of the family but extends to those 
larger groups of peoples, such as indigenous people, minority people, or 
people in isolated areas, who share a specific genetic heritage. Thus, they 
argued that the ‗key feature about genetic information is that it is typically 
information about a family, or even … about a larger community not just 
about an individual patient.‘182 Besides, unlike the use of physical material, 
information can be used at the same time by a great many people for various 
purposes without any loss or wastage. The comparison of knowledge 
contained in a book and genetic information contained in a gene was made 
previously and is relevant here also. For example, if I send a book to a friend 
as a gift, I no longer own the book or have any rights to control it again; 
however, if I have read this book, I can still make use of the knowledge 
gained from information within it. In addition, my use of this knowledge 
does not prevent the use of this information by my friend who now owns this 
book.  
(3) Genetic information could be a new basis for discrimination: ‗… genetic 
information and misinformation has been used by governments … to 
discriminate viciously against those perceived as genetically unfit to restrict 
their reproductive decisions.‘183  Genetic discrimination has been defined as 
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‗discrimination against an individual or against members of that individual‘s 
family solely because of real or perceived differences from the ―normal‖ 
genome in the genetic constitution of that individual.‘184 It has been argued 
that individuals and their family members might encounter genetic 
discrimination during any interaction with other social institution that 
provides a benefit or a service, especially in two areas: employment and 
insurance.185 From the discovery of DNA‘s double-helix structure in 1951 to 
the completion of the Human Genome Project in 2003, the development of 
genetic science and technology has been given wide publicity, and the 
potentially powerful effects of genetic science and technology have also 
been predicted, sometimes even overstated. For example, Francis Collins, 
director of the US National Institutes of Health (NIH) Genome Project, called 
the Human Genome Project (HGP) the ‗Book of Life.‘ 186  This kind of 
expression could lead to fears that scientists involved in this area are 
‗playing God‘, with all the negative connotations of that phrase.187  Resulting 
from the influence of this terminology, and media commentary, the public 
may be concerned that genetic testing will certainly predict a person‘s 
future diseases, even future behaviours, such as criminal behaviour. This 
may lead to or aggravate the potential risks of harms caused by genetic 
research, such as discrimination and stigmatization. 
From the arguments above, we can summarize that the supporters of genetic 
exceptionalism rely on two main considerations.  Firstly, the ability of genetic 
information to predict a person‘s future health status is presumed to be more 
precise than other forms of health information. Secondly, genetic information is 
unique when compared with other health information, in the sense that certain 
types of genetic information can be obtained from any individual, but may 
reveal the collective information of a certain family, even a group/community. 
Furthermore, the inappropriate disclosure or misuse of an individual‘s genetic 
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information could violate the interests of his/her family members or 
group/community members.  
Despite this, the opponents of the uniqueness of genetic information argue that 
this is an over-dramatic view of the significance of genes and genetic 
information in human life. They suggest that although there is something to be 
said for each of the above arguments, on reflection they are unpersuasive.  
(1) First, they argue, genetic information is ‗neither unique nor distinctive in its 
ability to offer probabilistic peeks into human‘s future health‘.188 They have 
explained that some other medical information or family history also could 
be used to predict the current and future health status of an individual and 
even his/her kin. For example, Murray argued as follows: 
Many other things afford equally interesting predictions … 
examples include asymptomatic hepatitis B infections, early 
HIV infection, and even one‘s cholesterol level. These have 
implications for future health that are every bit as cogent and 
sensitive as genetic predispositions.189 
(2) Second, Ross has argued that there being a difference between genetic and 
other medical information should be ‗rejected on the grounds that other 
types of health information also have significant implications for family 
members.‘190 For example, the fact that a family member or another person 
with very intimate relationships is HIV+ is certainly relevant to other family 
members, some of whom are possibly open to infection, as may be those 
who come into intimate contact with the infected individual.  
(3) Third, Ross concludes that ‗threats of discrimination and stigmatization will 
exist as long as there are differences and that these differences need not 
have a genetic basis, as current international conflicts illustrate‘. 191  In 
addition, Murray argues that the genetic discrimination argument is not a 
convincing one, because: 
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Institutions and individuals can and have used all sorts of 
information, both visible and occult, as the basis for 
discrimination…. But it is difficult to make the argument that 
it is fair to discriminate on non-genetic factors but unfair to 
discriminate on genetic ones.192 
(2) The Concerns that Arise from Genetic Research 
Despite the differing arguments discussed above, there are several facts that are 
accepted by both sides. Firstly, genetic information not only discloses 
information about a human subject, but also discloses genetic information about 
her/his relatives, and even certain groups and their members. Secondly, genetic 
information not only shows the present situation of human subjects, but also, 
potentially, future information about her/him and her/his relatives, and even 
group members associated with the individual. Thirdly, this future information 
may be reasonably predictable, although it discloses possibilities rather than 
certainties. It could, of course, be argued, as above, that these are not 
characteristics unique to genetic information, since some types of medical 
information, such as family histories, also have similar characteristics and 
potential.193 In the clinical context, it can be accepted that there is no essential 
difference between genetic information and some other medical information, 
such as family history. This is because, in the clinical context, the analysis of 
both genetic information and other health information, including family history, 
aims to contribute to an accurate diagnosis for this specific patient. However, in 
the context of genetic research, the situation is different. In fact, family history, 
which refers to the recollections of illness/disease by family members, is 
abstract knowledge, which is not necessarily accompanied by a confirmed 
medical diagnosis, thus may be lacking in accurate knowledge about why these 
members have become ill or died in the absence of a true understanding about 
the pattern of disease in this family.194 In contrast, genetic research in clinical 
care is targeted on identifying the origin and causes of certain diseases. Genetic 
information, which is the object of genetic research, can offer a high degree of 
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specificity in predicting the likelihood of disease in other family members, even 
certain group/community members. 
Therefore, in the context of research, I would contend that genetic information 
does have a uniqueness which distinguishes it from other forms of heath 
information, including family history. Under the current individualistic rules of 
consent, if an individual decides to participate in genetic research, the potential 
risks of harm, such as discrimination and stigmatizations based on its negative 
results, may be suffered by participants, her/his family members, even the 
fellow group members of the participants. Except for the human subject, the 
other family members and group/community members have no chance to make a 
decision about the implications of discoveries about their genetic information, 
and lack protection for their interests.  
Although expressions like ‗coded probabilistic future diary‘ and ‗likely medical 
future‘ can be seen as overstated, some of the views of Annas, Glantz and Roche 
are valuable; for example, when they say that compared to other health 
information, genetic information may have more significant unwanted 
consequences for families and population groups. In the context of genetic 
research, compared to other types of biomedical research involving human 
subjects, the real risk of harm to the subject of research is the inappropriate 
disclosure or use of negative genetic information, not the risks of harm to the 
physical body of the human subject. There are two problems which arise from 
this distinction. 
Firstly, in the past any harm that arose in biomedical research would almost 
certainly be physical harm to the participant and as such would not directly 
harm third parties‘ interests or public interests. The samples taken for genetic 
research usually are blood samples which are no different from the blood 
samples taken in routine medical examinations, so the physical harms of genetic 
research are slight. However, the potential harms of genetic research appear to 
be associated with the use of, and access to, information. The risks associated 
with the information-rich nature of genetic research have long been apparent, 
such as anxiety, distress, and other psychological harms to subjects who learn 
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that they carry genes that may predispose them to serious medical problems.195 
The risks of harm caused by genetic research may also include employment and 
insurance discrimination, discoveries of mis-attributed paternity, altered 
relationships between family members, and changes in self-perception. Thus, 
since these concerns had not been the main ones in traditional ethical 
frameworks, beginning in the early 1990s there emerged an important new 
theme in the ethics of biomedical research: namely, that genetic research posed 
the threat of genetic discrimination.196 
In consideration of the risks of harm that may be caused by the discovery and 
use of genetic information, since the Human Genome Project began in 1990 a 
number of national and international regulations and treaties have emerged 
aiming to prohibit genetic discrimination. These policy documents highlighted 
the fact that genetic information is in need of specific strict regulation, given its 
sensitive and distinctive properties which may lead to a high potential for 
discrimination. For example, in the Universal Declaration on the Human Genome 
and Human Rights,197 UNESCO devised special regulations for the human genome 
and for research subjects participating in research on it. In addition, some 
countries also have enacted legislation prohibiting genetic discrimination in 
health insurance. Two-thirds of the states in the US have enacted laws 
prohibiting genetic discrimination in employment, and other states also have 
legislation to regulate genetic discrimination in insurance, protect genetic 
privacy, and govern genetic testing. 198  In 2008, the federal legislation on 
prohibiting genetic discrimination in the US, the Genetic Information 
Nondiscrimination Act of 2008 (GINA),199 was signed. Its aim is to prohibit genetic 
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discrimination in employment and health insurance. These regulations show that 
the concerns of legislators have turned to the risks of psychological and social 
harm in genetic research, in contrast to previous concerns about medical 
research which concentrated on the physical harms to human subjects. 
Secondly, since the genetic information carried by an individual participant is 
shared by her/his blood family, even groups/communities, these potential harms 
could be suffered by the whole family, group/community of the subject. Any 
harm is not, therefore, limited to the participating individuals. This means that 
the other parties‘ interests and potentially the public interest could be at risk. 
Traditionally, the control of information is exercised by the person to whom the 
information belongs, or to whom it relates. It is widely accepted that health 
care professionals owe an obligation of confidentiality to their patients and that 
only rarely should disclosure without a patient‘s consent be made. While 
exceptions to the duty exist, in practice no breach should be made lightly or 
without good cause.200 Similarly, in the context of biomedical research, all of the 
international declarations and ethical guidelines highlight the significance of 
maintaining the confidentiality and privacy of human subjects by researchers 
and research institutions. For example, the Helsinki Declaration noted in its first 
principle that it is the duty of physicians to protection the privacy and 
confidentiality of personal information of research subjects. 201   In addition, 
Guideline 19 of CIOMS Guidelines is entitled ‗Safeguarding Confidentiality‘. It 
notes that  
The investigator must establish secure safeguards of the 
confidentiality of subjects‘ research data. Subjects should be told the 
limits, legal or other, to the investigators‘ ability to safeguard 
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confidentiality and the possible consequences of breaches of 
confidentiality.202  
Medical records are subject to confidentiality or privacy laws that, save in 
exceptional circumstances, require permission from the person whose records 
they are for them to be disseminated. 203  All of these regulations on 
confidentiality and privacy are rooted in the protection of the informational 
security of the individual who provides the information, as traditionally this is 
the person who would be harmed by unauthorised disclosure. However, in the 
context of genetic information, control of the information is more complicated 
because genetic information collected from an individual participant is shared by 
her/his blood relatives, or sometimes members of a particular group. For 
example, when one family member decides to participate in genetic research 
and tests positive for a disease-related gene, that person‘s parents, siblings and 
children all have a chance of carrying that same version of the gene. In addition, 
close community members may also carry this disease-related gene. Because of 
this, if research results are revealed in a manner enabling the participant or a 
group to be identified, not only the participant herself/himself, but also her/his 
family members and members of his or her community might suffer negative 
effects, such as an insurance company refusing to underwrite a life insurance 
policy unless they agree to be tested and are found not to have this disease-
related gene. Nevertheless, as I have mentioned above, 204  under current 
research guidelines on research involving human subjects, although family 
members and community/group members may be exposed to risks of harm 
caused by genetic research, they have no opportunity to be given relevant 
information about it or to decide whether or not to participate, unless the 
subject volunteers this information. What is more, current guidelines do not 
clearly require IRBs/RECs to provide the risk and potential benefits assessment 
on the interests of family members and community/group members of 
participants.  
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In summary, as distinct from the physical harm oriented traditional assessments 
of risks, the main risks of harm in genetic research are primarily related to the 
disclosure of information and research results that could lead to discrimination 
social stigmatization, familial disruption, or psychological distress to the human 
subject and her/his family members. 205 Other risks of harm that may be caused 
by genetic research include ‗inadvertent disclosure of painful facts about family 
relationships (such as non-paternity); stigmatization associated with having a 
genetic abnormality; and intra-familial discord.‘ 206 Although the possibility of 
the occurrence of these risks might be quite low, these harms can be 
devastating for individuals and communities if they occur. 
2.2.3 Concerns Raised by Human Population Genetic Research 
(HPGR) 
According to the discussion of genetic research above, we can conclude that the 
real risks of harm caused by genetic research mainly stem from the 
inappropriate disclosure of negative genetic information, in contrast to the 
physical harm that may be caused by other biomedical research. In the context 
of research, compared to other medical information, genetic information can be 
particularly sensitive. While some countries, such as the US,207 currently have 
laws prohibiting genetic discrimination in employment or insurance, these 
regulations have paid specific attention to the protection of the individual. This 
means that the subjects that these regulations try to protect are still individual 
human beings. However, human population genetic research (HPGR) focuses on 
the group/community collective genetic information of specific target 
groups/communities, not individual human subjects. Thus, some scholars have 
argued that research on human genetic variation can present collective risks to 
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all members of a socially identifiable group. 208  However, current research 
guidelines adopt the requirement for individual informed consent. This may 
provide some protection to human subjects, but the potential interests of a 
group/community as a whole have not been specifically addressed. This 
deficiency in current ethical and legal frameworks is more pronounced in HPGR. 
This section will argue that HPGR may lead to some additional, specific potential 
risks of harm to human subjects, as well as challenging existing legal regulations 
and ethical guidelines on research involving human subjects. 
(1) Potential Risks of Harm of HPGR 
Many of the risks of harm that may be caused by HPGR seem to be similar to 
those raised by general genetic research, since they are also related to the 
disclosure of negative information or research results rather than physical harms. 
However, the issues arising from HPGR have some differences too. HPGR, as with 
the Human Genome Diversity Project (HGDP), ‗provides no information on 
individual phenotypes — the only information provided about each sample is the 
population name, its geographical location in degrees of latitude and longitude, 
and the sex of each individual.‘209 This means that the information collected by 
HPGR will not lead to risks of harm to individual participants in exactly the same 
way as other types of genetic research might, since the information sought in 
HPGR is not individual, subject-identifiable information. The target genetic 
information of HPGR is group/community collective genetic information, which 
is carried by individuals in the target group. However, the collective genetic 
information of the target group is the result of thousands of years of evolution; 
thus, the interests affected by research on it cannot be seen as a matter relating 
solely to individuals, even though it relies on samples taken from individual 
members. Rather, some scholars have argued that group/community collective 
genetic information relates to the interests of the whole group. For example, 
McGregor has pointed out that there are two types of harms that may be caused 
by research: tangible harms and dignitary harms. Both of them can be suffered 
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by either the individual or the group.210 According to her, tangible harms to ‗a 
group include stereotyping or stigmatizing which can result in loss of social, 
political, or economic opportunities‘, 211  while dignitary harms to a group 
‗undermine the value and worth of the group in the eyes of others and the group 
itself‘,212 which may include ‗disrespectful or humiliating treatment of the group 
or community, or treating them as less than or subordinate to others.‘213 The 
disclosure of negative information or research results of HPGR could lead to risks 
of harm to the group as a whole, both externally and internally. Some examples 
of external and internal harms were briefly noted in the introduction but this 
issue will be explored further here.  
(1) External harms:  
Abuse of group/community genetic information might threaten national 
security and the survival of certain groups/communities. For example, 
there was a theory that severe acute respiratory syndrome (SARS), of 
which there was an outbreak in China in the spring of 2003, might have 
been a man-made biological weapon, because ‗there is no vaccine for this 
virus, its make-up is unclear, it has not been very widespread and the 
population is not immune to it.‘214 Although there was no clear evidence 
to support this view, it raised the issue of concerns about population 
targeted bio-weapons based on population genetic research. In developing 
this type of bio-weapon, scientists would try to exploit medical advances 
by identifying distinctive genes carried by the target population, and then 
create a genetically modified bacterium or virus. The distinctive genes 
carried by certain populations is the exact research target of HPGR; thus, 
the abuse of genetic samples collected by HPGR or the inappropriate 
disclosure of HPGR results could perhaps lead to this kind of devastating 
consequence. Imagine that there is a HPGR project involving a Chinese 
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ethnic minority - Miao Nationality - which has a population of more than 7 
million currently. The group‘s collective genetic information is disclosed 
to scientists who use that information to produce a kind of virus or 
bacterium which is more likely to infect and harm Miao people. The 
development of this biological profile is based on HPGR, which revealed 
the unique predisposition of Miao people.  If this kind of virus or 
bacterium is hard to destroy or protect against and the effects cannot 
easily be treated, the survival of the Miao Nationality would be seriously 
threatened. The risk of harm, which might be caused by abuse of the 
research results of HPGR or inappropriate disclosure of the group‘s 
collective genetic information, is relevant to the interests of the whole 
group, even the security of a whole country. Thus, the concerns about the 
risk of harms that may be caused by HPGR cannot simply be equated to 
those that may arise in other biomedical research involving individual 
human subjects. Although this type of bio-weapon targeted to a certain 
population is alarming, some would argue that this is an unrealistic 
scenario. However, there have been reports that this type of bio-weapon 
may become a reality. For example, in a front-page report in the London 
Sunday Times, November 15, 1998, the newspaper stated that  
Israel is working on a biological weapon that would harm 
Arabs but not Jews, according to Israeli military and Western 
intelligence sources. The weapon, targeting victims by ethnic 
origin, is seen as Israel‘s response to Iraq‘s threat of chemical 
and biological attacks.215  
According to this article, this secret Israeli program was based on 
research targeted on a small town southeast of Tel Aviv, conducted by the 
Institute for Biological Research in Nes Tsiona, which is the main research 
facility for Israel's clandestine arsenal of chemical and biological 
weapons. 216  Despite this, there is no clear evidence to support the 
existence of genetic based types of bio-weapons at present. However, if 
they were to be developed, this type of bio-weapon could be a serious 
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threat to national security and national population survival, since it would 
kill or harm some parts of the population but not others. 
Perhaps more likely though is the possibility that HPGR can expose a 
whole community/group and all of its members to stigmatization. 
Stigmatization of certain groups could include claims that a certain 
population is prone to particular diseases, such as schizophrenia, or 
behavioural problems, such as alcoholism.  The public‘s views of genetic 
determinism and reductionism could exacerbate this discrimination. If a 
HPGR result revealed that Miao Nationality people have a genetic 
disposition for alcoholism, for example, each member of the Miao might 
face the risk of higher automobile liability insurance premiums than other 
people, based on the perceived risk of higher numbers of car accidents as 
a result of the misuse of alcohol. As opposed to genetic testing of an 
individual in medical research which may have a negative effect on the 
individual, and possibly her/his family members, the potential risks of 
harm in HPGR could affect a broader range of people. Further, the 
discrimination caused by individual genetic research is often relevant to 
inappropriate disclosure of or access to the individual‘s and her/his family 
member‘s personal information or privacy. These risks of harm in this kind 
of research can be regulated by personal data protection regulations 
which protect the confidentiality and privacy of individual genetic 
information. What is more, some kinds of genetic research can be 
conducted anonymously and disclosure of genetic research results could 
also avoid the disclosure of personal identities of human subjects. 
However, HPGR aims to identify information about a specific human 
population; thus, it cannot avoid disclosing information about a specific 
group/community and the HPGR result may lead to negative effects for 
the target group. This disclosure would be likely to be a part of any report 
of the scientific research findings, which is the normal outcome of 
scientific research, even though these research findings could be the basis 
of discrimination against a whole group. 
There are other derivative negative effects on the group as a whole that 
may be caused by HPGR. For example, negative effects could include 
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economic ones: ‗downgrading the group/community‘s bond rating, making 
it more expensive to borrow money.‘217 Legal and political claims can be 
threatened, too. In the PRC, for example, there are some special benefit 
policies and special legislation for ethnic minorities, which might be 
threatened if, for instance, HPGR proves that the target group is not in 
fact related historically or geographically. One could also imagine claims 
that ethnic minorities are not really ethnic minorities at all, since their 
origins can be traced to alternative ancestries than those that had been 
previously believed to be the case. 
(2) Internal harms: 
Internal harms are the potential risks of harm which may occur inside the 
target groups of HPGR. They include the group‘s self-conception of 
genetic determinism and self-stigmatization, for example, ‗we Jews are 
defective because our genes make us prone to cancer‘ and/or ‗we 
American Indians are defective because our genes make us prone to 
alcoholism.‘218  Given that psychosocial stress and the disruption of family 
life are recognized and widely accepted by researchers as harms219 and 
are regarded as legitimate risks to be considered and minimized by IRBs in 
some countries,220 consistency dictates that community/group stress and 
the disruption of a group/community‘s constitution or core culture should 
also be treated as significant research-related harms in the context of 
HPGR, since target groups of HPGR almost always have their own unique 
cultural sensitivities.  The powerful identification of individual members 
with their group also means that group harms can have significant 
individual effects. 
In order to discuss group internal harms, it is significant at the outset to 
make clear what a group is. What constitutes a group is not only 
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problematic in the context of HPGR, but also in the recognition of group 
entities and interests by law. Although conceptually uncertain, it is 
evident that local, state, and national political entities, religious groups, 
cultural groups, corporate groups, minority groups, indigenous and tribal 
groups, and a myriad of others have distinctly recognized and protected 
interests in law.221 
‗Group‘ is a common term that occurs frequently in legal publications. In 
fact, like the other most common terms, such as dignity and rights, there 
is no consensus on what constitute a group even in the context of 
international law, although several studies have attempted to define it 
and use various terms to describe it, such as ‗people‘, ‗community‘, 
‗communality‘, ‗social group‘ and the most prevalent one ‗minority.‘222 
There is a related definition of what constitutes a ‗people‘. The following 
definition was provided by experts of the United Nation Education, 
Scientific and Cultural Organization (UNESCO) in 1990: 
A group for the rights of peoples in international law, 
including the right to self-determination, has the following 
characteristics: 
1. A group of individual human beings who enjoy some or all of 
the following common features: (a) a common historical 
tradition; (b) racial or ethnical identity; (c) cultural 
homogeneity; (d) linguistic unity; (e) religious or ideological 
affinity; (f) territorial connection; (g) common economic life. 
2. The group must be of a certain number who need not be large 
(e.g., the people of micro state), but must be more than a 
mere association of individuals within a state. 
3. The group as a whole must have the will to be identified as a 
people or the consciousness of being a people—allowing that 
groups or some members of such group, though sharing the 
foregoing characteristics, may not have the will or 
consciousness. 
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4. Possibly, the group must have institutions or other means of 
expressing its common characteristics and will for identity.223 
Another related concept is ‗minority group‘. The most widely accepted 
definition of a minority group is ‗a group which is numerically inferior to 
the rest of the population of a state and in a non-dominant position, 
whose members possess ethnic, religious or linguistic characteristics 
which differ from those of the rest of the population and who, if only 
implicitly, maintain a sense of solidarity, directed towards preserving 
their culture, traditions, religion or language.‘224  
Although the terms ‗people‘ and ‗minority‘ are closely related to group, 
‗minority‘ emphasizes their political situation, while ‗people‘ focuses 
more on the social situation of a group.  
Other theorists also provide explanations as to what is a group in 
particular contexts. For example, Thomas Pogge argued that an ethnic 
group has the following three features: the members of this group must 
identify themselves as descendants of members of a historical society, 
which is a board concept of society, including tribes, principalities, and 
others; this group has a unified culture, or partial culture, among which 
its members can be connected, through a continuous history; and the 
group must contain most of the persons who, within the relevant state, 
are taken to share the group‘s descent and culture.225 Natan Lerner, in an 
analysis of group recognition in international law, stressed the purposes 
and goals of the group, the connections and distinctions between the 
group and other relative groups, the history and permanence of the group, 
the naturalness or spontaneity of the group, and the voluntariness of 
group membership.226 There are other definitions of a group, too, which 
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focus on shared normative understandings, the importance of the group to 
personal identity, and whether the well-being of group members is at 
least in part determined by group well-being.227   
These definitions all reflect some features of a group, but none of them 
has been universally accepted as an explanation to make it clear what a 
group is. However, through all those efforts, scholars and legal 
practitioners have developed two widely accepted criteria for defining a 
group; one of which is subjective while the other is objective. The 
subjective criterion is the group and its member‘s self-perception of the 
group‘s distinctiveness, and the desire of the individual members of the 
group to identify themselves as a group. The objective criterion is the 
existence of objective characteristics which distinguish the group from 
the remainder of the population, such as history, geography, ethnicity, 
economics, language and religion. It is important to keep in mind that 
neither of these two criteria is sufficient on its own to constitute a group. 
Only if a group fulfils both of these two criteria can it be seen as an 
independent group.228  
If something leads to negative effects on members of a group, this could 
also cause harm to the constitution of the group itself. In this situation, 
the interest of group as a whole would also be harmed, not only its 
individual members. Some scholars have argued that ‗the most common 
and damaging risk of harm to communities is community disruption,‘ and 
in respect of genetic research, that ‗the disruption is usually at the stage 
of publication and release of the research results or secondary use of 
existing specimens.‘229 HPGR is just this kind of research which may cause 
intra-group harms to the target group. For example, HPGR specific to an 
ethnic minority in China might prove that this group has no genetic 
difference to other Chinese people. This result may lead the group 
members to reassess their origins and relationships to one another. This 
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may threaten ‗group members‘ self-identity and the identity of the group 
as a whole, as well as causing cultural harms to spiritual traditions and to 
their sense of who they are and where they are from, all of which upset 
their historical narrative.‘ 230  Some HPGR, such as that looking into 
migration pattern research, can also challenge or disrupt a group‘s 
cultural or spiritual values. For example, the cultural narratives of Miao 
Nationality people in China say that they are the descendants of a 
butterfly and a bubble; thus Miao people believe that they are distinct 
from other people. The HPGR‘s result might, however, show that they 
have no essential biologically based distinction from other people. Under 
current research guidelines, this type of risk of harm would not even need 
to be disclosed to the individual human subjects. This means that the 
target group and its members could suffer risks of harm which they have 
not consented to; indeed, the risk has not even been disclosed to them. 
Since HPGR aims to discover variation that could lead to knowledge about 
genetic disorders, possible cures, and the origin and migration patterns of 
target groups, the results of HPGR may challenge or disparage target 
groups‘ spiritual traditions, historical narratives, or traditional beliefs, 
which can be defined as cultural harms. Rebecca Tsosie, as noted earlier, 
defined ‗cultural harms‘ as the violation of groups‘ rights to their own 
culture.231 Her definition was based on the theory of Avishai Margalit and 
Moshe Halbertal 232  on culture, which defined culture as the ‗material, 
spiritual, and artistic expression of a group that defines itself‘, 233 and 
maintains that ‗human beings have a right to culture – not just any culture, 
but their own.‘ 234  The target groups of HPGR are almost all ethnic 
minorities or isolated groups in rural areas of developing countries. Their 
rights to their own culture, including a comprehensive way of life by 
which a group defines itself, have been accepted in international human 
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rights law. For example, Article 27 of the International Covenant on Civil 
and Political Rights (ICCPR) reads as follows: 
In those States in which ethnic, religious or linguistic 
minorities exist, persons belonging to such minorities shall not 
be denied the right, in community with other members of 
their group, to enjoy their culture, to profess and practice 
their own religion, or to use their own language.235 
HPGR results, for example, those that provide evidence that an historical 
spiritual leader of a certain group does not genetically belong to that 
group, could lead to cultural harms. In addition, the result of HPGR as 
scientific proof to challenge group identity and group members‘ self-
understanding could also be defined as causing cultural harms. The group 
members‘ self-consciousness is crucial to a group‘s coherence. HPGR 
results which question the historical narratives of the target group, may 
decrease group members‘ belief and pride in the group tradition and 
culture, which can also lead to negative effects on the group‘s cultural 
rights. 
Some scholars have argued that cultural harm, such as undermining a 
group‘s beliefs about its origins, is not a real risk which needs to be 
disclosed in the research protocol and when seeking consent; therefore, 
the risks of cultural harms caused by HPGR should equally not be taken 
into account. For example, Reilly said that  
Should a potential subject be warned that one or more 
findings may challenge his religious beliefs? This strikes me as 
beyond the appropriate boundaries of the duty to warn, for it 
suggests that scientists must censor their inquiries if 
conducted in the shadow of religion. When Galileo trained his 
telescope on the heavens and saw four moons orbiting Jupiter, 
he set in motion forces that would destroy the narratives built 
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around a geocentric universe— no doubt upsetting the world 
views of a lot people.236 
This example is inappropriate, however, in the context of HPGR. 
Admittedly, in general, scientific research does not need to take into 
account existing ideology and public beliefs. However, this argument 
cannot apply to HPGR, which is specifically conducted on certain groups. 
HPGR needs the target group and its members to participate voluntarily. 
If the research results may cause one of the potential risks that could 
challenge the common group belief, such as the narrative origins of the 
group, I would argue that the group and its members do have the right to 
be informed of that risk before deciding on whether or not to participate. 
If the target group and its members decide not to participate in this 
research, this potential risk, which is specific to them, would not arise.  
In summary, HPGR could lead to additional risks of harm other than those raised 
by other genetic research. All of the international declarations and ethical 
guidelines on research involving human subjects have noted that the welfare of 
the individual research subject must take precedence over all other interests. It 
needs to be highlighted that the welfare of target groups in HPGR should also be 
considered. 
(2) The Application of Consent to HPGR 
In 1914, in the US, Justice Cardozo argued that ‗[e]very human being of adult 
years and sound mind has a right to determine what shall be done with his [or 
her] own body.‘237 This influential statement paved the way for the development 
of the importance of individual autonomy and consent in the medical setting. As 
has been discussed,238 the primary legal and ethical considerations in biomedical 
research have traditionally revolved around the individual subject, ranging from 
issues as to how a piece of research will affect a human subject to whether the 
human subject will have the opportunity to provide voluntary and sufficiently 
                                         
236
 Reilly, P. R. 1998, "Rethinking Risks to Human Subjects in Genetic Research", American 
Journal of Human Genetics, vol.  63, pp. 682-685, at 684. 
237
 Schloendorff v. Soc'y of N.Y. Hosp., 105 N.E. 92, 93 (N.Y. 1914), abrogated on other grounds 
by Bing v. Thunig, 143 N.E.2d 3 (N.Y. 1957). 
238
 Discussion on requirements of consent on biomedical research can be seen in 2.1.4. 
Chapter 2 
Harms in Human Population Genetic Research  99 
 
informed consent. In brief, given the competence of human subject to give a 
valid consent, consent is a two step process in biomedical research: first, 
researchers present appropriate information to the human subject. Secondly, 
the human subject is free to either agree or refuse to participate in a given 
biomedical research project, based upon this information disclosure. 
As we have seen, HPGR is research on specific groups which can generate 
valuable knowledge. As has been discussed above, the acceptability of non-
therapeutic research without direct and immediate benefits to participants has 
historically been based on a requirement that the research subject consents to 
exposure to risks of harm which may be caused by the research, with full 
disclosure of relevant information to enable him or her to make a decision on 
whether or not to participate. Consent is also important in HPGR. However, the 
application of the current approach to consent to participation in biomedical 
research to the specific context of HPGR is problematic.  
Under the ethical justification of respect for individual autonomy, in non-
therapeutic research the subject who may suffer harm caused by the research 
should make the decision as to whether or not to participate. In most other 
biomedical research, the potential risks of harm would be posed to the 
individual human subject, so again the human subject would make the decision 
on research participation, based on the consideration of her/his own interests. 
Thus, in these types of research, under current research guidelines, the simple 
consent of individual human subjects based on the consideration of their own 
interests is ethically and legally justifiable. 
As discussed above,239 in HPGR, the research objective is obtaining the collective 
genetic information shared by members of a target group. Therefore, it could be 
argued that the target group/community of HPGR is the research subject of 
HPGR, and it is the group which should make the decision on whether or not 
participate. However, the current dominant ethical principle of ‗respect for 
persons‘ is secured through individual consent. The moral basis of consent as 
currently understood in law is an individualised model of autonomy. This means 
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that current research protections are not aimed at protecting populations, 
communities, groups, or other possible third-party victims.  
In addition, the uniqueness of genetic information is that the genetic samples 
obtained from human genetic research subjects contain not only her/his genetic 
information, but also genetic information about her/his blood relatives, and 
even potentially genetic information about the group of which s/he is a member. 
However, HPGR, which targets specific groups, can be conducted with the 
participation of only some of the members of the group. Nonetheless, the 
potential risk of harm could be created for every member of the target group, 
and even the group itself.  
Thus, the individual human subject has no overwhelming superior moral 
justification to give consent to participate in HPGR than any other member of 
the group who may be affected, other than the fact that s/he must undergo the 
procedure upon his or her body to allow a blood sample to be taken. Individuals 
have no superior rights to consider issues concerning the welfare of the group, 
though they may wish to take them into account for themselves as part of the 
information process before giving consent to participate. The issue of 
information disclosure will be returned to later. However, for the moment, 
current ethical and legal frameworks of consent help support autonomy and self-
determination, protect the vulnerable, and promote the welfare and equality of 
human beings; but this focuses primarily on individual rights and does not always 
see individuals as part of wider social orders and community.240 The application 
of current individualistic ethical frameworks of consent for medical research to 
HPGR is problematic.  
This chapter has discussed the concept of relational autonomy as part of a 
reconsideration of the individualised Western idea of autonomy.241 It examined 
the idea that individual‘s decision making depended on their position within 
social networks. It argued that individuals may wish to take account not only of 
personal interests, but also the welfare of her/his group which could be 
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influenced by the decision. Applying this relational autonomy model to HPGR 
would provide one means of greater protection of the interests of target group, 
as well as recognising the need for such issues to be considered as part of an 
individual‘s decision-making process. Based on the relational autonomy model, I 
will suggest that ways to incorporate this model might include two important 
developments: adding the risks of harm to the target group/community as a 
whole as one aspect of ethical review of the project, before seeking participants, 
and adding the risks of harm to the target group as a whole as relevant 
information that needs to be disclosed to potential participants. One further 
issue that arises is the need for cultural sensitivity. 
(1) Adequacy of Information disclosure 
As I have considered above,242 the rule of consent in the medical treatment 
context has a different purpose than in the biomedical research context. In 
general, because there might be a greater potential for harm in biomedical 
research, it may be considered that there must be more relevant information 
disclosed to the research subject than to a patient. Thus, many international 
declarations, ethical guidelines and national legislation on biomedical research 
provide a list of items of information that must be disclosed to the potential 
human subject. For example, the following are those elements of information 
considered relevant to the vast majority of research projects in US federal 
legislation: 
(I) A statement that the study involves research, an explanation of the 
purposes of the research, and the expected duration of the subject‘s 
participation, a description of the procedures to be followed, and 
identification of any procedures which are experimental; (2) A 
description of any reasonably foreseeable risks or discomforts to the 
subject; (3) A description of any benefits to the subject or to others 
which may reasonably be expected from the research; (4) A disclosure 
of appropriate alternative procedures or courses of treatment, if any, 
that might be advantageous to the subject; (5)A statement describing 
the extent, if any, to which confidentiality of records identifying the 
subject will be maintained; (6) For research involving more than 
minimal risk, an explanation as to whether any compensation and an 
explanation as to whether any medical treatments are available if 
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injury occurs and, if so, what they may consist of, or where further 
information may be obtained; (7) An explanation of whom to contact 
for answers to pertinent questions about the research and the 
research subject‘s rights, and whom to contact in the event of a 
research related injury to the subject; and (8) A statement that 
participation is voluntary, refusal to participate will involve no 
penalty or loss of benefits to which the subject is otherwise entitled, 
and the subject may discontinue participation at any time without 
penalty or loss of benefits to which the subject is otherwise 
entitled.243 
From this list of information that needs to be disclosed, it can be shown that 
existing legal regulations and ethical guidelines concentrate on immediate risks 
to individual research participants and do not explicitly require researchers to 
consider potential harms to non-participants.  
Nonetheless, HPGR is a good example of the argument that when research 
involving human subjects places non-participating members of specific 
groups/communities at risk, these potential harms should be considered by 
persons conducting, reviewing, and participating in the research. Compared to 
other types of harm that research may cause, the risks of harm from HPGR are 
collective and could be suffered by all members of the group, not simply 
individual participants. For this reason, I would argue that potential researchers 
should demonstrate respect for the diverse social and cultural traditions of many 
communities and acknowledge that research findings can disrupt social 
relationships within and between communities. These considerations suggest 
that in order to protect certain groups/communities from HPGR related harm, 
the scope of information disclosure should be expanded to risks at group level, 
not limited to the immediate risks to individual participants. Thus, the 
information disclosure requirements in existing legal regulations and ethical 
guidelines are inadequate in HPGR, since only potential risks of harm to 
individual participants would normally be disclosed, while risks of harm that may 
potentially be suffered by the target group as a whole are not required to be 
disclosed. 
In fact, there are rare examples in Western genetic research which indicate that 
information disclosure concerning wider risks than those to participants 
                                         
243
 Title 45 CFR§46. 116, See supra note 161. 
Chapter 2 
Harms in Human Population Genetic Research  103 
 
themselves, under what might be considered a relational model of autonomy, 
would be appropriate. For example, a study of 30 women on  the breast cancer 
BRCA1/2 mutation  showed that the dilemma relevant to information disclosure 
on issues which may affect others, in this case female relatives, was not whether 
or not to inform participants of these kinds of factors, but how to tell them.244 In 
this study, over 90% of participants‘ intention to participate was in order to 
obtain information for their relatives. Hence, the authors concluded that ‗we 
need to ground consent upon an ethic that takes into account the social nature 
of human beings.‘245 This example indicated that individual benefits or risks of 
harm are not the only factors which influence individual decision-making, 
especially in the context of genetic research. The interests of relatives or 
families may also be essential. In such cases, the potential interests of their 
relatives would be the determinative factor influencing their decision on 
whether or not to participate in certain kinds of genetic research. Although this 
example related to the issues of families in genetic research, it may be 
reasonable to require researchers to provide information about potential effects 
on a group of other people as well as the participants, it would enable potential 
participants to consider such issues as part of their own risk/benefit analysis 
before they are asked to consent. 
(2) The interests which should be considered in consent 
Since the research target groups/populations of HPGR are usually ethnic 
minorities or isolated groups in rural areas in developing countries, in some of 
these groups/populations, such as in the PRC, the understanding of the nature of 
a person may be in line ‗with more relational definitions of the person found in 
other societies … which stress the embeddedness of the individual within society 
and define a person by his or her relations to others.‘246 In these areas, where 
the notion of persons as individuals is not dominant, the individual consent 
process may not be suitable, and there may be a need to widen the focus from 
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the individual to the family or to the community, and to accept that their 
involvement may be a cultural expectation. For example, in India and West 
Africa, great respect and deference may be given to clinicians, healers and 
elders.247 Clinton also indicates that: 
…Indians and many non-Westerners, often have a very different view 
of the nature of their rights and legal relationships... human beings 
are born into a closely linked and integrated network of family, 
kinship, social and political relations. One‘s clan, kinship, and family 
identities are part of one‘s personal identity and one‘s rights and 
responsibilities exist only within the framework of such…networks.248 
The model of relational autonomy also concluded that individual decisions might 
be influenced by external considerations, without such influences necessarily 
amounting to improper, or undue, influence. In addition, the cultural 
sensitivities of some developing countries are also conducive to the adoption of 
relational autonomy. HPGR projects are almost always conducted on target 
groups from isolated rural areas of developing countries, where cultural 
ideologies are different from Western ones. For example, in a traditional 
Chinese group/community, the group/community is the background to personal 
acts and decisions. When facing decision-making issues relevant to group 
collective interests, it may be a cultural expectation that individual members of 
target group for HPGR would wish to rely on the opinion of group/community 
leaders, or group/community leaders would make the final decision directly. 
Although it is not argued in this thesis that a group member should be compelled 
to participate in HPGR if approval of the research was given by a group leader, 
or that individual consent should not be sought from potential participants, what 
is at issue here is the need for respect for cultural sensitivity to enable the 
involvement of others than participants in decision-making and consideration of 
the welfare of those in the group who are not actively participating. In this 
respect, HPGR participation would be considered as a group collective affair or a 
collective interest. Thus, cultural sensitivities would also be an important factor 
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to be considered in HPGR. The issue of cultural sensitivities in HPGR will be 
discussed in more detail in Chapters 3 and 4.  
In HPGR, adopting a relational autonomy model would be even more appropriate. 
In HPGR, unlike the situation of most medical treatment which primarily has 
consequences for the individual, since the research target is group collective 
genetic information, the main risks of harm would be group harms which may 
affect the group as a whole as well as each group member. A relational 
autonomy model, as has been discussed above,249  requires that the interests of 
all relevant parties should be considered in the decision-making process. 
Applying a relational autonomy model in HPGR would require researchers to 
disclose information about both about individual risks and potential group harms 
posed by HPGR, because the interests of the group could be affected by the 
decision whether to participate, and whether or not target groups and other 
group members would be negatively affected could be a determinative factor to 
the decision makers. 
Accordingly, the current Western research ethical and legal frameworks of 
consent have not sufficiently addressed the harms that may be suffered by the 
target groups of HPGR. The individualistic frameworks can neither fit into the 
cultural sensitivities of target groups in HPGR from some developing countries, 
nor properly provide for disclosure of the main risks of harm that may be posed 
by HPGR. In HPGR, the relational autonomy-based consent model is superior to 
the highly individualised autonomy based consent model, particularly in 
developing countries like China where collective decision-making is not 
uncommon. 
Recently, some scholars have discussed group protection measures as 
supplements to individual informed consent. 250  They have argued that a 
group/community/population ought to have moral status in HPGR, especially in 
respect of research in developing countries, for the following reasons: (1) people 
do not view themselves atomistically, but as members of one or more 
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communities that constitute their values and self-understanding; (2) a variety of 
communities are already given the authority to make binding decisions on behalf 
of individual members on certain issues; (3) the primacy of the individual versus 
the community varies from one community to the next.251 Yet, although there is 
a clear need for alternative model which include group consideration, it could 
be argued that there are concerns with models which take the group as the unit 
of ethical concern. It is arguable that it might be problematic to determine the 
boundaries of the group/community and to find a mechanism for balancing 
interests within a group. The most essential ethical issue here is whether or not 
‗individuals and their claims of right will be crushed beneath the greater weight 
of groups and their claims of right.‘252 Other scholars have argued that group 
consent is hard to obtain in practice. There are three main difficulties: (1) the 
extent of the affected parties‘ participation in decision-making; (2) the 
identification of the parties whose consent should be sought if collective consent 
procedures were adopted; (3) the veto power problem: the possibility of a group 
veto power over individual decisions to participate or not would make collective 
consent extremely difficult to support.253 The alternative to the ethical principle 
and rule of individualistic consent, such as ‗respect for community‘ or ‗group 
consent‘, will be discussed in detail in the next chapter. However, while 
supporting group and community involvement in reviewing HPGR, it needs to be 
emphasized that this thesis does not intend to substitute group consent for 
individual consent, but to supplement individual consent with additional 
considerations concerning the interests of target group, based on the relational 
autonomy model. 
(3) The Application of Risk- benefit Assessment to HPGR  
Compared to clinical research, in most cases genetic research cannot produce 
direct and immediate benefits to human subjects. This characteristic is even 
more apparent in HPGR. Thus, in the risk-benefit analysis of HPGR, the risks of 
harm should be considered more carefully. It should not only consider the risks 
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and potential harms to each member of the target group, but also the risks and 
potential harms to the group/community as a whole and all of its members. 
Recognizing that additional protections are needed in the research context, all 
of the international declarations and conventions, such as the Helsinki 
Declaration,254 the CIOMS Guidelines,255 as well as some national legislation, such 
as those in the US, require institutional review boards (IRBs) or research ethics 
committees (RECs) to ensure that research is conducted ethically and with the 
fully informed consent of the participants. IRBs or RECs provide the initial 
approval of the proposed research and then conduct a continuing review of the 
research to ensure ongoing compliance with institutional policies and procedures. 
Under the terms of the Helsinki Declaration, ethical review committees must 
‗take into consideration the laws and regulations of the country or countries in 
which the research is to be performed as well as applicable international norms 
and standards but these must not be allowed to reduce or eliminate any of the 
protections for research subjects set forth in this Declaration.‘256 Ethical review 
committees are responsible for reducing unnecessary risks for the participants in 
research and for guarding against the exploitation of those subjects. US federal 
common law also notes that the specific role of the IRBs is to assure the 
protection of research subjects and ‗to ascertain the acceptability of proposed 
research in terms of institutional commitments and regulations, applicable law, 
and standards of professional conduct and practice.‘257  Thus, one of the core 
functions of RECs or IRBs is to review the potential risks of harm that may be 
caused by research to ensure that the interests of human subjects are protected. 
However, considering the criteria for IRB‘s or REC‘s approval of biomedical 
research involving human subjects, the essential risks of harm that may be 
caused by HPGR may not be identified by them. For example, the US Common 
Rule noted that IRBs must ensure that: 
Risks to subjects are reasonable in relation to anticipated benefits, if 
any, to subjects, and the importance of the knowledge that may 
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reasonably be expected to result. In evaluating risks and benefits, the 
IRB should consider only those risks and benefits that may result from 
the research (as distinguished from risks and benefits of therapies 
subjects would receive even if not participating in the research). The 
IRB should not consider possible long-range effects of applying 
knowledge gained in the research (for example, the possible 
effects of the research on public policy) as among those research 
risks that fall within the purview of its responsibility.258 (emphasis 
added) 
According to these criteria, IRBs are only requested to consider the risks of harm 
which can be clearly foreseen, and these are focused on individual participants. 
These types of risks might befall anyone: physical harms, hurts or injuries and 
psychological harms including pain and suffering. It might be suggested that IRB 
members will tend to identify the risks of harm they themselves might expect to 
experience if they were to take part in the proposed research. However, the 
target groups of HPGR are ethnic minorities and isolated groups in rural areas of 
developing countries. IRB members almost always are at a social and cultural 
distance from them; thus, they are not likely to have a cultural awareness of the 
target groups. Consequently, they are not likely to recognize the circumstances 
and traditions of these groups, so they may not be able to appropriately identify 
the possible and potential harms that may occur to certain groups correctly, 
especially internal or cultural harms.  
Similar to the focus on individual autonomy in current ethical and legal 
guidelines on informed consent, with regard to welfare, the basic ethical 
principle of ‗respect for persons‘ results in the concentration of IRBs and ethical 
review committees on individual human subjects. For example, the human 
subject in the US Common Rule is defined as ‗a living individual about whom an 
investigator (whether professional or student) conducting research obtains data 
through intervention or interaction with the individual, or identifiable private 
information.‘259 Thus, according to this definition, the risks of harm IRBs need to 
consider are the risks of harm that individual participants may suffer. In the 
context of HPGR, existing ethical guidelines do not require an assessment of 
risks of group harm in to be addressed in the ethical review process.  
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In fact, it is worth noting that a number of scholars have indicated their 
concerns about the interests of groups and communities in research ethics. For 
example, as far back as the National Bioethics Advisory Commission‘s (NBAC) 
first meeting, Emanuel argued that the three principles, ‗respect for persons, 
beneficence, and justice,‘ and their related guidelines do not adequately 
address the interests of communities.260 Levine also argued that the Belmont 
Report overemphasized individual rights and failed to talk about the community. 
He noted:  
In each of its publications, it [the National Commission] seems to 
embrace an atomistic view of the person. The person is seen as a 
highly individualistic bearer of duties and rights; among his or her 
rights, some of the most important are to be left alone, not to be 
harmed, and to be treated with fairness. Except, perhaps, in its 
report on research involving children, there is little or no reference to 
persons in relationship to others or as members of communities.261 
On the other hand, the consumerist movement swept America in the early 1970s 
and concern for individual rights was very much a part of the zeitgeist. The 
Belmont Report was undoubtedly also influenced by these larger societal forces. 
Nonetheless, the failure of the Belmont Report to deal adequately with families 
and communities does not, Levine argues, render it useless: ‗Having said this, I 
do not think the Commission‘s recommendations are obsolete. . . . [I]t is usually 
quite appropriate to view investigator-subject relationships as relationships 
between strangers. Thus, in general an individualistic ethics is appropriate.‘262 
Along with the development of biomedical science and technology, especially 
the prevalence of population genetics, the NBAC came to realize the need to 
protect groups/communities. For example, the NBAC‘s specific recommendation 
on stored human biological materials indicated that: 
Research using stored human biological materials, even when not 
potentially harmful to individuals from whom the samples are taken, 
may be potentially harmful to groups associated with the individual. 
To the extent such potential harms can be anticipated, investigators 
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should to the extent possible plan their research so as to minimize 
such harm and should consult, when appropriate, representatives of 
the relevant groups regarding study design. In addition, when research 
on unlinked samples that poses a significant risk of group harms is 
otherwise eligible for exemption from IRB review, the exemption 
should not be granted if IRB review might help the investigator to 
design the study in such a way as to avoid those harms.263 
This recommendation seems to indicate the NBAC‘s awareness of the possibility 
of specific research protocols posing a risk to a specific group, and its concern 
that, if this risk can be anticipated it should be disclosed during the informed 
consent process. However, this has not been reflected in current ethical 
guidelines, such as the Declaration of Helsinki, nor in legal regulation. 
Nevertheless, HPGR may pose some risks of internal group harm, which are hard 
to recognise or identify by people who are outside the group. Thus, under 
current frameworks, similar risks posed to target groups in HPGR would very 
probably not be taken into account in the risk-benefit analysis of IRBs/RECs. 
In summary, HPGR may lead to specific risks of harm to the target 
groups/communities. However, existing legal and ethical frameworks on human 
subject protection, such as consent and risk-benefit assessment, are ill-equipped 
to provide a comprehensive solution to avoid the potential risks of harm posed 
by HPGR.  
In addition to these concerns, the target groups/communities in HPGR are also 
distinguished from participants in many other types of biomedical research. They 
are almost always deliberately selected as target groups because they are in 
isolated groups/communities in rural areas of developing countries, which may 
lead to the potential for vulnerability in HPGR participation. Thus, the next 
chapter will go on to consider the issues of protecting target 
groups/communities as potentially vulnerable populations in HPGR. 
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Chapter 3 – Group Protection in Human Population 
Genetic Research  
As discussed in Chapter 2, since HPGR aims to identify specific aspects of the 
diversity of the human genome, target groups are often ethnic minorities or 
isolated groups in rural areas of developing countries, whose members are 
believed to share the same community or group collective human genetic 
information. This chapter will suggest that these target groups should be 
considered to be vulnerable in respect of HPGR, and need specific protections. 
3.1 The Vulnerability of Target Groups in HPGR 
Vulnerability itself is a complex and ambiguous concept. Although several 
influential national laws and international declarations concern special 
protection for vulnerable groups, such as racial minorities, ethnic minorities, or 
groups with disadvantaged economic and social resources,1 the specific aims of 
these documents did not focus on HPGR, so the definition and scope of 
vulnerability of these groups in this context has not been addressed.2 Despite the 
available codes of research ethics and regulations describing certain individuals 
and groups as vulnerable, little consensus exists on what this actually means, 
even in the context of human subject protection in medical research. 
The World Medical Association‘s Declaration of Helsinki (Helsinki Declaration),3 
for example, noted that ‗[s]ome research populations are particularly vulnerable 
and need special protection. These include those who cannot give or refuse 
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consent for themselves and those who may be vulnerable to coercion or undue 
influence.‘4 It also points out that ‗the particular needs of the economically and 
medically disadvantaged must be recognized.‘5 According to this explanation, 
the target groups of HPGR, ethnic minorities and isolated groups in developing 
countries, which often go hand in hand with limited social resources, poverty, 
low level of education, little familiarity with genetic research, and lack of 
access to health care, should be seen as vulnerable.  
Guideline 13 of the International Ethical Guidelines published by the Council of 
International Organizations of Medical Sciences (CIOMS) entitled ‗Research 
Involving Vulnerable Persons‘ noted that: ‗[s]pecial justification is required for 
inviting vulnerable individuals to serve as research subjects and, if they are 
selected, the means of protecting their rights and welfare must be strictly 
applied.‘ 6  The meaning of vulnerable people was also addressed in the 
commentary on this guideline as follows: ‗[v]ulnerable persons are those who are 
relatively (or absolutely) incapable of protecting their own interests. More 
formally, they may have insufficient power, intelligence, education, resources, 
strength, or other needed attributes to protect their own interests.‘ 7 It also 
listed several types of populations and individuals who could be seen as 
constituting vulnerable groups, including ‗some ethnic and racial minority 
groups‘.8 In addition, in the reference and commentary on Guideline 12 it was 
noted that: 
Not only may certain groups within a society be inappropriately 
overused as research subjects, but also entire communities or 
societies may be overused. This has been particularly likely to occur in 
countries or communities with insufficiently well developed systems 
for the protection of the rights and welfare of human research 
subjects. Such overuse is especially questionable when the 
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populations or communities concerned bear the burdens of 
participation in research but are extremely unlikely ever to enjoy the 
benefits of new knowledge and products developed as a result of the 
research.9 
Article 8 of the Universal Declaration on Bioethics and Human Rights,10 adopted 
by the United Nations Educational, Scientific and Cultural Organization (UNESCO), 
is entitled ‗Respect for human vulnerability and personal integrity‘. This article 
noted that:  
[I]n applying and advancing scientific knowledge, medical practice 
and associated technologies, human vulnerability should be taken into 
account. Individuals and groups of special vulnerability should be 
protected and the personal integrity of such individuals respected.11  
It can be seen from this Article that this declaration made a claim as to the 
necessity of special protection for vulnerable individuals and groups in 
biomedical research, but it did not explain the meaning and scope of human 
vulnerability.  
In addition to the international declarations and ethical guidelines above, some 
national laws or ethical guidelines also mention the vulnerability of certain 
groups. For example, the US National Commission‘s Belmont Report12 includes 
‗racial minorities, the economically disadvantaged, the very sick, and the 
institutionalized‘13 in their list of vulnerable populations. The Common Rule, the 
core of the US human subject protection regulation, did not define vulnerability, 
but it mentioned ‗economically or educationally disadvantaged persons‘ 14  as 
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vulnerable populations, which is a general characteristic of target groups of 
HPGR in developing countries. 
From the above, it can be seen that despite broad agreement that the 
vulnerable have a claim to special protection, the definition and scope of 
vulnerable persons or populations are not clear. In addition, the pattern of 
defining vulnerability in international declarations and ethical guidelines, or 
national legal regulations and ethical guidelines, is to focus on particular 
populations, for example prisoners, children, or ethnic minorities. This pattern 
has been criticized as it may lead to the implication that individuals who are 
members of these populations are inherently vulnerable in all types of 
biomedical research. For example, the National Bioethics Advisory Commission 
(NBAC) argued that ‗vulnerability is sensitive to context and individuals may be 
vulnerable in one situation but not in another.‘15 Thus, NBAC suggested that 
vulnerability should be defined in terms of situations in which individuals might 
be considered vulnerable, rather than in terms of groups or populations. The 
situation of the vulnerability of target groups in HPGR is similar. Ethnic 
minorities or groups which live in poverty or with fewer social resources may be 
categorized in international declarations and ethical guidelines as ‗vulnerable 
groups‘, but this does not prove that these groups are necessarily vulnerable in 
HPGR. The concept of the vulnerability of target groups in HPGR has been 
defined so broadly and inconsistently16 that it is tempting to conclude that it is 
incapable of providing any meaningful ethical guidance.  
Coleman has pointed out that the core of fully understanding vulnerability is 
determining the nature of the human subject‘s vulnerability — i.e., what are 
vulnerable human subjects actually vulnerable to?17 He argued that vulnerability 
should be linked to the basic principles that underlie society‘s regulation of 
human subject research, as reflected in regulatory standards and internationally 
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agreed-upon ethical guidelines. 18  According to this framework, a vulnerable 
person or group can be seen as an individual or a group at risk of being enrolled 
in research in violation of one or more of the interests defined by regulations 
and ethical guidelines. Vulnerability should be examined from three distinct 
perspectives — consent-based, risk-based, and justice-based. 19  Consent-based 
and risk-based vulnerabilities make more sense when conceptualized as 
individual issues, but justice-based vulnerabilities are hard to understand as 
anything other than a population-based concern.20 
There are several reasons to agree with this understanding of vulnerability in 
human subject research. Firstly, avoiding these three kinds of vulnerability is the 
baseline of permitting researchers and research institutions to invite human 
subjects to participate in their research, since their research may cause risks of 
harm to the participants without any compensating benefits, medical or 
otherwise. According to principles such as ‗respect for autonomy‘, ‗beneficence‘, 
and ‗justice‘, the following conditions should be fulfilled before conducting 
research: the IRB‘s or ethical REC‘s determination that the risks of the study are 
reasonable in relation to its total anticipated benefits (both direct benefits to 
subjects and potential long-term benefits to society), that the risks have been 
minimized to the extent reasonably possible, and that the subjects will be able 
to provide voluntary, informed consent. If an individual or a certain group is 
identified as vulnerable, their interests will be more susceptible to violation 
than those of other individuals or groups. Thus, in order to clarify the nature of 
vulnerability of target groups in HPGR, we should explore what are these groups 
vulnerable to from these three distinct aspects: consent-based, risk-based and 
justice-based. Secondly, the division of authority and responsibility between 
IRBs or RECs, research subjects and legislators within this framework is clear. It 
can be seen that the conditions mentioned above require human subjects to 
determine whether or not to participate in the research; meanwhile, IRBs or 
RECs should decide whether or not the risks of the study are reasonable in 
relation to its total anticipated benefits, as well as whether the risks have been 
minimized to the extent reasonably possible; then, the legislators stipulate the 
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legal requirements for the implementation of research subject‘s consent and the 
ethical review conducted by IRBs or RECs. Coleman has argued that the roles of 
individuals and IRBs or RECs are not well-balanced: 
At one extreme, we could let competent adults participate in any 
type of research, regardless of the study‘s objective risk-benefit ratio, 
on the theory that autonomous individuals have the right to take 
whatever risks they find personally acceptable. We do not have such a 
system: if the study does not offer a net social benefit, then the IRB is 
not supposed to approve it, even if a fully informed subject would be 
willing to participate. At the other extreme, we could require IRBs to 
determine that participating in research would be in the individual 
best interests of all the subjects in a study….21 
Neither of these two extreme situations is acceptable. As Coleman continues: 
‗we defer to individuals‘ choices to take research-related risks for idiosyncratic 
reasons — but only if they are genuinely capable of acting autonomously, and 
only if the risks are ―worth it‖ from a societal point of view.‘22  
As a result, a reasonable division of authority between ethical review agents and 
research participants should respect competent individual participants‘ decisions 
to participate in research, but only if the risks of harm are deemed reasonable in 
relation to the importance of the knowledge to be gained from a societal point 
of view. 
According to this framework, the risks to vulnerable individuals or groups can 
arise from different sources. First, consent-based vulnerabilities can create or 
exacerbate barriers to obtaining sufficiently informed consent to research, 
potentially violating the requirement that consent to the research risks be 
voluntary. Second, risk-based vulnerabilities may enhance the level of risks 
associated with subjects‘ participation in human subject research, thereby 
calling into question the study‘s underlying risk-benefit ratio. Finally, justice-
based vulnerabilities can raise concerns about the distribution of the benefits 
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and burdens of the research, and these distributional concerns may also be 
relevant to the risk-benefit analysis.23  
According to these concerns, it can be suggested that target groups of HPGR are 
vulnerable in respect of consent, benefit-risk assessment or exploitation, 
because of a low educational level, lack of economic and social resources, 
cultural sensitivities and an absence of effective and adequate legal regulations 
and ethical guidelines in most developing countries.  
3.1.1 Consent-based Vulnerability of Target Groups in HPGR 
Consent-based vulnerability refers to the diminished ability to protect one‘s own 
interests, leading to a compromised capacity to give sufficiently informed or 
voluntary consent. This diminished ability may render a particular individual or 
group more susceptible to impaired decision making, coercion or undue 
influence in research.  
In the context of HPGR, there are several factors which may lead to the consent-
based vulnerability of target groups. Target groups and their members may have 
difficulty giving valid consent and protecting their own interests and could thus 
be classed as vulnerable. 
HPGR aims to study isolated populations to find out the impact of their history 
on their genetic makeup, so target groups of HPGR are often located in isolated 
areas, where transportation is inconvenient; the members of target groups are 
relatively homogeneous with respect to ethnic group, environment, occupation, 
and diet, and the groups will have existed for several thousand years with a 
stable population. For example, Arizona State University (ASU) conducted 
several research projects on the Havasupai tribe, which is a small tribe 
numbering in the few hundred living in an isolated community in the Grand 
Canyon, accessible only by foot, mule, or helicopter.24 The Harvard University 
research in the Anhui province of the PRC was also conducted on isolated groups 
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in rural areas.25 It is quite normal that the members of target groups in HPGR are 
less-educated than the majority population and unfamiliar with the implications 
and possible consequences of genetic research. For instance, according to the 
Second National Agricultural Census by the National Bureau of Statistics of the 
PRC,26 at the end of 2006, the total of the rural labour force numbered 478,520 
persons, occupying 90.1 percent of the total labour force resources; however, 
among these rural labourers, 6.8% had no formal education, 49.5% had junior 
middle school education level and 32.7% had primary school education. 27  It 
showed that 89% of the population in the rural areas in the PRC have less than 9 
years of education. This low-educational situation might have a negative 
influence on their understanding of information disclosed and their evaluation of 
the potential risks of harm in HPGR.  
These groups or individuals may have limited health literacy and may not 
appropriately understand the exact meaning of sample collection procedures or 
the possible outcomes of the research project. For example, in 1984, a US 
physician, Dr. Arthur Bosley, who conducted medical research in developing 
countries, told of the dilemma he faced in the application of informed consent.28 
According to his report, in most developing countries, ‗the germ theory of 
disease causation is yet to be accepted, particularly among the not so-educated 
members of the population.‘ 29  What is more, most of the people in these 
countries thought that a blood test was a good thing, because ‗if your blood is 
good, then you are all right‘. Thus, if Dr. Bosley wished to invite patients 
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attending the clinic to undergo a blood test, they would consent readily.30 In 
addition, information about HPGR, including the risks involved, may be difficult 
to understand. The majority of members of target groups in HPGR may not be 
able to read and write. Even those who can read may not understand all the 
medical terms that such information is bound to contain. If the consent form is 
in a normal Western style, which often lists possible risks over multiple pages, 
but does not explain them in common terms or spell out the seriousness, 
probability, or consequences of each possible risk in simple terms, the difficulty 
can be exacerbated. If the target groups are in developing countries, whose 
members are not aware of the potential risks of harm of biomedical research, 
even if they agree to participate in it,31 these difficulties increase even further.  
Any decision whether or not to participate in scientific research that is based on 
incomplete understanding or misunderstanding of research information or on an 
inaccurate assessment of potential risks of harm is ethically and may be legally 
problematic. In fact, normal competent people sometimes do participate in 
research studies without a good understanding of the study purpose and risks, 
even in non-HPGR projects. Competent individuals may sometimes consent to 
research without fully understanding each sentence of the consent form; 
however, these individuals often have background knowledge on research, can 
realize the scope of risks roughly and are capable of making an appropriate 
evaluation of potential risks. Thus, they may be deemed capable of 
understanding the research information sufficiently. It could therefore be argued 
that understanding may be correlated with educational level32 but the person‘s 
social and cultural context will also play an important role.  
The members of target groups of HPGR may be less capable of understanding, 
and hence more vulnerable to impaired decision making, because of their lack of 
education, cultural orientation, or limited health and medical knowledge. In 
other words, target groups do not have the experience to weigh up the 
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advantages and disadvantages as they are unused to making these kinds of 
decisions. Target groups of HPGR and their members who do not understand 
what the purpose of HPGR is may not know what they are actually consenting to 
and may misunderstand or not realize the risks of participation. Thus, they are 
vulnerable when making a decision on whether or not to participate in HPGR. 
Therefore, explanations with adequate accuracy and articulation, easily 
understood by people with a low level of education, are essential requirements 
both for the ethical conduct of this type of biomedical research and for the 
protection of subjects‘ interests. In the context of HPGR, as in any other 
research, the burden is on the researchers and research institutions to inform 
individuals in a way that ensures that the target groups and their members can 
appreciate the risks and requirements of participation while minimizing the 
possible impact of educational or cultural barriers that may distort 
understanding.  
The second possible type of consent-based vulnerability is that if medical 
services, or other goods are offered in connection with participating in an HPGR, 
these may be so attractive that members of target groups, especially with 
limited economic and social resources, will irrationally disregard the risks and 
requirements of the research. These attractive offers are referred to as ‗undue 
inducements‘ in biomedical research. According to Emanuel, there are four 
elements to undue inducement, and each of these four elements is necessary for 
undue inducement to exist:  
(1) An Offered Good—Individuals are offered something that is 
valuable or desirable in order to do something. (2) Excessive Offer—
The offered good must be so large or in excess that it is irresistible in 
the context. (3) Poor Judgment—The offer leads individuals to 
exercise poor judgment in an important decision. (4) Risk of Serious 
Harm—The individual‘s poor judgment leads to sufficiently high 
probability that he or she will experience a harm that seriously 
contravenes his or her interests.33 
According to this account, it could be argued that HPGR may only offer some 
free common medicine or access to limited primary healthcare treatment, which 
can be seen as normal compensation for research participation and would not 
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lead to the undue influence of potential participants. In fact, just as happened 
in the Harvard project in China, in order to recruit participants from rural areas 
of developing countries, researchers might seek to provide some medical 
services or standing drugs for free. In 2001, Outlook Weekly published a survey 
on the Harvard case, describing one of the participants, Chu Mianzhai, whose 
whole family had twice taken these kind of free ‗physical examinations‘, given 
blood samples and received a little money as compensation for loss of working 
time, as well as two packages of instant noodles.34 The first time, on 5 November 
1996, the family gave a blood sample for which they were given 10 Yuan each as 
compensation. The second time, on 10 March 1997, they gave more blood and 
were given 20 Yuan each. Chu also received a bottle of medicine for his high 
blood pressure. A similar situation also arose in the case of Havasupai. In this 
case, taking part in the research would result in access to some free summer 
school for students from the Tribe.35 Thus, the question arises whether target 
groups of HPGR should be considered vulnerable to undue inducement if such 
benefits were offered. 
An example, provided by McGregor, of an impecunious mother with a very sick 
child and a lecherous millionaire can illustrate that whether or not something is 
an undue inducement should be decided by the specific situation of the subject, 
although the example is not in the context of research: 
The millionaire proposes to the impecunious mother that he will pay 
for the medical treatment that her child needs if she will become his 
mistress.36 
This hypothetical situation satisfies the first element of undue inducement: an 
irresistible offer. The offer to fund the treatment of a very sick child is not an 
excessive one for a millionaire, but it is an irresistible one for the child‘s mother, 
given her inability to pay for the treatment. Poor judgement is less obvious, 
because from the perspective of the child‘s welfare, accepting the offer is 
reasonable, but on the other hand, accepting unwanted sexual interactions 
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would generally not be seen as reasonable. To some extent, whether or not this 
leads to a serious harm would be decided by the subject‘s circumstances and 
values (for example, if the mother here was a prostitute, she might think this 
exchange is not a serious harm).37 Thus, undue inducement would occur where 
an attractive offer distorts the individual‘s ability to make rational decisions for 
himself or herself, according to their own values and preferences. Such offers 
may be especially irresistible to those individuals who lack economic and social 
resources. That is to say, the main concern of undue inducement is that 
individuals are offered some good that, effectively without reference to their 
better judgement, makes them assume risks of harm that compromise their 
welfare.38 
In the context of HPGR, considering the level of economic development and 
actual living conditions of most target groups, their members may be vulnerable 
in the face of what may appear to others to be small and reasonable offers. 
Indeed, HPGR conducted in some developing countries may offer payments or 
primary healthcare service to the Western standard as part of research 
participation, such as free health care or other benefits such as free housing, etc.  
However, these offers could be enticing enough to impair decision making, such 
that members of target groups participate in HPGR disregarding risks or not 
giving risks appropriate weight in the decision-making process. In the Harvard 
case, an individual participant Chu and his family lived in Toutuo, an 
impoverished village in Yuexi district with an average yearly wage of less than 
2,000 yuan.39 Thus, although 10 Yuan or 20 Yuan can be seen as a small sum and 
normal compensation in medical research, compared to the low annual wages of 
target group members in HPGR, the compensation offered might amount to an 
undue influence. 
From the above case, we can appreciate that seemingly simple offers could be a 
decision-impairing inducement rendering members of target groups in HPGR 
incapable of appropriately considering research risks. In this situation, they have 
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fulfilled the definition of CIOMS that they are ‗relatively or absolutely incapable 
of protecting their own interests.‘40 
In addition, there are also other concerns about the potential vulnerability of 
target groups of HPGR, especially in developing countries, such as the PRC. In 
China, medical care in each county is administered through a three-tier (county, 
township, village) service network, which was established a quarter of a century 
ago to provide medical services for all residents.41 It is quite convenient and 
efficient to conduct biomedical research through collaboration with this medical 
care service network. Meanwhile, in pursuing a better future for their personal 
career, some physicians in developing countries like to conduct collaborative 
HPGR with Western research institutions. In these HPGRs, they may dispatch 
personnel to be trained in foreign research institutions, experience how foreign 
researchers conduct HPGR and even publish co-authored journal articles. 42 
However, these physicians are also practitioners in the health service network of 
the country; thus, they are relied on by the local people. HPGR conducted by 
these local physicians may provide a misconception to members of target groups 
of HPGR that the project is risk-free and might be good for their health. This 
situation would exacerbate the consent-based vulnerability of target groups of 
HPGR and there might be a risk of undue influence if local doctors encourage 
participation.  
3.1.2 Risk-based Vulnerability of Target Groups in HPGR 
Risk-based vulnerability refers to a situation where the risks to subjects are not 
reasonable, compared to the potential benefits of the research. According to 
Coleman, risk-based vulnerability may be ‗jeopardized if some subjects are at 
risk of greater than usual harms from participating in research.‘43 For example, if 
the primary risk of an HPGR is the potential disclosure of the genetic evidence of 
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the origin of ethnic or isolated group, the target group can be considered 
vulnerable if it has its own narrative origin stories which have been believed to 
be the foundation of its collective identity.  
In general, IRBs or RECs should address risk-based vulnerability and require 
additional safeguards to protect the subjects‘ interests. In the context of HPGR, 
however, the situation is more complicated. As discussed in Chapter 2, the 
potential risks of harm caused by HPGR include external harms, such as group 
discrimination and group stigmatizations as well as internal harms, such as group 
self-conception of genetic determinism and self-stigmatization. External harms 
might perhaps be assessed by IRBs or RECs, although they are not usually 
required to do so, but internal harms, which are specific to an ethnic or isolated 
group, are difficult to identify correctly by any agent outside of the specific 
group. Foster, Sharp et al provided an example from the Indian Health Service 
(IHS) Headquarters IRB, which can illustrate this point. 
… the Indian Health Service (IHS) Headquarters IRB has 28 members, 
20 of whom are Native Americans (including MD- and PhD-level 
researchers, health professionals, and laypersons from Native 
communities). Despite its unique composition, however, the IHS IRB 
sometimes is unable to predict what a specific Native community 
views as the primary risks to itself. Two recent examples include 
worries about the use of genetic research into migration history to 
attack tribal sovereignty and concerns about the use of mitochondrial 
DNA and Y chromosome research in claims about who is or is not 
‗Indian.‘ These risks were identified only by community review, not by 
any IRB.44 
In this case, the HIS IRB included many American Indian and American Native 
(AI/AN) members, which reflected the IRB‘s regard for the sensitivity of 
indigenous communities. However, even here there have been instances where 
the IHS IRB has failed to identify potential risks of internal group harms that 
were of concern to members of the target population, such as culturally specific 
harms. The reason why the IHS IRB, with its unique composition and wide range 
of experiences with AI/AN communities, failed to identify such potential risks 
may include following two aspects: firstly, the members from certain target 
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groups often fully understand their socio-cultural traditions, but they may lack 
sufficient knowledge on biomedical research and sufficient training on the 
proper conduct of ethical review. Secondly, ordinary IRBs or RECs members, due 
to deficiency in knowledge of cultural background of target groups, could not 
correctly identify potential the potential risks of internal group harms or give 
them sufficient weight. Therefore, unless IRBs include target group 
representatives with appropriate training on ethical review, and there is 
sufficient community consultation and investigation of group cultural sensitivity, 
IRBs may be unable to assess these potential risks correctly. 
The absence of sufficient understanding of the cultural sensitivities of target 
groups by researchers may also lead to a failure to address these risks of harm in 
their research protocol or not providing adequate information disclosure on 
these risks. For example, in the Havasupai Indian Tribe case,45 ASU researchers 
collected more than 200 blood samples from tribe members for research on 
diabetes and genetics in 1990. The consent form described the project as 
studying ‗the causes of behavioural/medical disorders,‘ 46 but in the pre-research 
communications with tribal leaders, it was agreed that the samples should be 
used in research focused on diabetes. However, the researchers used the 
samples in several other research projects unrelated to diabetes, sharing them 
with other researchers, and publishing several articles based on data from tribal 
members‘ blood samples. 47  Among these research publications, ‗some of the 
papers generated from the blood samples dealt with schizophrenia, inbreeding 
and theories about ancient human population migrations from Asia to North 
America.‘48 The focus on schizophrenia raised stigmatization issues for the tribe 
along with concerns related to a cultural belief that inbreeding brings harm to 
one‘s family. Furthermore, evolutionary-genetics research suggested that, 
contrary to the tribe‘s own origin story, its ancestors migrated across the Bering 
Sea, creating the possibility of cultural harms.49 Although the core legal question 
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of the Havasupai case was whether the downstream uses of the samples fell 
within the scope of the donors‘ informed consent, it also illustrates that the 
unique cultural beliefs of a target group might be a barrier to researchers and 
IRBs or RECs actually identifying potential risks of harm that may be caused by 
research to target groups and their members. It also implied the responsibility of 
researchers to ensure that the study population‘s perspectives are understood 
and considered. Thus, isolation and specific cultural sensitivities can increase 
the risk-based vulnerability of target groups in HPGR. 
3.1.3 Justice-based Vulnerability of Target Groups in HPGR 
This kind of vulnerability concerns the violation of the principle of justice in 
research ethics. The concern that target groups of HPGR are particularly 
vulnerable to exploitation is a consideration of justice-based vulnerability. 
Exploitation is a complex concept which has been explained in several different 
ways. Generally, there are two elements considered to be essential to 
exploitation: (1) using people as mere means for the ends of others (a Kantian 
sense of exploitation) 50 and/or (2) taking unfair advantage of people.51 Thus, 
exploitation usually occurs ‗when wealthy or powerful individuals or agencies 
take advantage of the poverty, powerlessness, or dependency of others by using 
the latter to serve their own ends (those of the wealthy or powerful) without 
adequate compensating benefits for the less powerful or disadvantaged 
individuals or groups.‘52 
In the context of HPGR, target groups who are usually poor, less-educated and 
lacking social and economic resources, may not understand that they might be 
used as means to others‘ ends, or might agree to participate in an exchange 
without realizing its inherent unfairness. As noted previously, researchers or 
research institutions may provide some free primary drugs or simple treatment 
in exchange for the genetic samples and consent forms signed by participants. 
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These participants may not even realize that the outcome of the research may 
not benefit them and will have no (positive) meaning for them. Thus, they are 
likely to become ‗mere means‘ of HPGR. This could lead to justice-based 
vulnerability in this situation as they cannot realize they might be exploited by 
others. Identifying whether or not researchers are in fact taking unfair 
advantage of target groups in HPGR is more complex. The core issue here is to 
assess whether the level of benefit which the researchers or research institutions 
will get is fair or unfair. Exploitation would be identified if benefits are unfair, 
and would not require the existence of actual harm to have occurred. 
In addition, the isolated locations raise another possible source of vulnerability 
for target groups of HPGR. They have rare opportunities to get the offers 
provided by HPGR researchers, such as free primary healthcare services, 
common drugs or trivial amounts of cash. Fewer choices and limited bargaining 
power may exacerbate the justice-based vulnerability of target groups in HPGR. 
For example, a research institution affiliated to a university, such as the 
research organization in the Harvard case in China, could offer several summer 
course places to students of ethnic minorities or isolated groups in rural areas in 
developing countries in exchange for 1,000 genetic samples and signed consent 
forms from these groups. Although this offer costs only a trivial amount for the 
research institution, it could be immensely attractive to target groups, because 
without this offer they will have no other such opportunity. Thus, target groups 
probably feel that they have to take this offer. Meanwhile, compared to the risks 
of harm, such as the internal and external harms that may be caused by HPGR 
that I have discussed in Chapter 2, several summer course places may be 
perceived as an inadequate benefit. Therefore, target groups of HPGR might be 
considered to have been exploited if they accept this offer.  
On the other hand, some might argue that although from the perspective of a 
neutral observer, this offer is inadequate, nevertheless, for target groups, 
several summer course places at a top university could be a reasonable 
recompense for their participation in HPGR. To those target groups, even this 
arguably unfair benefit is an option that could let several students of these 
groups gain further education. Thus, they may question whether these target 
groups are being exploited. The following example can illustrate why to use the 
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viewpoint of the vulnerable groups as the standard of fairness is problematic. If 
a rich man from a developed country offers an extremely poor man a substantial 
payoff to induce this poor man to be her/his slave, this substantial payoff could 
help the poor man to afford to give his whole family a better life. He has no 
alternative way to gain a better life for his family. However, this substantial 
payoff actually is trivial to the rich man; and to be a slave is a violation of 
primary human rights. Thus, this is obvious exploitation. Therefore, it requires a 
neutral standard of fairness to be used as a tool for distinguishing between fair 
and unfair benefits, thereby protecting vulnerable parties from exploitation. In 
the context of HPGR, the objective baseline of fairness should be drawn by the 
ethical review committees with the involvement of target group representatives, 
based on the specific economic and cultural context of certain target groups. 
Without a neutral standard of fairness, target groups may be vulnerable to 
exploitation in HPGR. 
The justice-based vulnerability of target groups in HPGR is also relevant to the 
background conditions in the developing countries where the HPGR is conducted. 
The background conditions include lack of effective legal regulations and ethical 
guidelines on human subject protection together with poor law enforcement, 
inadequate experience of or capacity for conducting ethical and scientific 
review of proposed research; poor local infrastructure; untrained personnel and 
limited technical capacity for conducting the proposed research itself. Most 
developing countries have no stringent rules on the basic requirements of 
research involving human subjects, such as informed consent or the welfare of 
human subjects, not to mention effective legal regulations and ethical guidelines 
on human subject research. This situation has led to several troubling examples 
of research trials in developing countries. For example, the Pfizer incident in 
Nigeria during an epidemic of meningitis in children in 1996 illustrates these 
issues, although it involved clinical research, rather than HPGR. Pfizer, an 
American multinational pharmaceutical company, conducted a trial of an 
antibiotic at the site of the outbreak of a meningitis epidemic in the northern 
state of Kano, where 15,000 people were alleged to have died from these 
epidemics. Kano is a typical poor area in a developing country, so even the Kano 
Infectious Diseases Hospital, where the trials took place, was reported to be at 
the time a poor, dirty hospital with few beds, poor power supply, and no clean 
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water. Pfizer conducted the clinical trials in Kano to investigate whether the 
oral form of Trovan was more effective and efficient in treating children 
infected with meningitis than other existing treatments, including Ceftrixacone, 
the gold standard treatment. Pfizer‘s Trovan had not been previously tested in 
children. However, about 200 infected children participated in the Kano trials. 
100 of the children took Trovan while another 100 were put on Ceftrixacone. 11 
died in the trials, 5 of whom were on the experimental drug, Trovan, given 
orally, while the other 6 were on injections of Cetrifaxone. There were also 
other children involved in the trials who suffered seizures, or became paralysed. 
While there is no evidence that Trovan was responsible for the deaths and 
injuries to children, the trials were conducted within a period of two weeks and 
Pfizer left immediately thereafter. 53  This case was first publicised by the 
Washington Post in an investigative article on the conduct of clinical trials by 
developed country researchers in developing countries. According to the report, 
there was no informed consent, no follow-up of the children after conclusion of 
the trial and no parents of the children had been adequately informed about the 
trial. What is more, there was no approval of the research protocol by an 
independent ethics review committee - there was no ethics committee in the 
hospital at the time of the trial.54 There were no legal regulations or ethical 
guidelines in Nigeria at the time of the trial requiring Pfizer to obtain any such 
approval. When charges of unethical conduct were made, Pfizer alleged that 
apart from the goals of obtaining information about the efficacy of the drugs, 
‗another major reason for conducting the trials was to provide humanitarian 
services to the infected victims who were obviously in need of medical 
assistance at the time.‘55  
This case highlights the common situation of lack of effective legislation and 
regulations on biomedical research governance and human subject protection in 
developing countries. 56  It has been suggested that researchers and research 
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institutions have all too often defended their apparent double standards of 
research ethics in research conducted in developing countries. On the one hand, 
they apply a higher standard of research ethics in their own countries according 
to the relevant legal regulations and ethical guidelines, as well as undertaking 
strict implementation of those rules. On the other hand, these researchers and 
research institutions have proposed and accepted a less demanding standard of 
research ethics in developing countries, where effective and adequate legal 
regulations and ethical guidelines on human subject protection is lacking.57 They 
may also argue that they have offered participants free physical tests - even free 
treatments such as drugs, - which are needed by these participants and would 
benefit them. However, it can be argued that those researchers and research 
institutions take unfair advantage of their richness in economic and social terms. 
Accordingly, Macklin suggests that whole communities or countries may be 
vulnerable to exploitation, particularly if ‗investigators or sponsors are from a 
powerful industrialized country or a giant pharmaceutical company and the 
research is conducted in a developing country.‘ 58  Therefore, the absence of 
specific regulations and standards for HPGR together with poor law enforcement 
in most developing countries make target groups of HPGR particularly open to 
justice-based vulnerability. 
Consequently, what is significant to note about HPGR in developing countries, is 
that even if the relational autonomy model is applied, which lets individual 
participants take into account the interests of the group and other group 
members when considering whether to consent to participate, given the 
vulnerability of target groups stated above, it is possible that this would not be 
sufficient to take account of the need to protect all of those who had interests 
at stake. Thus, it is reasonable to suggest that additional protection for target 
groups in HPGR, such as the involvement of the target group as a whole in some 
way, is needed. Nevertheless, it also needs to be reiterated that arguing for 
group involvement in review of HPGR does not mean advocating group consent 
instead of individual consent. The following section will nevertheless propose 
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that the target group, or representatives of it, should and could be involved in 
the protection of the group‘s interests. 
3.2 Justifications for Protection of Groups in HPGR 
3.2.1 Critiques of Group Protection in HPGR 
The suggestion that the group as a whole should be protected in HPGR has been 
criticized, since some researchers have doubted that HPGR may lead to potential 
harms for the group as a whole. They have argued that the actual human groups 
under study, human demes, are unidentifiable before research begins, since it is 
only when genetic relationships have been established as a result of the HPGR 
study that such a group can be said to exist,59 thus, there is no group collective 
interest to be harmed in HPGR. Furthermore, the idea of a group as a rights-
holder has been met with scepticism or outright rejection by some researchers, 
ethicists, and legal scholars. The opponents of group protection in HPGR have 
argued that it is hollow rhetoric to set up a group as an independent entity to be 
protected from the risks of harm in HPGR.60 Their arguments almost always focus 
on the argument that groups lack moral standing and that seeking to obtain prior 
group permission is not possible in HPGR. 
To explain these criticisms in more detail, Juengst argues that there are two 
different understandings of a group in HPGR. Firstly, the term ‗target groups‘ in 
HPGR refers to genetic populations or human demes: in his opinion, this type of 
group has no moral standing and cannot be approached for group consent or 
group permission, since these groups are unidentifiable until the research itself 
has been conducted.61 Human demes or genetic populations are groups which are 
‗picked out, described, and compared in the course of population-genomics 
research‘;62 thus, they are not identical with named social groups which might 
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perhaps deserve respect as an independent entity. Since they are the nameless 
demes which are created by researchers of genetic research, as well as ‗the 
results of mixed lineages that make hash of most of our familial origin stories 
and social groupings,‘ 63  Juengst considers that these human demes are ‗not 
autonomous, self-identified human groups, and it would be dangerous to devise 
a system that suggested that demes should be invested with special social value 
or identity.‘64  Juengst goes on to state that: 
…. given our species‘ long history of using putative genetic 
relationships as the basis for nepotism, tribalism, racism, and 
aggression, aspiring to invest human demes with special moral 
standing seems wrong-headed in the first place. If we are right in our 
convictions that our biological roots should be irrelevant to the ways 
in which humans regard each other, promoting our demes as groups 
with interests of their own makes no more sense than reviving old 
eugenic attempts to reify the concepts of ‗race,‘ ‗genetic stock,‘ or 
‗germ plasm.‘ 65  
He concluded that the genetic concept of a human group should just be a tool 
that helps in organizing scientific data in HPGR, but not a way of classifying the 
members of the human species.66 Thus, if a human deme does indeed mean the 
same as the target group of HPGR, there is neither moral standing of group 
collective interests, nor would seeking group consent or group approval in HPGR 
be possible or necessary. 
Secondly, even if the group refers to self-identified groups, morally authoritative 
social groups, then in most cases we could approach them for permission; 
however, Juengst insists that group permission in HPGR has its internal 
limitations. In the first place, the problem of how to define the group still exists, 
which has also been described as the ‗nesting‘ of local and larger communities. 
The example of the Mohawk,67 provided by Sharp and Foster, can illustrate this 
problem well. In the United States and Canada, individuals who consider 
themselves Mohawk may have distinct understandings on what a Mohawk 
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community consists of. Some may base this understanding on factors such as 
whether members reside in a discrete local community, located on a single 
reservation. However, several of these reservation-based communities define 
themselves collectively, for example as ‗a part of the League of Iroquois, a 
political and religious organization comprised of six culturally related American 
Indian communities‘.68 Thus, they argued that nesting all the members of a self-
identified group is a hard obstacle. Sharp and Foster warned that ‗the nesting 
problem results from the possibility that the concerns of local communities may 
fail to correspond with those of communities at broader levels of 
inclusiveness.‘69 Juengst argues that the practice of nesting local groups within 
larger social categories, as well as cross-cultural immigration, would lead to 
group consent not having the moral reach to decide for potential participants in 
HPGR.70 He also points out that there are resource issues if groups are seen as 
the right-holders: 
Accepting them [groups as right-holders] would significantly 
complicate the work of population genomicists. If groups have 
interests that require protections like those of individual subjects, a 
layer of research arrangements would be necessary that our 
individually-oriented biomedical research ethic is ill-prepared to 
define or delimit. What would it mean for a group‘s collective 
permission to be ‗informed‘ and ‗voluntary‘? If group consent is 
required, are other protections, such as the right to withdraw from 
research, or to confidentiality, also important for groups? How should 
the ‗researcher-group‘ relationship be managed administratively? 
Moreover, if the logic behind the argument for group rights in 
population-genomics research is accepted, it is likely to be applied to 
other biomedical spheres as well. 71 
Sharp and Foster described the costs and demands on researchers when formal 
community approval is required to indicate the same point. 72  They further 
argued that the practice of group consent is also problematic. They summarized 
this in terms of ‗the dispersion of community‘: 
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A related objection to group consent, one that also can be extended 
to other forms of community review, notes how features of a study 
population‘s geographical distribution can undermine the 
effectiveness of involving communities in the review process. It has 
been argued that the dispersion of individual members and the lack of 
frequent social interactions between members of a study population 
combine to limit the effectiveness of community review.73 
Using these reasons, the opponents of group protection in HPGR have suggested 
that there is no group collective interest that needs to be protected from the 
risks of harm in HPGR, nor could group consent be reasonably obtained and any 
purported group consent would lack moral and legal validity. 
3.2.2 Perspective on Groups as Right-holders 
On the other hand, with respect to target groups of HPGR, there are several 
scholars who consider that a group should be seen as a right-holder in HPGR. 
First, in HPGR, the effect on individual‘s purely private interests, which are the 
most significant potential risks of harm in other types of genetic research, could 
be protected by anonymising samples. However, the wider risks of harm that 
may arise from HPGR, such as stigmatisation of groups, as has been discussed, 
can only threaten individual participants‘ welfare through their group 
identities. 74  Thus, the advocates of group protection support their argument 
from the necessity of respect for group identity. For example, Gostin argues that: 
The importance of group identity, and of treating social communities 
with dignity and respect, is increasingly well recognized. Human 
beings gain security, happiness, and enjoyment by forming networks 
based upon their special national or sub-national characteristics. 
Respect and beneficence for populations requires researchers to 
observe choices made by local communities, and to avoid any activity 
which stigmatizes, demeans, harms, or disintegrates human 
populations, intentionally or inadvertently.75 
In addition, as has been discussed in Chapter 2, members of target groups of 
HPGR tend to identify themselves through and with certain groups to which they 
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belong, and not as isolated existential individuals. Therefore, members of target 
groups in HPGR are more likely to largely accept their group‘s values and 
priorities as their own, and accordingly they tend to be protective of their 
group‘s interests as reflective of their own interests. This tendency seems to 
support the practice of interests of group as a whole should be considered in 
HPGR by both researchers and ethical review committees. 
Secondly, it has been morally and legally accepted that certain human groups 
can practice collective decision-making. Even those who envision human groups 
as simply free associations of atomistic contractors have to recognize the moral 
authority of many kinds of groups to make collective decisions about the best 
interests of their members.76 For example, Sanders points out that: 
Group organizations have a particular legitimacy or standing to assert 
rights on behalf of their members, which gives them certain 
advantages over individuals seeking redress for rights violations. They 
are the best bodies to seek affirmative action programs, initiate test-
case litigation, handle educational programs, engage with the media, 
lobby governments, and choose spokespeople for the group.77 
In fact, as the proponents of group protection further argue, the concept of 
autonomy, or self-governance, which is widely accepted and adopted by 
international human rights declarations, such as The United Nations 
International Covenant on Civil and Political Rights,78 in defence of individual 
freedom, has its roots in efforts to protect the ability of particular human groups 
to govern themselves.79 For example, Michael McDonald supports the community 
as an independent entity of value in this way: 
What the liberal takes as basic and unquestionable is the idea that the 
individual is the measure of everything; hence, the liberal believes 
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that correct normative principles treat the individual as the 
fundamental unit of value….Individuals are regarded as valuable 
because they are choosers and have interests. But so also do 
communities make choices and have values. Why not then treat 
communities as fundamental units of value...?80 
Many scholars would agree that if we do not let groups be the entity to make 
decisions on issues related to group identity, it would undermine both the 
integrity and the autonomy of those groups that enjoy the moral standing to 
make such decisions. 81  For example, Underkuffler points out that on both a 
theoretical and a practical level, the assumed anti-group bias in the Western 
tradition is fraught with weaknesses. She illustrated that all of the negative 
assertions about group collective interests and rights in Western ethics are based 
on the proposition that ‗all moral value is rooted in the well-being of individual 
human beings.‘ 82  Thus, she argues that if one accepts the moral value of 
distinctly collective interests, the group collective interests would have their 
own moral value as well. On this view, it is normal to entitle a group to be an 
independent right holder to ‗protect distinctly collective interests, such as 
larger societal recognition and respect for the group‘s decision-making 
mechanisms, rights, and powers.‘83 She further argues that:  
From the point of view of what rights do, there is no structural reason 
why legal rights – which guarantee particular states of affairs in law – 
cannot be afforded to groups as well as to individuals. Indeed, the 
idea that Western jurisprudence shuns group rights is, itself, an 
obvious conceptual fallacy. In international law, governments – which 
recognize and enforce individual rights – are themselves groups with 
recognized legal status. In addition, groups of all kinds are recognized 
in a myriad of circumstances. Binding international agreements and 
non-binding international declarations recognize group rights in the 
contexts of cultural property, education, religion, and genocide. 
National, ethnic, religious, and linguistic minorities, as well as 
indigenous peoples, are afforded group rights.84 
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Using this argument, the justification for group collective rights in international 
law seems strong. 
3.2.3 Justifications for Protection of Groups in HPGR 
In the first place, in respect of Juengst‘s first problem, which is that target 
groups of HPGR refer either to human demes or social identified groups, it is 
clear that the target groups will already have been identified by the researchers 
in the context of HPGR. As has already been said, they are almost always ethnic 
minorities or isolated groups in rural areas of developing countries, whose 
members share the same community or group collective human genetic 
information. Even if the result of a particular research project is that the target 
group is not in fact a group given their genetic makeup, this in itself could also 
lead to cultural harms to the target group, as was discussed in Chapter 2. Hence, 
nesting problems cannot be an argument against offering protection to groups in 
HPGR.  
Indeed, a great many arguments and supporting evidence can be found to 
provide a justification for group collective rights in international law and human 
rights law. For example, Article 1 of The United Nation International Covenant 
on Civil and Political Rights85 stated that:  
All peoples have the right of self-determination. By virtue of that 
right they freely determine their political status and freely pursue 
their economic, social and cultural development.86 
No matter how ‗peoples‘ are defined, they must be collectives consisting of 
more than one individual. There are also examples, such as the U.N.‘s nation-
building efforts in East Timor and other countries‘ recognition of East Timor as a 
sovereign nation, which can illustrate that the U.N. and other countries regard 
self-determination as a right belonging to an abstract ‗East Timorese people,‘ 
which is a group as a whole.87 In this case, self-determination is regarded as a 
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collective right independent of the rights of any individuals who make up this 
group, so the right of self-determination was implemented in good faith for the 
benefit of this abstract group. Since the right belonged to an abstract group 
above and beyond any of its individual members, the implementation of the self-
determination right was not a matter that was determined by reference to any 
of the individuals, but rather to the abstract group. Thus, although not each 
individual of East Timor voted to be part of a sovereign nation, according to the 
collective ideas of the group, East Timor became a sovereign nation.  
Additionally, in the context of medical law, there are also arguments concerning 
collective human rights to public health which have been used to advance health 
rights in a globalized world. For example, Meier pointed out that although The 
United Nations International Covenant on Economic, Social and Cultural Rights 
(ICESCR)88 endorsed the right to health and declared the obligation of states to 
provide the ‗highest attainable standard‘ of health for all, 89  this highest 
attainable standard is for each individual, while the ‗right to health has been 
ineffective in compelling states to address burgeoning inequalities in underlying 
determinants of health, focusing on individual medical treatments at the 
expense of public health systems.‘90 Distinct from individual human rights that 
need to be enforced by personal action, collective rights operate at a societal 
level, considering the well-being of the whole public, which can only be enjoyed 
by the whole society of people and cannot be fulfilled solely through individual 
rights mechanisms.91 According to Meier, collective health rights could be a new 
type of independent human right, which would mean that the abstract society or 
state, not each individual, would be the right holder. 
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Thirdly, proponents of group protection also argue that there are real interests 
at stake for human groups in HPGR. This issue has already been addressed, but it 
is worth reconsidering here. Edlin has explained that some genetic 
epidemiological research may lead to risks of harm to participants and their 
group members. Such research, aimed at identifying genes associated with 
disease, for example, may find that a certain group carries a relatively greater 
genetic propensity for alcoholism. This may be interpreted as universally 
predictive for the group, which could lead to further harms, such as 
discrimination, stigmatization and even self-stigmatization. 92  What is more, 
Sawyer and Hartl have argued that most HPGR, such as the comparative 
genealogical efforts of the molecular anthropologists, would pose significant 
risks to groups. According to them, the genetic differences that most 
contemporary molecular anthropologists use to assess the relatedness of human 
groups consist of medically irrelevant molecular variations in the non-coding 
regions of the DNA, which are then compared to the DNA for functional genes. 
Single mutations are quick to accumulate and can be used quite precisely to 
establish ancestries. 93 Identifying these genomic hallmarks of particular groups 
would produce more sensitive gene-based tools for identifying members of 
target groups, which may raise the risks of the harm of racism or discrimination. 
Moreover, Tsosie also illustrated this point by the example of the Havasupai 
Tribe, referred to earlier: 
...in a case brought by the Havasupai Tribe and its members over the 
use of blood samples, handprints, and genealogy information initially 
taken by researchers at Arizona State University for a diabetes project. 
These materials were then allegedly used by researchers at ASU and 
other institutions for a multitude of unauthorized purposes, including 
research into the frequency of mental health disorders and the origin 
of human populations. Consequently, the affected members sued for 
damages under several legal theories. However, underlying all of 
these claims was the allegation that this unauthorized use of genetic 
resources and data not only injured the individuals who gave samples, 
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but also caused a collective harm to the Havasupai Tribe and the 
cultural and spiritual beliefs of its members.94 
She further pointed out that most of the concerns about biotechnology raised by 
indigenous peoples should be regarded as ‗cultural claims‘ that rest on a concept 
of ‗cultural rights.‘ Although the standard model used to evaluate cultural 
claims suggests that ‗such rights ought to be adjudicated within pluralistic 
societies according to a secular model of rights that respects individual claims to 
autonomy, equality, and liberty,‘ in certain situations, ‗special‘ rights for 
particular groups to ensure their equal treatment in society can also be 
accepted. 95  According to her, HPGR is one of those special situations that 
deserve the recognition of group rights. 
Nevertheless, there remain significant problems in suggesting that target groups 
of HPGR should be deemed to be rights holders in a legal sense. In fact, it would 
be difficult to regard a target group as a rights holder, even if they could be 
identified for a specific HPGR project. As Hartney noted that  
… not all goods (or interest) generate rights ... Goods (or interests) 
may generate duties (e.g., of protection) but these duties do not 
correlate with rights, unless there is some specific moral reason for 
protecting these good. There is an importance deference here 
between legal and moral rights. In order to determine whether a 
certain legal rights exists, one determines first whether the law has 
imposed a legal duty on someone, and then whether that duty can be 
interpreted as owed to somebody; since the law can create duties for 
all sorts of reasons, including relatively unimportant, and the 
importance of this thing or of the reason for the legal duty do not tell 
us whether there is a right to it. On the other hand, a moral right 
implies a good (or interest) sufficiently important that it warrants 
protection by duties on others. Thus, there are no unimportant moral 
duties, and an estimate of the importance of the good or interest in 
question is central to the determination of the existence of a moral 
right. We have all sorts of legal rights which do not correlate with any 
moral right.96 
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This statement indicated that there is a difference between recognising a group 
as a legal entity, such as East Timorese mentioned above, and recognising that a 
group have interests that can be harmed. In the context of HPGR, undoubtedly a 
target group may have interests, as they may be harmed, but it does not 
indicate that target groups should be the right holders. In HPGR, it is difficult to 
argue how a target group could hold rights or enforce them in the context of 
HPGR. Therefore, it can only be suggested that the interests of target groups 
should be taken into account and need protection in HPGR. 
Furthermore, the idea, that a group could be the holder of a legally enforceable 
right to decide whether HPGR  can proceed, would not least face the dilemma of 
creating conflicts between individuals and groups, whether it were to give the 
group a right of veto to research proceeding, or to allow group consent to 
override individual refusal of consent. Doing so would challenge the baseline of 
respect for fundamental individual rights. Despite this, it is reasonable to argue 
that issues relevant to collective interests should and could be considered in 
HPGR, even though a group or community approval of HPGR could not be a 
substitute for the decisions made by individual members. Accordingly it needs to 
be emphasized that group consent is not the only way to recognise the concept 
of group/community interests in HPGR. As will be proposed in more detail later, 
the recognition of the possibility of group harms might be achieved in a number 
of alternative ways. These would include group involvement in the design and 
review of research before individuals are asked to participate, taking group 
collective views into account by IRBs/RECs, asking representatives of target 
groups to be involved in the ethical review process and subsequent monitoring of 
the research and providing them with appropriate training and support to enable 
them to do so effectively.   
3.3 Protection of Groups in HPGR 
3.3.1 Protection of Groups 
At present, most guidelines for the protection of groups/communities in 
research have been drafted for research involving specific indigenous peoples, 
such as American Indians, Alaska Natives, Inuit Peoples, Australian Aborigines, 
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and Maori People. There are three main considerations of these guidelines. First, 
indigenous peoples are often geographically isolated and have their own unique 
histories, cultures, beliefs and traditions. The members of these indigenous 
people often distinguish themselves as a unique and independent group from the 
dominant ones. Second, it has been accepted as a common political aspiration 
by several international political declarations that indigenous peoples have their 
own rights to self-determination and autonomy. There are increasingly 
arguments that the responsibility for governance should belonged to the 
groups/communities themselves. For example, Article 3 of the United Nations 
Declaration on the Rights of Indigenous Peoples97 confers on indigenous peoples 
the right of self-determination and states that ‗by virtue of that right they freely 
determine their political status and freely pursue their economic, social and 
cultural development‘. 98  Article 4 of the Declaration also provides that ‗in 
exercising their right to self-determination, indigenous peoples have the right to 
autonomy or self-government in matters relating to their internal and local 
affairs‘. 99  Third, indigenous peoples are increasingly concerned that research 
may adversely affect them and their values. 
Therefore, there are several guidelines that have been drafted for the 
protections of indigenous peoples in research. For example, in Australia, the 
National Health and Medical Research Council drafted the Guidelines on Ethical 
Matters in Aboriginal and Torres Strait Islander Research 100  in 1991; and the 
Aboriginal Health Research Ethics Committee of South Australia drafted the 
Ethical Considerations for Health Related Research Involving Aboriginal People101 
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in 1998. In the US, the American Indian Law Centre published a Model Tribal 
Research Code102 in 1999. 
In addition, there are also some guidelines to protect communities beyond 
indigenous peoples, including the CIOMS Guidelines for Epidemiological 
Research,103 and Canada‘s Tri-Council Working Group on Ethics document, Code 
of Conduct for Research Involving Humans, 104  which articulate guidelines to 
protect a variety of collective interests of groups. 
According to the reviews of the Australian National Health and Medical Research 
Council 105  and the American Indian Law Centre, 106  the requirements for the 
protection of a group/community can be organized into five themes. If they are 
to provide adequate protection to a target group/community in HPGR, however, 
there are several shortcomings in each theme, which need to be addressed. 
(1) Consultation in protocol development: almost all of the guidelines require 
that researchers respect the culture of the community, suggesting widespread 
agreement about the need for consultation early in the research development 
process.107 For example, Guidelines on Ethical Matters in Aboriginal and Torres 
Strait Islander Health Research noted that  
1. In the preparation of the research proposal, the researcher has 
sought advice not only from State, Territory and Federal Aboriginal 
and Torres Strait Islander Health agencies, but also from local 
community-controlled Aboriginal and Torres Strait Islander health 
service and agencies. 
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2. The Aboriginal and Torres Strait Islander community, or appropriate 
community controlled agency able to represent the Aboriginal and 
Torres Strait Islander group which is the focus or context of research, 
has indicated that the research being proposed will be potentially 
useful to the community in particular or Aboriginal and Torres Strait 
Islanders in general, and will be conducted in a way that is sensitive 
to the cultural and political situation of that community.108  
However, none of these guidelines provides guidance on how to cope with 
circumstances when it may be unclear who represents a particular 
group/community. In addition, none addresses the problem of oppressed 
individuals within a group/community. 
(2) Consent process and informed consent: most of the research guidelines 
require that informed consent be obtained from individual research subjects and 
from community leaders on behalf of the community. For instance, Guidelines 
on Ethical Matters in Aboriginal and Torres Strait Islander Health Research, 
which regulations on informed consent has also been applied by Ethical 
Considerations for Health Related Research Involving Aboriginal People noted 
that  
3. The researcher has obtained written documentation of consent 
from the communities in which it is proposed to conduct research and 
where this has not been possible, the reasons should be documented. 
In such circumstances, informed consent should be shown to have 
involved: (a) provision of information in a form accessible to 
community members and able to be readily understood by them. This 
information should have included details of the collection and analysis 
of data, and the drafting and publication of reports. It should also list 
any potential costs to the community as well as potential benefits; (b) 
face-to-face discussions with community groups and individuals 
concerned wherever possible and where this has not been possible, 
the reasons should be documented; (c) the allowance of sufficient 
time for the community and the individuals concerned to assimilate 
and respond to the information offered; (d) demonstration of a 
process for obtaining free consent from individuals as well as written 
evidence of consent by the community-at-large; (e) provision of 
information to participants that consent may be withdrawn at any 
time.109 
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However, there is no guideline considering the situation that the target group 
has the cultural tradition of collective decision-making, thus no guideline 
provides for a specific, clear mechanism for obtaining community permission if 
needed. Besides, these guidelines do not address the issue of consent to changes 
in research design. If consent is required for the research to proceed, then it 
would seem logical that major changes in the agreed-upon protocol should also 
be agreed to by the community. 110  The same problem occurs in respect of 
withdrawal of consent. 
(3) Involvement in the conduct of research: some research guidelines suggest 
that community members be trained to help conduct the research, and some 
think that they should be employees of the research and receive fair 
compensation for their work.111 For example, Guidelines on Ethical Matters in 
Aboriginal and Torres Strait Islander Health Research stated in relation to 
community involvement that  
4. Members of the Aboriginal and Torres Strait Islander community 
being studied will be offered the opportunity to assist in the research 
and will be paid for the assistance, and the funds to support that 
assistance are included in the research budget proposal. Specifically, 
Aboriginal and Torres Strait Islander women, as advised by the 
community, will be involved when research deals with women‘s and 
children‘s issues; and the specific cultural and social needs of 
Aboriginal and Torres Strait Islander men would be similarly 
recognised.112 
However, it is rare to see the requirement that group/community 
representatives be involved in the conduct and ethical review of research. 
(4) Access to data and samples: because of the historical exploitation and abuse 
suffered by aboriginal communities in Australia and the US, the need for 
group/community consent for future use of data is urgent.113 However, current 
guidelines only provide regulations on the secondary use of personal identifiable 
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and sensitive information. For example, Code of Conduct for Research Involving 
Humans, provided by Tri-Council Working Group in Canada, noted that 
Article 3.4 If identifying information is involved, REB approval must be 
sought for secondary uses of data. REB approval is not required for 
access to non-identifying data. 
Article 3.5 Depending on the sensitivity of the information and on 
feasibility, the REB may also require that a researcher‘s access to 
secondary use of data be dependent on: (a) the informed consent of 
those who contributed data; or (b) an appropriate strategy for 
informing the participants; or (c) consultation with a representative 
group of those who contributed data.114 
There are seldom statements on the related requirement of storage of research 
samples and data. Such requirements would refer to the need for researchers 
and communities to discuss where data or samples will be stored, whether or not 
any will be destroyed, and who ultimately controls them after the completion of 
the research.115 Guidelines are almost all silent on this issue. 
(5) Dissemination and publication of research results: most of the guidelines 
require that a draft report be circulated for comment before publication, that 
the participation of the community be acknowledged, and that the consent of 
the community be sought concerning whether the community is identified in the 
final report. 116  For example, Canada‘s Tri-Council Working Group on Ethics 
document noted that  
... participants have the right to know whether they will be identified 
directly or indirectly in publications resulting from the research. It is 
important that prospective participants know whether or not they will 
be given an opportunity to comment on research findings prior to 
publication. (Affording participants an opportunity to review and 
comment on research results is one way of building a stronger trust 
relationship between researchers and participants.) In some cases 
(e.g., when there has been a history of alleged misrepresentation), 
individuals or groups may be unwilling to participate unless they are 
guaranteed the right to review research results and even have their 
comments incorporated in resulting publications. Reviewing research 
results with participants may also improve the quality of research 
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(e.g., in terms of correcting mistaken impressions on the part of 
researchers or by including a more comprehensive perspective) and 
also help protect the researcher (e.g., against claims of libel).117 
These requirements point toward ‗a tension between the acknowledgement 
requirement and protecting the identity of the community in research where 
confidentiality is a particular concern.‘118 
While there are therefore, shortcomings in the coverage of individual guidelines, 
their existence nevertheless illustrates the possibility of taking into account 
collective risks posed by HPGR. The need for the involvement of target groups or 
their representatives in identifying issues of concern to them and reducing 
vulnerability are also highlighted. The question of vulnerability, however, 
deserves some further consideration.  
3.3.2 Protection of Vulnerable Groups 
If we accept that target groups of HPGR are vulnerable, as I have argued 
above,119 several influential national legislation and international declarations 
advocate special protection for vulnerable groups in biomedical research, such 
as the Helsinki Declaration, CIOMS Guidelines and Universal Declaration on 
Bioethics and Human Rights; however, there has not been a specific approach 
focused on HPGR and group issues. In the US, federal regulations stipulate that 
institutional review boards (IRBs) are charged with the task of protecting human 
research subjects from coercion and unreasonable risk, and assessing a variety of 
scientific and ethical factors in research.120 IRBs also must pay attention to the 
emerging interest in the inclusion of vulnerable minority populations in research, 
including the trend of biomedical research that focuses exclusively on minority 
populations. The confluence of this new emphasis on the role of vulnerable 
ethnic minorities or isolated groups and some increased willingness on the part 
of these populations to participate in order to obtain healthcare or economic 
benefits, raises some difficult scientific and ethical questions for IRBs. The 
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research community should proceed with caution, focusing primarily on human 
subject protections and special protection for vulnerable groups, but IRBs also 
should evaluate questions of protocol design and scientific validity as they affect 
the inclusion of target groups.  
In order to do so it can be proposed that specific regulations to ensure that the 
interests of vulnerable groups in HPGR are properly considered are essential. 
Hurst has argued that the ‗concept of vulnerability  …serves to identify groups of 
individuals that do, in fact, need and merit this special care in the application of 
criteria for ethical research.‘121 He also argued that the actions required for 
special protection would need to be tailored to the sort of risks to be avoided 
and to the source of the specific vulnerability as follows:  
(1) Breach of confidentiality: as researchers or healthcare providers 
may be at greater risk, IRBs should share in the duty of protection, 
and could require specific anonymisation of data to limit colleagues‘ 
access to their personal information. (2) Unfavourable risk/benefit 
ratio: vulnerable populations are, for example, terminally ill patients, 
so IRBs share in the duty of protection; their risk/benefit ratio should 
be specifically examined by researchers and IRBs rather than assumed 
to be the same as for other potential subjects. (3) Being enrolled 
without valid consent: consent is sought at that time only for those 
parts of the protocol that are truly urgent; the remaining problems 
with consent at that time can be compensated by including a 
requirement that an independent clinician confirm that enrolment is 
not contrary to the potential subject‘s interest. (4) Being denied the 
benefit of research: participants in developing countries who lack 
access to healthcare are excluded from an important part of the 
social benefits of research; although IRBs are not alone in bearing 
some responsibility for this, it is among the points they should 
examine in general, and thus also for the purposes of protecting the 
vulnerable; minimization: reasonable availability aims to minimize 
this problem; compensation: fair benefits aim to compensate it [the 
benefit of research].122  
This approach concentrates on the responsibility of IRBs which have a moral and 
legal function to protect vulnerable populations. However, the actual situation 
of HPGR conducted in developing countries is that there are rarely legislation or 
ethical guidelines which require the existence of IRBs or ethical committee to 
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conduct ethical review on research involve human beings. Therefore, it is 
proposed that developing countries that do not have IRBs or RECs should set 
them up, governed by appropriate regulations concerning review. Furthermore, 
members of target groups in HPGR, with proper training on ethical review, 
should be part of IRBs or RECs in order to provide a level of consideration and 
protection of group interests. As a result, in order to provide adequate and 
appropriate protections to vulnerable target groups of HPGR the existing 
guidance on research involving human beings needs to be reconsidered. 
3.3.3 Attempts to Protect Groups in HPGR 
There have been several attempts to revise the guidelines to protect groups in 
genetic research. For example, there has been the suggestion that a fourth 
principle of ‗respect for communities‘ should be added to ‗respect for persons,‘ 
‗beneficence‘ and ‗justice‘ – the three basic ethical principles which were 
referred to in the Belmont Report. 123  In addition, Sharp and Foster have 
developed an account of ‗community review‘ that includes groups‘ interests in 
the research process. Both of these approaches have pointed out some of the 
unique issues of research with groups or communities and the need to devise 
strategies to bring communities into the process and provide insight into the 
risks that the proposed research might pose to communities/groups. The 
following section will analyse these proposals. 
(1) A fourth ethical principle: ‘respect for communities’ 
Since existing ethical frameworks, such as that established by the Belmont 
Report, ignore the interests of community in research, some scholars have 
argued that the basic principles need to be reconsidered. For example, Childress 
has argued that a new meaning of ‗person‘ in the principle of ‗respect for 
persons‘ is necessary. He noted that: 
Any serviceable account of biomedical ethics in a liberal society 
requires a central place for the principle of respect for autonomy. 
However, its demands are often unclear because of the complexity of 
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personal actions and values, and because it is not the only source of 
moral guidance. In fact, the richest resolutions of debates in bioethics 
presuppose attention to the claims of other ethical principles as well 
as a fuller interpretation of selves in time and community.124 
What is more, according to Weijer, the communitarian argument ‗has been 
successful in establishing two claims:  first, that self-determination is impossible 
unless we presuppose an individual located within a community (otherwise 
choice can never ‗get off the ground‘); second, that the interests of the 
individual may include the continuation of certain communal practices.‘125 He 
argued that according to these two claims and Childress‘s assertion, it can be 
concluded that the existing framework of ethical principles needs to be enriched. 
He then analysed several attempts which were intended to accomplish this. For 
example, Levine called for a principle of ‗respect for culture,‘ which focused on 
‗Perhaps instead we should recognize the validity of certain forms of cultural 
relativism and have each culture decide how it should show respect for its own 
persons.‘126 McCarthy suggested that attention should be paid to respect for the 
family and the community of the research subjects, noting that contemporary 
Western principles stress individual liberty and place less emphasis on the rights 
and dignity of the community, while many third world countries have much to 
teach developed nations about community values.127 
Weijer then argued for the creation of a new ethical principle: respect for 
communities. He suggested that there are at least three arguments that support 
the development of this ‗fourth principle‘: 
…First, even if the continuation of some communal practices is in the 
interest of the individual, community interests are separable from 
individual interests. Indeed, individual and community interests may 
even conflict…. Second, an ethical principle does not merely serve the 
purpose of capturing existing moral debate; in other words, principles 
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are not merely descriptive. Ethical principles also serve to 
acknowledge the moral status of players…. A new ethical principle, 
respect for communities, would similarly accord moral status to the 
community and require that the wishes and interests of the 
community be taken seriously…. Third, the principle of respect for 
communities can be justified as other ethical principles have been. 
The sorts of justification required to establish a new principle depend 
on just what one thinks ethical principles are…. Concerns about the 
community in research, and ultimately moral rules regarding the 
proper treatment of the community, may be loosely collected under 
the placeholder ―Be sure and think about the community‖—the 
principle of respect for communities.128 
According to him, the principle of respect for communities would ‗obligate 
researchers to respect the values and interests of the community in the research 
and, wherever possible, to protect the community from harms.‘129  
After making his case for the need for this new principle, Weijer went on to 
discuss how it would be implemented. He found that ‗clear guidelines exist for 
research involving first nations communities, and the guidelines must be 
respected and ought to be enforced‘,130 through careful observation of existing 
research guidelines for researchers working in communities, both at the 
international and the domestic level. The guidelines include the Council for 
International Organizations of Medical Sciences (CIOMS)‘s two sets of guidelines: 
International Ethical Guidelines for Biomedical Research Involving Human 
Subjects, and International Guidelines for Ethical Review of Epidemiological 
Studies; the US Department of Health and Human Services regulations pertaining 
to standards for international research; as well as other guidelines for research 
in first nations communities, such as the National Health and Medical Research 
Council Guidelines on Ethical Matters in Aboriginal and Torres Strait Islander 
Research in Australia, the American Indian Law Centre published Model Tribal 
Research Code in the US and Canada‘s Tri-Council Working Group on Ethics 
document, Code of Conduct for Research Involving Humans, However, he also 
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concluded that ‗difficult challenges lay in the way of developing guidelines for 
research on other sorts of communities.‘131 
One advantage of Weijer‘s proposed fourth principle of respect for communities 
is that it clarifies the reasons why communities and groups require separate 
consideration: since the interests and potential risks for communities are 
separate from those potentially posed for each individual within the community. 
Thus, in his revision of individualistic research ethics, he highlighted the 
significance of community interests. This proposal goes further than simply the 
provision of some special measures to protect a community in through the 
process of informed consent. Thus, this revision is targeted at challenging the 
individualism of current research ethics through emphasis the interests of 
community, not just at making some supplementary adjustments to current 
requirements for individual informed consent, though his premise on personhood 
is still stuck at the isolated individual without consideration of her/his other 
social relationship and context.  
There are, however, some disadvantages. Firstly, he was not able to identify a 
clear pattern of the use of the word ‗community‘. Having investigated existing 
research guidelines he found that there were different ways to use the word 
‗community‘. Moreover, these research guidelines only extended to ‗aboriginal 
communities‘, such as American Indians, Alaska Natives, Inuit Peoples and other 
indigenous peoples, but did not comment on how to protect other kinds of 
communities.  
Secondly, he failed to establish the relationship between the fourth principle 
and the other three principles. Thus, if there is conflict between individual and 
communal choices, for example between the principle of respect for persons and 
respect for communities, he offers no practical approach to resolve it. 
Thirdly, he failed to provide a practical strategy for implementation of the 
fourth principle in research. Merely, he says: 
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The protections are arranged chronologically, beginning with the 
issues pertaining to consultation with the community on research 
design and ending with issues arising from the dissemination and 
publication of research findings. The order is as follows: consultation 
in protocol development, consent process and informed consent, 
involvement in research conduct, access to data and samples, and 
dissemination and publication of research results.132 
Therefore, having analysed the gaps in research guidelines in respect of the 
protection of communities, he concluded that the existing protections are 
incomplete, but failed to provide an effective alternative recommendation. 
(2) Community review 
Another attempt to revise current ethical framework to protect a 
community/group in HPGR was put forward by Sharp and Foster. They suggested 
that the target group/community of HPGR is similar to other vulnerable 
populations, such as children, pregnant women, and prisoners, which have 
already been singled out for special protection. Their approach stresses the need 
for members of study populations to be directly involved in the review process, 
particularly when the research aims to identify genetic variations that may be 
unique to, or more prevalent among, members of those populations.  This 
requirement they encapsulated in the principle of ‗community review.‘133 
Sharp and Foster proposed that the term ‗community review‘ was ‗a general 
category describing various approaches to involving populations in the evaluation 
of genetic research.‘134 They argued that the goals of community review are: 
reviewing research protocols considering the cultural sensitivities of specific 
target group; identifying and minimizing the risks of harm that may be caused by 
research to all the involved parties, including individual participants, 
participating communities, and others community members; promoting 
collaborations and longer partnerships between researchers and target groups, 
through communicating interests and concerns with each other; establishing 
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trust between researchers and target groups through researchers‘ respect for 
the social and cultural structure in place within those communities; helping 
provide additional protection for individual participants by assisting them in 
assessing the risks and benefits of the research.135  
Community review takes four forms; each one attempts to achieve the different 
goals described above. Sharp and Foster described them as follows: 
Community dialogue: this form of review includes both formal and 
informal discussion of a proposed study and its potential implications 
for a socially identifiable group. These discussions may be initiated by 
researchers or arise independently within a community after contact 
with researchers. Community dialogue is meant to identify collective 
concerns and consider ways of minimizing research-related risks, but 
does not provide a comprehensive review of the research in question 
and often will not engage a representative sample of community 
members. 
Community consultation: in contrast to community dialogue, this type 
of review is more structured. Community consultation documents and 
records the concerns of a socially identifiable group by consulting a 
representative subset of its individual members and organizations. 
Other reviewers can then incorporate these perspectives in their 
assessments of the research. How these perspectives are documented 
will vary, ranging from structured community forums to the creation 
of an independent community review panel. These forums and review 
panels may choose to endorse or oppose the research in an explicit 
way, but with community consultation, these evaluations are not 
binding on researchers. 
Formal community approval (disapproval): an even more structured 
type of community review is the negotiation of a formal contractual 
agreement between researchers and a study population. This 
arrangement can be thought of as roughly analogous to obtaining 
informed consent from individual research participant. In this form of 
review, members of a study population (or recognized political 
representatives) are asked to give their collective permission for a 
research study. That collective decision, however, is not binding on 
individual community members, who still may choose to participate in 
the research (or not to participate). 
Community partnership: the most structured way to involve members 
of a study population in the review process is to make them partners 
in the research. As partners, members of the study population are 
involved early in the design of the research project and ‗review‘ the 
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study by helping to define its goals and methodology, and implement 
its experimental design.136 
It is argued that these different forms of community review could be used at 
various stages of a HPGR, as there are subtle differences in emphasis between 
them. For example, community consultation could be a way to identify 
community concerns in the initial design of a HPGR proposal; while ‗subsequent 
consideration of these concerns could prompt researchers to seek community 
approval at a later stage in the research, perhaps in connection with the 
publication of research findings.‘137 In addition, these four forms of community 
review are highly dependent on each other. For instance, community dialogue 
and consultation both help to ‗convey respect for members of study populations, 
seeking formal community approval demonstrates respect for the decision-
making authority of the constituent communities.‘ 138  Similarly, community 
partnership ‗goes further and suggests a deeper sense of respect for study 
populations by taking note of the unique social and cultural arrangements that 
exist within participating communities.‘139 
Sharp and Foster also argued that the form of community review adopted should 
be tailored to be appropriate to a given community, or a particular study, and 
depend on the following factors: (1) the frequency of social interaction among 
members of the study population; (2) the extent of shared socio-cultural belief 
and values that are distinctive to the study population.140 The determination of 
the most appropriate community review form for a particular HPGR for a given 
community should take these two features into account. According to them, and 
as noted before, the risks that may be caused by HPGR are of two distinct types: 
‗external risks‘ which refer to the possible discrimination and stigmatization of 
members of the study population; and ‗internal risks‘ which result from the 
disruption of interactions among members of the study population. For instance, 
in a population where interactions between members are infrequent, and their 
distinctive beliefs few, the main risks of HPGR involve potential misuse of 
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genetic information by others outside the community, possibly resulting in 
discrimination and stigmatization. These risks are not unique to any particular 
group and often can be identified by individuals who are not themselves 
members of the population placed at risk. Nevertheless, community dialogue or 
consultation can still be helpful in identifying research- related risks and 
assessing how members of the study population view the significance of these 
risks.141 In contrast, where the frequency of social interaction between members 
of a population is high, and the distinctive shared socio-cultural beliefs help to 
distinguish members of the population from other communities, HPGR can cause 
additional risks, such as that genetic findings could reveal that their shared 
socio-cultural belief is mistaken. Therefore, in these communities, the full range 
of community review is essential to identify the risks that may be caused by 
HPGR.142 In addition, they also offered a model agreement for genetic research 
in socially identifiable populations, which ‗defined the scope of research, 
provided options for naming the population in publications (including anonymity), 
and addressed the distribution of royalties from intellectual property, the future 
use of archival samples, and specific cultural concerns.‘143 
There are several advantages to Sharp and Foster‘s ‗community review‘ 
approach to protecting target groups/communities in HPGR. Firstly, they address 
the unique risks that groups/communities may face in HPGR, especially ‗internal 
risks‘ which can probably only be recognized within the group; and suggested 
that these implications should be factored into the risk-benefit evaluation of 
proposed research. 144  Although IRBs and other review measures could be 
instructed to pay special attention to possible intra-community risks, including 
the disruption of existing social arrangements and relationships between 
members of a study population, the active involvement of the target group in 
community review can help identify internal risks in populations whose socio-
cultural traditions and structures differ from those of IRB members. Secondly, 
they illustrated four distinctive forms of community review and their main 
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features, and proposed a means to choose the most appropriate forms of 
community review for the target group in a specific HPGR. Thirdly, they 
established a model agreement for obtaining community consensus for HPGR in 
an Apache tribe in Oklahoma. The essence of the model is that research should 
be preceded by careful efforts to understand how decisions are made in the 
particular community. This process of reaching communal consensus provides a 
feasible approach to generating a general model which may be suitable as a 
standard for evaluation of the collective risks for target groups in HPGR. 
There are, however, also disadvantages to community review. Firstly, its 
feasibility is problematic for two reasons: (1) the nesting of community - there 
are difficulties resulting from the fact that individuals are members of multiple 
communities, many of which are nested within each other. The complexity of 
human population structure poses more than practical difficulties for the notion 
of community review. For example, as has been discussed, Juengst has argued 
that the nesting problem results from the concerns of local communities that 
may fail to correspond with those of communities at broader levels of 
inclusiveness; hence, consulting with larger communities may fail to identify the 
unique cultural concerns of local communities, and correspondingly, the 
concerns of local communities may fail to reflect those of larger communities.145 
(2) The extent of dispersion within communities: it has been argued that the 
dispersion of individual members and the lack of frequent social interactions 
between members of a study population combine to limit the effectiveness of 
community review.146 In widely dispersed populations, individuals may be viewed 
by outsiders as members of the same community, though they rarely interact 
with each other socially. 
Secondly, community review is only one element of protecting members of a 
community/group if an individualistic approach is taken to consent in research. 
The community collective interests would be considered by researchers and 
ethical review committees through group involvement. Nevertheless, the final 
decision of an individual on HPGR participation might still be based on the 
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information on potential effects on him or her, rather than taking into account 
the need for information disclosure to include potential group harms.  
Thirdly, the inappropriate use of community review may harm the target 
group/community in HPGR. As Juengst noted, ‗acting as if social groups were the 
groups under study suggests that they are reducible to the demes we construct 
around them, setting the stage for new forms of scientific racism and providing 
new tools for discrimination; moreover, geneticists expect that the biological 
populations they pick out will ultimately ―correct,‖ rather than respect, the 
indigenous beliefs that they were ostensibly commissioned to celebrate.‘ 147 
Hence, researchers implementing a community review approach to socially 
identified groups without fully cultural sensitivity consultation might harm them 
by reifying race, ethnicity, and other socially constructed categories, since it 
might reinforce the idea that biological differences underlie social differences 
between communities. 
Therefore, although the application of both ‗respect for community‘ and 
‗community review‘ would offer some help for group protection in HPGR, since 
both of them have some weaknesses, neither of them alone would provide 
sufficient protection to the interests of target groups in HPGR.  
In summary, a target group may be vulnerable in the context of HPGR, especially 
where the HPGR is conducted in developing countries. Target groups, are 
vulnerable to all three types of vulnerability: consent-based, risk-based, and 
justice-based because of low education levels, difficulties in correct 
understanding of the risks of HPGR, or undue inducement. These common 
characteristics of target groups all make them more likely to accept risks that 
are either not understood or appreciated, or that are unfair. Target groups of 
HPGR are thought to be vulnerable to exploitation, because the researchers or 
research institutions of HPGR, who are mostly research institutions or companies 
from developed countries,  may be more likely to take unfair advantage of their 
inadequate economic and social resources by offering target groups unfair 
‗benefits‘ in exchange for their participation. If HPGR relies on individual 
consent to enrol participants who are vulnerable, target groups may not be able 
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to protect their own interests properly. Furthermore, the absence of effective 
and adequate legal regulations and ethical guidelines in most developing 
countries, as well as poor law enforcement, also exacerbate the vulnerability of 
target groups in HPGR. Therefore, the target group and its members need to be 
protected as vulnerable groups in HPGR by specific legal and ethical regulations, 
regarding the specific situations and cultural sensitivities of target groups. In 
addition to information disclosure on group harms to potential participants to 
enable individuals to consider such issues as part of their own risk-benefit 
assessment before they are asked to consent, the collective ideas of target 
groups on issues relevant to group collective interests should also be considered. 
It can be suggested the target group involvement in HPGR is needed. An 
alternative model of group protection in HPGR, with the consideration of both 
appropriate information disclosure and group involvement, will be offered in 
Chapter 5 in the context of the PRC. In order to explain the particular context of 
HPGR in the PRC, the next chapter will consider the social and legal factors 
relevant to such research. 
Chapter 4 – People’s Republic of China: A Mother 
Lode of Genes? 
4.1 Current Legal Regulations and Ethical Guidelines on 
HPGR in the People’s Republic of China 
It has been indicated that, in this thesis, the People‘s Republic of China will be 
used as a model to demonstrate the difficulties associated with HPGR in 
developing countries.  For that reason, this chapter will provide a description of 
the current legal system in China and will evaluate the relevant law/guidelines 
currently in place in respect of human subject research, with particular 
consideration of their relevance and adequacy in respect of HPGR. 
4.1.1 Brief Introduction of Chinese Legal System 
The People's Republic of China (PRC) is a socialist State. Since the Third Plenary 
Session of the Eleventh Central Committee of the Communist Party of China 
(CPC) in 1978, China has attached more importance to the role of law in State 
administration and social life by strengthening the legislative framework. It has 
sought to steadily improve legislative procedures, laying stress on legislative 
techniques and the quality of legislation. At present, ‗ruling the country by law‘ 
is the fundamental guideline to administer the state and manage society under 
the leadership of the CPC, and this was written into the Constitution of the PRC1 
in 1999. The PRC has been actively building and seeking to improve its legal 
system since its foundation. As a result, a socialist legal system, with the 
Constitution as its core and with Chinese characteristics, has taken shape.2  
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The Chinese legal system is similar to the civil law systems of Japan, France and 
Germany.3 The primary sources of law in PRC are written legislation. The PRC‘s 
legal system contains branches as follows: constitutional and related law, civil 
and commercial law, economic law, administrative law, social law, criminal law, 
litigation and non-litigation procedural law. 4  Cases cannot be cited as legal 
sources in Chinese courts.  
According to the Constitution, China implements a unified legislative system, 
which is to say that there is only one legislative system, albeit of multiple levels, 
in the country. The Constitution stipulates that the National People‘s Congress 
(NPC) and its Standing Committees exercise the legislative power of the State to 
enact laws. The State Council formulates administrative regulations according to 
the Constitution and laws. The National People‘s Congress and its Standing 
Committee of each province, autonomous region or municipality directly under 
the Central Government formulate local regulations, which must not contravene 
the Constitution, laws or administrative regulations. The People‘s Congress of 
each national autonomous area has the power to enact regulations on the 
exercise of autonomy5  and separate regulations in the light of the political, 
economic and cultural characteristics of the nationality or nationalities in the 
area concerned. Departments of, and agencies with, administrative functions 
directly under the State Council formulate rules according to the laws and 
administrative regulations of the State Council. In addition, the people‘s 
government of each province, autonomous region or municipality, as well as the 
people‘s government of the city where a province or autonomous region is 
located, and of the city where a special economic zone is located or larger cities 
designated by the State Council, may formulate rules. As to a special 
administrative region, which refers to Hong Kong and Macao, according to the 
principle of ‗one country, two systems‘6 and the provisions of Article 31 of the 
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Constitution, the system (including the legislative system) in a special 
administrative region shall be stipulated by law enacted by the National People‘s 
Congress. 7  The sources of Chinese law include the Constitution, laws, 
administrative regulations, local regulations, regulations of national autonomous 
areas, regulations of special economic zones, rules, basic laws of special 
administrative regions, international treaties and practices.8 
The Legislation Law of the People‘s Republic of China (hereinafter the 
Legislation Law 2000) lays down the general rules of the hierarchy of Chinese 
law.9 Under the Legislation Law 2000, legislation can be divided into at least 
seven different categories: the Chinese Constitution 1982; basic laws and 
national law; administrative regulations; local regulations, autonomy regulations, 
separate regulations; administrative rules and local rules (including provincial, 
autonomous and municipal rules, and decrees by major cities). The chart below 
shows the Hierarchy of the Chinese Legal System. The Chinese Constitution 1982 
has the highest legal authority.10 National law is enacted by NPC or its Standing 
Committee. It can be divided into two sub-categories: basic laws and others. 
There is no clear definition of what laws can be basic laws. The Legislation Law 
2000 does not clearly provide that basic laws are higher than other national laws. 
In practice, however, basic laws are generally considered more important than 
other national laws. Administrative rules are issued by the ‗various ministries, 
                                                                                                                           
inalienable part of the People's Republic of China, such a region is allowed to implement 
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commissions, the People‘s Bank of China, the Auditing Agency, and a body 
directly under the State Council exercising a regulatory function‘.11  
 
Figure 4-1 The Hierarchy of the Chinese Legal System 
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4.1.2 Legal Regulations and Ethical Guidelines on HPGR in the 
PRC 
The main legal regulations and ethical guidelines on biomedical research in the 
PRC include ‗Measures for the Ethical Review of Biomedical Research Involving 
Human Subjects,‘ 12  and ‗Interim Measures for the Administration of Human 
Genetic Resources.‘ 13  Both of these documents are formulated by various 
ministries of State Council, so they are administrative rules in the hierarchy of 
the Chinese legal system. 
1) Measures for the Ethical Review of Biomedical Research Involving Human 
Subjects (Measures 2007) 
‗Measures for the Ethical Review of Biomedical Research Involving Human 
Subjects‘ (Measures 2007) is the most substantial legal regulation on 
biomedical research involving human subjects in the PRC. It was promulgated 
by the Ministry of Public Health of the PRC on Jan. 11th 2007.  
The targets of the Measures 2007 are regulating biomedical research 
involving human subjects, protecting human life and human health, 
safeguarding human dignity, as well as respecting and protecting the legal 
rights and interests of human subjects of biomedical research.14 Measures 
2007 contains thirty articles and is divided into five sections. In respect of 
biomedical research involving human subjects, it essentially sets regulations 
for the principles of ethical review including the establishment of ethics 
committees, measures and procedures for ethical review, as well as the 
administration and supervision of such review. In Measures 2007, ‗biomedical 
research involving human subjects and the application of its relevant 
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techniques‘ are defined as research activities on human subjects, adopting 
modern physical, chemical and medical methods, which focus on human 
physiological and pathological phenomena, as well as the diagnosis, 
prevention and treatment of diseases and trial application activities of 
medical health techniques or products on human subjects through biomedical 
research.15 From the perspective of protecting human subjects‘ interests and 
dignity, Measures 2007 highlights that ethical review shall abide by state laws, 
regulations, relevant rules and well-known bioethical principles. Furthermore, 
the process of ethical review should be independent, objective, fair and 
transparent.16 
In Measures 2007, the ethical review principles include: 
(1) Respect for and protection of a human subject‘s self-determination and 
right to decide whether or not to participate in certain research, strict 
requirements for informed consent, avoiding any improper approach, such as 
deception, coercion or bribery, to gain a human subject‘s consent and 
allowing a human subject‘s withdrawal from any process of research; 17  
(2) The security, health and interests of human subjects are absolutely 
superior to the consideration of scientific and social interests; to endeavour 
to enable the human subject to be benefited to the greatest degree and to 
avoid harm as much as possible;18  
(3) To reduce or exempt the human subjects‘ financial losses to enable him 
or her to benefit from research;19 
 (4) To respect and protect the privacy of the human subject, inform the 
human subject about the storage and use of his/her private data and the 
security measures to protect such data;20  
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(5) To ensure timely treatment and appropriate compensation for the human 
subject, if he/she is injured in research;21  
(6) To provide special protection to vulnerable groups, such as children, 
pregnant women, persons with learning disabilities, mental patients, 
prisoners and persons in poor and less-educated positions.22 
Measures 2007 clarifies the role and responsibilities of institutional ethics 
committees, as well as their establishment, membership composition and 
powers of examination and approval. 23  Meanwhile, Measures 2007 also 
proposes that, according to need, the Ministry of Health and the provincial 
administrative departments of public health should establish an ethical 
review guidance and counselling organization, which will discuss significant 
ethical issues, offer consultations for the drafting of regulations, provisions 
and policy measures, organize ethical review on some major research 
projects, and guide and supervise the ethical review by institutional ethical 
committees.24 
In addition, Measures 2007 stresses the role of government in ethical review 
of biomedical research involving human subjects. In order to ensure the 
quality of ethical review, the Ministry of Health and the provincial 
administrative departments of public health will supervise the multiple levels 
of ethical review committees, including the establishment of institutional 
ethical committees, ensure compliance with principles for ethical review and 
monitor results.25 Foreign researchers or research institutions who conduct 
biomedical research involving human subjects inside the PRC should obtain 
approval from the relevant Chinese ethical committees and review their 
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research projects according to Measures 2007, regardless of whether or not 
their research projects have been reviewed in their own countries.26 
2) Interim Measures for the Administration of Human Genetic Resources 
(HGR Measures 1998) 
‗Interim Measures for the Administration of Human Genetic Resources‘ was 
drafted by the Ministry of Health and the Ministry of Science and Technology, 
and promulgated by the General Office of the State Council upon the 
approval of the State Council of the PRC on Jun. 10th 1998.  
The primary targets of HGR Measures 1998 are efficiently protecting and 
rationally utilizing human genetic resources in the PRC, strengthening the 
research and development of human gene technology and promoting 
international co-operation and exchange on the basis of equality and mutual 
benefits.27 In HGR Measures 1998, ‗human genetic resources‘ are defined as 
materials such as human organs, tissues, cells, blood specimens, preparations 
of any types or recombinant DNA constructs which contain the human 
genome, genes or gene products. They also include information related to 
such genetic material.28 HGR Measures 1998 mainly regulates such activities 
in the PRC as sampling, collecting, researching, developing, trading or 
exporting human genetic resources outside the territory of the PRC.29 It has 
six sections and twenty-six articles and contains detailed regulations on the 
administration of human genetic resources and also the examination and 
approval of research on human genetic resources in the PRC. It includes 
provisions concerning benefit-sharing of intellectual property rights, as well 
as rewards and penalties in respect of such research. 
In general, in accordance with HGR Measures 1998, the PRC adopts a 
reporting and registration system. Any institution or individual who discovers 
or holds important pedigrees and genetic resources in specified regions shall 
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immediately report to the Human Genetic Resources Administration of China 
(HGRAC). No institution or individual may sample, collect, trade or export 
human genetic resources, including both physical samples and relevant 
genetic information, or take them outside the territory of the PRC, or 
provide them to other countries in any form without permission.30 The State 
adopts a unified review and approval system, regulated at different levels, 
over human genetic resources. The Administrative Department of Science and 
Technology and the Administrative Department of Public Health under the 
State Council are jointly in charge of the administration of the human genetic 
resources of China at national level and had responsibility for establishing the 
Human Genetic Resources Administration of China (hereinafter referred to as 
the HGRAC) to carry out routine duties.31 
The HGRAC has the following responsibilities: 
(1) To draft the relevant rules and implementing documents; to promulgate 
such rules for entering into force upon approval and to ensure the 
enforcement of the Measures through co-ordination and supervision; 32 
(2) To be in charge of the registration and administration of the important 
pedigrees and genetic resources in the specified regions;33 
(3)  To review and examine international collaborative projects involving 
human genetic resources in China;34 
(4)  To review and approve applications for export of human genetic 
resources, and thereafter to issue Export Permits for Human Genetic 
Materials and;35 
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(5)  Other duties related to the administration of human genetic resources in 
China.36 
Where human genetic resources from China are involved in any international 
collaborative project, the Chinese collaborating party is responsible for going 
through the appropriate formalities of application for approval. Institutions 
directly under the Central Government must apply to the relevant 
administrative department under the State Council and local institutions or 
institutions without a specific supervisory department must apply to the local 
administrative departments. Upon receiving the approval of the relevant 
departments, the Chinese collaborating party must apply to the HGRAC for 
examination and approval prior to entering into an official contract. 37  In 
addition, relevant departments under the State Council and local 
administrative departments, in reviewing any application for international 
collaborative projects, will consult the relevant local administrative 
departments of the region where human genetic materials are to be 
collected. 
In terms of the intellectual property rights of human genetic resources, HGR 
Measures 1998 provides that the Chinese research and development 
institution shall have priority in accessing information about the human 
genetic resources within the territory of the People‘s Republic of China, 
particularly the important pedigrees and genetic resources in the specified 
regions and the relevant data. Providing information and specimens and any 
transfer of such human genetic resources to other institutions are prohibited 
without permission. No foreign collaborating institution or individual who has 
access to the above mentioned information may publicize, publish, apply for 
patent rights or disclose it by any other means without permission.38 What is 
more, international collaborative projects involving human genetic resources 
must follow the principles of mutual benefits, credit and trust, joint 
participation and sharing of achievements. All of the rights and obligations of 
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each party should be set out in advance, in order to fully and effectively 
protect their own respective intellectual property rights.39  
According to HGR Measures 1998, if any Chinese institution or individual, in 
violation of the provisions stipulated in HGR Measures 1998, exports human 
genetic materials without authorization by any means, the human genetic 
materials will be confiscated by Chinese Customs and the institution or 
individual will be punished. Punishment ranges from administrative sanctions 
to prosecution by the judicial department, according to the seriousness of 
the circumstances.40 If anyone, in violation of the provisions stipulated in the 
Measures, provides human genetic materials to foreign institutions or 
individuals without permission, the human genetic materials will be 
confiscated and the institution or individual will be fined. If the 
circumstances are serious, he will be investigated for liability according to 
Chinese law.41 
4.1.3 Critical Evaluation of Existing Legal Regulations and Ethical 
Guidelines on HPGR in the PRC 
While it might seem that the PRC has confronted the issues involved in human 
subject research and particularly genetic research in a serious manner, on 
reflection these regulations are not well suited to HPGR and do not provide 
adequate protection for participants in such research. The deficiencies can be 
described as follows: 
1) The current rules are still essentially reactive. This means that when 
certain cases cause risks or harms to certain individuals or groups, 
legislation or ethical guidelines will be promulgated, designed to avoid 
the recurrence of similar cases. For example, HGR Measures 1998 was the 
reactive legislation to a number of scandals,42 such as the Harvard case, 
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which has been described above. At that time, in order to reserve the 
benefits relevant to genetic resource and avoid similar genetic resource 
loss cases, China stipulates in HGR Measures 1998 that reserves claims for 
all benefits derived from international biomedical research using Chinese 
biological sources. Hence, as a reactive legislation, the otherwise puzzling 
focus on the interests of the State in genetic research and the absence of 
protection to human subject and target group in HGR Measures 1998  
becomes understandable. Accordingly, these reactive legal regulations 
lack the full anticipation of possible scenarios and are not reviewed in the 
light of the development of biomedical technology. Furthermore, they are 
not at the highest level of the hierarchy of the Chinese legal system. In 
fact, as measures which legislated by the ministries of State Council, 
Measures 2007 and HGR Measures 1998 only have the lowest legal effect in 
national legislation. If conflicted with other higher level legislation, those 
higher level legislation shall prevail. Thus, Measures 2007 and HGR 
Measures 1998 are not powerful enough.  
2) The starting points of these legal regulations and ethical guidelines are 
the State administrative system; hence, they concern the interests of the 
State more than the interests of the individuals or groups who are the 
targets of biomedical research. Thus, the core regulations of HGR 
Measures 1998 provide for reporting and registration systems for 
important pedigrees and genetic resource, as well as the regulations of 
export and intellectual property of human genetic resources in the PRC. 
Nevertheless, Measure 2007 made some positive efforts toward human 
subject protection. For example, it clearly confirmed that informed 
consent should be an essential requirement which needs to be strictly 
reviewed by ethical committees.  It also stipulates that information 
disclosure when seeking consent should be expressed by simple words; in 
minority areas, it can be expressed in local languages to seek to ensure 
that the potential participants have a proper understanding of what is 
involved.43 When the research is to be conducted in minority areas, the 
membership of ethical review committees should consider including 
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members from ethnic minorities in advance. 44  However, these 
considerations remained based on an individualistic model of autonomy, 
and were lacked reference to protection of the interests of group or 
information disclosure on group risks. 
3) Given that these legal regulations and ethical guidelines are essentially 
reactive, they lack unified ethical or legislative principles and have not 
developed a complete set of general rules that can guide the ethical 
conduct of biomedical research and ensure the interests of human 
subjects.  
For example, despite the requirement for informed consent by research 
subjects set out in Measures 2007, this Measure only gives limited 
guidance to ethics committees on how to conduct ethical review of 
biomedical research involving human subjects. There is little specification 
of the method and standards required for the conduct of the informed 
consent process other than the need for information to be provided in 
understandable language. This means that there is no legal requirement 
as to the scope and standard of information disclosure by researchers, nor 
as to other elements of seeking consent from participants in biomedical 
research involving human subjects in the PRC.  
There are some legal requirements relevant to informed consent in the 
PRC in ‗Guidelines for the Moral Principles in Human Embryonic Stem Cell 
Research‘ 45  (HESCR Guidelines 2004). This was promulgated by the 
Ministry of Health and the Ministry of Science and Technology of the PRC 
on Jan. 14th 2004, and contains twelve articles. It stipulated the principle 
of informed consent and the need for approval of research by ethics 
committees. In Article 8 of HESCR Guidelines 2004, it is noted that to 
protect the privacy of the subjects, research on human embryonic stem 
cells must be conducted in earnest pursuance of the principles of consent 
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and agreement provided on the basis of full knowledge of all facts on the 
part of the subject. A letter of consent must be properly signed recording 
this.46 For consent to be properly obtained, the researchers must have 
advised the gamete providers as to the aims and the possible 
consequences and risks of the research in accurate, clear and common 
language.47 According to the HESCR Guidelines 2004, an ethics committee 
must be set up within a research unit conducting research with human 
embryonic stem cells, consisting of research and managerial staff from 
biology, medical sciences, law or sociology etc. The duty of the ethics 
committee is to exercise comprehensive inspection, consultation and 
supervision as to the underlying principles and scientific aims and conduct 
of human embryonic stem cell research.48 However, the applicable scope 
of the HESCR Guidelines 2004 is limited to human embryonic stem cell 
research, which does not include HPGR or any other biomedical research 
involving human subjects. 
Apart from HESCR Guidelines 2004, there are some other laws in the PRC 
which contain articles that may be relevant to informed consent, 
including ‗Law of Licensed Doctors of the People‘s Republic of China‘49 
and ‗Managerial Regulation of the Medical Institutions of the People‘s 
Republic of China‘.50 Article 26 of Law of Licensed Doctors of the PRC 
stipulates that doctors who wish to conduct any experimental clinical 
treatment shall obtain the approval of the hospital authorities and the 
consent of the patient himself or his relatives.51 Although this law is at the 
level of other national laws, and was promulgated by the Standing 
Committee of the NPC, it only stipulates some simple regulations on 
                                         
46
 Ibid., Article 8. 
47
 Ibid. 
48
 Ibid., Article 9. 
49
 Zhong Hua Ren Min Gong He Guo Zhi Ye Yi Shi Fa [Law of Licensed Doctors of the People’s 
Republic of China] (in Chinese), available on the official website of the Ministry of Health of the 
PRC: http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohzcfgs/s3576/200804/18250.htm, 
last visited on 2010-05-06. 
50
 Yi Liao Ji Gou Guan Li Tiao Li [Managerial Regulation of the Medical Institutions of the People’s 
Republic of China] (in Chinese), available on the official website of the Ministry of Health of the 
PRC: www.moh.gov.cn/uploadfile/200591152042127.doc, last visited on 2010-05-10. 
51
 See supra note 49, Article 26. 
Chapter 4 
People‘s Republic of China: A Mother Lode of Genes? 174 
 
patients‘ consent, not concerns specifically relating to the interests of 
human subjects in biomedical research. Article 33 of Managerial 
Regulation of the Medical Institutions of the PRC also stipulates that the 
medical institution shall obtain the consent of the patient himself, and 
shall also obtain written consent from his family members or other 
relatives, before conducting any operation, special testing or special 
treatment, though this does not provide a clear mechanism to deal with 
the possible conflicts between patient and her/his family.52 However, the 
applicable scope of this Regulation is innovative treatment rather than 
biomedical research involving human subjects. 
Therefore, although the Measures 2007 has clearly established general 
principles for biomedical research involving human subjects, such as the 
need to obtain informed consent, which are widely accepted by both 
international guidelines and most Western countries, the legislative 
framework of the PRC only provides broad principles, not more specific 
regulation to protect the interests of individuals and groups who may be 
asked to participate in HPGR. 
4) These legal regulations, such as they are, are not designed to fit the 
particular position of China.  They are based on Western principles that 
focus on individual autonomy and in many cases are copied word for word 
from Western regulations. For example, the rules of Measure 2007 on 
informed consent are almost directly transplanted from the relevant rules 
of the CIOMS Guidelines and the Helsinki Declaration. The following 
section will argue that the cultural tradition of bioethics in the PRC is not 
entirely the same as in Western countries. Thus, it is reasonable to 
suppose that these transplanted regulations may not work effectively or 
be culturally appropriate in the PRC, where the traditional ethic 
emphasises social harmony over individual interests.  
Having discussed the deficiencies of current Chinese legal regulations, it is 
important to stress once again that current dominant Western legal regulations 
and ethical guidelines, which are still grounded in an individualistic autonomy 
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model, are also ill-suited to take account of the particular concerns surrounding 
group/community collective genetic information and the vulnerability of target 
groups in HPGR. Effective regulation of HPGR in the PRC will need to consider 
these matters.  
4.2 HPGR in the PRC 
It has been argued here that the current legal legislation and rules which relate 
to human subject research in the PRC cannot provide adequate and systematic 
protection for research subjects of HPGR. This is problematic, not least because 
the PRC, which has rich human genetic resources, seems to be an ideal mother 
lode for human population genetic research.  
4.2.1 Brief Introduction of HPGR in the PRC 
Facing the new era of genetics, the PRC has its own ambitions and problems. 
HPGR projects in the PRC, especially those conducted by foreign researchers, 
are highly controversial.  
On the one hand, The PRC‘s active participation in the Human Genome Project 
and its completion of the sequencing of the rice genome indicated that China is 
seeking an advanced place in genetics and genomics. 53 In the area of human 
population genetics, HPGR has also been encouraged and supported by the 
government. China began its own HPGR, the Chinese Human Genome Diversity 
Project (CHGDP) in November 1993, which still continues on a large scale. It was 
designed to ‗collect the cell lines of the 56 official ethnic groups in China in the 
National Cell Line Repository in the Kunming Institute of Medical Biology (part of 
the Chinese Academic of Medical Sciences) and Beijing Institute of Genetics 
(part of the Chinese Academic of Sciences).‘54 According to a paper by Chu et 
al.,55 CHGDP has collected genetic information and cell-lines from the official 
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ethnic groups and has tested their DNA.56 The project was also concerned with 
determining the types and incidences of genetic diseases and preserving each 
ethnic group‘s genetic information.57 Along with the rapid development of the 
Chinese economy, transport between different areas in PRC became easier and 
faster, which has led to an increase in intermarriage between different people 
from different areas, and it may also lead to the dilution of the unique 
population genetic information of China‘s minority ethnic groups. The Chinese 
HPGR proposed to collect the DNA samples of ethnic minorities and store the 
collections in gene banks, especially those of some of the rural populations and 
ethnic groups of Central and Southwest China. For example, a large gene bank 
for ethnic minorities in Yunnan Province, which aims to study the diversification 
of inheritance and inherited diseases of the ethnic minorities, has stored 1,250 
men‘s DNA from 25 ethnic groups.58 Given that the participants in this project 
live in isolated rural areas in Yunnan, they are thought to have ‗no history of 
marrying other ethnic peoples, and every man has the same ethnic origin for at 
least three generations in succession,‘59 so their genetic information is deemed 
to have high purity. So far this is the largest data bank of its kind in the world.60 
This type of HPGR project is thought to be helpful to ‗reconstruct the history of 
populations by studying genetic variation to determine patterns of human 
migration.‘61 Hence, some scholar even noted that ‗the leaders of the People‘s 
Republic hope that the biotech revolution — now shaking the formerly isolated 
communist nation — will have similar effects to those induced by the Soviet 
Union‘s legendary Sputnik space programme, bringing the country to the world‘s 
attention.‘62 
The encouraging attitude of Chinese government toward genetic research, 
arguably combined with a considerable lower level of standards in biomedical 
regulation, or a weakness in enforcing the related guidelines, has promoted a 
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number of foreign researchers to conduct HPGR in China. For example, a French 
company, Genset, sent a letter to the Chinese Academy of Medical Science 
(CAMS) seeking research co-operation. The plan was to employ some of CAMS‘s 
researchers to collect DNA and diagnose genetic conditions. Genset and its 
partner, the French trading company Tang Frère International, would then 
analyze these DNA samples in France, using gene-sequencing machines, to 
develop new diagnostic methods and new drugs. In this letter, they declared 
that ‗[w]e view gene research as extremely important for Chinese health care in 
the 21st Century and we are convinced that our joint effort will lead to 
fundamental discoveries which will benefit not just China but the rest of the 
world.‘63 The Harvard study is also a typical HPGR project. A newspaper report 
described the Harvard case as following: 
The China project was hatched in the office of Geoffrey Duyk, a 
Harvard geneticist who had one foot out the door to industry. At the 
time, 1994, genetics seemed the next big thing in American medicine. 
Among those enamored was Scott Weiss, a prominent Harvard 
respiratory epidemiologist. Weiss had come to Duyk for help in 
launching a study into genetic causes of asthma and similar illnesses. 
Duyk perked up when Weiss said he had a line on an unusually 
homogeneous population of 62 million people in Anhui province, a 
region isolated by geography and poverty for 2,000 years….The 
research required thousands of volunteers, nearly impossible to obtain 
in such a remote place without an experienced guide. Weiss had just 
the person -- he had mentored a post-doctoral fellow, Xu Xiping, who 
came from Anhui and had conducted several public health studies 
there. Xu was an epidemiologist with no real expertise in genetics, 
but he had hometown connections and a proven aptitude for getting 
things done in China. 64 
Therefore, the appeal of the PRC as a HPGR sample lode has been widely 
acknowledged. 
On the other hand, along with the breakout of scandals associated with HPGR, 
such as the Harvard study, a sensitive debate on HPGR has also been raised in 
the PRC.65 Advocates have argued that HPGR in China could help to discover 
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more about the diversity of human genetic information and the causes of some 
diseases, which could benefit the progress of medical research both in China and 
elsewhere.66 Opponents have argued that HPGR conducted by foreign research 
institutions in the PRC could result in risks of harm to both the interests of the 
target groups and the national security of the PRC. According to Yang, HPGR 
conducted by foreign countries in the PRC could lead to the collection of Chinese 
genetic information by foreign organisations to produce medicine which could 
then be sold to China at a high cost,67 as well as potentially being used to create 
genetic weapons targeted at Chinese people. 68  Furthermore, some bioethical 
scholars, such as Sleeboom, are concerned that it also could be used to ‗make 
claims on disputed territory, resources, and self-determination.‘69 Meanwhile, 
given the absence of relevant ethical and legal regulations on HPGR in PRC, 
HPGR may also lead to the violation of the interests of both target groups and 
individual participants.70 In the Harvard study, the blood and genetic samples of 
200 million Chinese people were taken to the US. If there are no effective legal 
regulations or policies, these samples will be analyzed in foreign counties and 
potentially be developed into new diagnostic methods and new drugs, without 
ensuring the interests of the Chinese target groups and individual participants 
who provided their population‘s genetic information. 
4.2.2 Attractions of Conducting HPGR in the PRC 
Although some points have been outlined above and in Chapter 1, the special 
advantages of the PRC as a research target of HPGR should be reinforced and 
explored in more details: 
1) Due to size, geographic diversity, and social traditions and customs, there 
are a great many isolated populations within China.  
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The population size makes it possible to recruit a large number of 
participants for HPGR.71 To be accurate, according to the China Statistical 
Yearbook (2008) of the National Bureau of Statistics of China, by the end of 
2007, the total population of China was 1,321,290,000 persons; what is 
more, the rural population consists of 727,500,000 persons.72 
In addition, the Chinese people have remained relatively isolated in the 
past, which has preserved the relative genetic homogeneity of the 
population in many regions, especially in the areas where the minorities 
are living, for reasons such as that little modern transportation exists in 
rural China, or that there is a tradition for most members of Chinese 
families to live together. Therefore, China contains rich genetic resources 
and several isolated areas which have idiographic cultures. The tradition of 
Chinese populations, which are relatively stable, with relatives tending to 
live in the same area, makes it easier to study certain groups/communities 
and carry out long-term follow-up. Furthermore, divorce is rare in rural 
China; thus, the households are stable. This facilitates the collection of 
comparative data. 
2) It is very cost-beneficial to conduct HPGR in China. The current per-capita 
income of rural China is still very low. According to data from the National 
Bureau of Statistics of China, by the end of 2007, the per capita annual 
income of rural household was 4140.4 73 yuan.74 Medical services in rural 
China do not work well; a large number of people there cannot be provided 
with basic medical care. Hence, research institutions and researchers can 
recruit large numbers of participants by providing simple free physical 
examinations or providing some cheap standing drugs, such as vitamins and 
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hypotensors. The story of poor farmer Chu in the Harvard case, 75 which has 
been mentioned previously, illustrates this well. His family provided several 
blood samples, but only received a little amount of money and some simple 
food. 76 The difficulties in ensuring that participants are not exploited but 
at the same time are not subjected to undue influence have been discussed 
in Chapter 3. 
3) Conducting collaborative HPGR in China seems to be relatively easy. 
China‘s ambitions in genetics and Chinese genetic researchers‘ desire to 
collaborate HPGR projects with foreign research institutions with advanced 
technology and wide experience also contribute to it. Before the Harvard 
case, there were few legal regulations or government policies on 
conducting HPGR, even HPGR conducted by foreign researchers or 
institutions. For example, according to Xiong et al‘s reports, in 1996, a new 
co-operative medical centre was set up in Yuexi district sponsored by Xu 
Xiping, from which more than 1,400 genetic samples were taken.77 After 
this case, since 1998, researchers or research institutions need State 
permission for HPGR and also permission to take samples abroad. However, 
researchers or research institutions can conduct HPGR by running their own 
laboratories or through jointly operated laboratories with Chinese 
researchers in China. Some Chinese researchers prefer to conduct these 
kinds of co-operative projects in HPGR. For example, Fang Zhi-an, head of 
the committee for health and education of the Anqing City‘s Peoples‘ 
Congress‘ Standing Committee, was satisfied with his co-operation with Xu 
Xiping, who is an associate professor at Harvard University, and the Harvard 
project. He believes that it has initiated the development of local hygiene 
work and has trained both Chinese talents locally, in Anqing, and nationally. 
What is more, Fang and Xu have co-authored more than 10 articles in 
international academic journals. 78 However, some foreign researchers‘ 
Chinese partners felt that the collaborations were not balanced and that 
Chinese academic interests have been frustrated. For example, Liu Jianhui, 
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the vice-director of science research management of Anhui Medical 
University, who is the other partner of Xu Xiping in the Harvard studies, 
complained that the Chinese should receive more information on the 
outcome of the research.79  
In summary, due to the large size of the population, the unique genetic history, 
geographical diversity, high participation rates, low cost and stable social 
traditions and customs, China is an ideal research target of HPGR. Hence, not 
only Chinese, but also foreign, researchers and research institutions are 
enthusiastic about conducting HPGR which targets certain groups/communities 
here. 
4.3 Target Group Protection in HPGR in the PRC 
Given the substantial number of ethnic minorities and isolated groups in rural 
areas, in the foreseeable future there are likely to be more domestic Chinese 
and foreign researchers or research institutions intending to conduct HPGR in the 
PRC. Nevertheless, these ethnic minorities and isolated groups in the PRC have 
their own cultural sensitivities, which are distinct from Western ones. The PRC 
has its own specific legislation and policies on ethnic minority protection, which 
will be evaluated in the following section in the light of these sensitivities.  
4.3.1 Cultural Sensitivity of Target Groups in HPGR in the PRC 
As has been demonstrated in previous chapters, conducting HPGR without 
understanding the cultural sensitivities of the target group may lead to harms to 
target groups. 
(1) A Brief Introduction to Bioethics in the PRC 
Although bioethics as a discipline does not formally exist within traditional 
Chinese culture, undoubtedly China has its own unique bioethical traditions 
which are distinct from Western bioethics. For example, Bowman and Hui have 
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explained that in traditional Chinese medicine the view of illness is entirely 
different from Western views. They note that in Chinese traditional medicine, 
the body, soul and spirit are viewed as an integrated whole. Furthermore, 
because human beings are considered products of nature, humankind and the 
natural environment are seen to be inseparably and interdependently related; 
protecting the integrity of the human–nature dyad is thus fundamental to 
health.80 
In the context of ethical discussion, in the traditional Chinese medical view it is 
commonly acknowledged that Confucianism dominated medical ethics in pre-
modern China. Generally speaking, Confucianism is an ethic that teaches people 
how to be human. Different from Western individual-oriented political and social 
philosophy, Confucianism focuses on the collective interests of family, 
community, society, even nation. Qiu describes Confucian teaching and its basis 
as follows: 
For Confucians, demarcation between a human and an animal lies in 
whether you care for others or you care only yourself. The basic 
concept of Confucianism is ren, which means ‗loving people‘. The 
golden rules of Confucianism are: ‗you should not do to others what 
you don‘t want to do to yourself,‘ and ‗after establishing yourself, you 
should help others to establish themselves; after you develop yourself, 
you should help others to develop.‘… One reason is that Chinese hold 
a different concept of the ‗person‘ from the Westerners. For the 
Chinese, a person is not as independent as some Westerners presume. 
No person can survive without support from others; so a person is a 
relational person or a person in relation. Metaphorically, a person is 
an atom in the west, but a person is a drop of sea water in China. For 
some Westerners, if an individual person does not exist, the whole 
world becomes meaningless. But for Chinese a drop of water 
evaporates, but the sea will still exist. So the collective is more 
important than the individual in China. If there is any conflict of 
interest between the individual and the collective, the former should 
be subordinated to the latter.81   
However, in order to fully understand traditional Chinese medical morality, one 
must take into account the influence of Taoism and Buddhism, as well as 
Confucianism. In Confucian teaching, death is seen as a type of accomplishment 
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in this world, such as the fulfilment of ‗ren‘. ‗Ren‘ denotes ‗the cultivation of 
positive human attributes such as humaneness, charity and beneficence.‘ 82 
Hence, one‘s death can be a ‗good‘ one, which is to say worthy and acceptable, 
for the person has fulfilled his/her moral duties in life. If a patient has been 
cured, it means that he/she has unfinished business, which is worth the ‗Tian‘83 
extending his/her life to complete unfinished tasks or fulfil moral duties. 
Another significant position is based in Taoism, which ‗teaches the post mortem 
survival of the whole bodily person and an afterlife of torture and suffering in 
endless Hell.‘84 Hence, Taoism teaches people to pursue maintaining youth and 
attaining longevity and immortality. However, philosophical Taoism has a 
radically different perspective, which is reflected in the phrase, ‗Man comes into 
life and goes out to death.‘85 Thus, one should view death calmly. Buddhism 
provides a more unpredictable response to the suffering of dying and the event 
of death. This philosophy claims that ‗if the person maintains his or her belief in 
the impermanence and cyclical nature of life, he or she may be easily resigned 
to death; but if the person sees the suffering of the dying event as an occasion 
to ‗work out‘ his or her karma (which may include suffering from one‘s bad 
deeds) in this lifetime, then the person may not welcome death quite so 
readily.‘86 The views of Chinese traditional medicine were deeply influenced by 
each of these three philosophical traditions.  
In addition, Chinese bioethical perception is not influenced by a single 
theoretical perspective. From 1949, when the PRC was established, 
communitarian ethics gradually became the dominant paradigm; especially 
during the Cultural Revolution.87 Traditional Chinese moral norms were officially 
                                         
82
 Ibid. at 399-400. 
83
  In traditional Chinese Culture, everything was mastered by Tian (in Chinese ‗天‘). Tian is not an 
Elohim, such as Heaven. Tian is a kind of power that cannot be denied, like destiny. 
84
 See supra note 80, at 400. 
85
 Ibid. 
86
 Ibid. 
87
 The Cultural Revolution is ‗The Great Proletarian Cultural Revolution‘. It was a violent mass 
movement that resulted in social, political, and economic upheaval in the People‘s Republic of 
China starting in 1966 and ending officially with Mao's death in 1976. It was launched by Mao 
Zedong, the chairman of the Communist Party of China, on May 16, 1966; he alleged that 
"liberal bourgeoise" elements were permeating the party and society at large and that they 
wanted to restore capitalism. Mao insisted, in accordance with his theory of permanent 
revolution, that these elements should be removed through revolutionary violent class struggle 
Chapter 4 
People‘s Republic of China: A Mother Lode of Genes? 184 
 
attacked as the ‗pernicious influence of feudalism,‘ and ideas from the West, 
except Marxism, were censured as the ‗bourgeois fallacy.‘88 However, traditional 
Chinese values never completely disappeared; along with the new policies of 
openness and reform, traditional medical ethics started to revive. Thus, as Fox 
and Swazey89 have pointed out, contemporary Chinese medical morality is an 
unbalanced combination of Maoism-Marxism-Leninism, Confucianism, Taoism, 
and Chinese Buddhism.90 Despite this, many Chinese scholars also hold that there 
exists a characteristic Chinese way of thinking about and acting in public and 
private life, interpersonal interactions, and moral issues in medical practice. For 
example, Qiu, who is currently a leading bioethical scholar in the PRC, argued 
that although there is an ‗awakening of the rights sense, especially in 
intellectuals, university students, and the young, along with the advance of 
modernization,‘91 however, he summarized the common Chinese view of Chinese 
medical ethics as follows: 
A quasi-holistic socio-political philosophy has been developed from 
Chinese cultural tradition. It is based on two thousand years of power-
centralized, autocratic monarchy—one that has lacked any rights-
oriented, individualistic, liberal democratic tradition. In recent 
decades, Marxism—rather, a mixture of Russian and Chinese versions 
of Marxism—has become the dominant ideology. The historicism and 
social holism of this system, inter woven with traditional ideas, puts 
the greatest emphasis on nation, society, and country rather than on 
individuals.92 
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Along with China‘s Economic Reform and Open Policy published in 1978, 93  a 
significant number of Western ideas flooded into the PRC. Some Chinese scholars 
who favour Western bioethics have used this to illustrate the theoretical blind-
spots and practical deficiency of Chinese medical ethics and to stress the 
importance of learning from the developed Western countries.94 Currently, most 
of the medical institutes in the PRC have set up bioethics courses and conduct 
educational bioethics activities based on internationally acknowledged ethical 
norms such as the Nuremberg Code, 95  the Declaration of Helsinki 96  and the 
International Standards of Ethical Examination of Biomedical Research Involving 
Human Subjects.9798 Meanwhile, ethics committees have been established in most 
large-scale hospitals in the PRC, with responsibilities for ethics education and 
ethical review consultation for medical professionals on how to implement the 
principles of bioethics.99 Hence, medical professionals and the highly-educated 
populations in the PRC are mostly influenced by, and accept, Western bioethics.  
Therefore, Nie has argued that ‗[I]n today‘s China, one can easily find in the way 
people actually live, and even in official State publications, the co-existence of 
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traditional Confucianism, Taoism, and Buddhism along with sinonized Western 
Marxism and communism; the conceptions of filial piety and loyalty to the 
country along with the ideals of individual happiness, self-fulfilment, and self-
perfection.‘ 100  For example, Chinese people‘s unique view on truth-telling in 
health care can illustrate that although almost Chinese people believe the 
combined ideology of Maoism-Marxism-Leninism, Confucianism, Buddhism and 
Western bioethics, their moral experience and practices, when ill, are very 
unlikely to reach the same answer.101 
With regard to truth-telling in health care, there is not a single 
distinctive Chinese approach—e.g., toward either disclosing or 
concealing the diagnosis of terminal disease. For the sake of patients‘ 
well-being, many contemporary Mainland Chinese physicians, along 
with family members and friends, do not directly tell the whole truth 
to patients who are suffering terminal diseases. But this is far from 
standard practice in traditional China. Partly (and only partly) due to 
Western influence, more and more physicians prefer to discuss frankly 
and openly all the related medical issues with their patients. Many 
patients know the nature of their disease from other sources as well, 
including the ward in which they are hospitalized, the department in 
which the doctor works, and the gestures of people in and around 
their family. It is not uncommon, however, for a patient who knows 
the truth to pretend otherwise to his or her loved ones in order to 
reduce their suffering. For the physician to speak directly to the 
patient is just one way of telling the truth.102 
As a result, in general, contemporary Chinese bioethics is indeed a mixture of a 
great number of values and beliefs—ancient and modern, Western and Eastern. 
(2) Cultural Sensitivity of Target Groups of HPGR in the PRC 
Given that the target groups in HPGR are ethnic minorities and isolated groups in 
rural areas in the PRC, their bioethical conceptions, decision-making processes 
and cultural sensitivities are more likely to be influenced by traditional 
Confucianism and Marxism. Therefore, the bioethical background of the most 
likely target groups of HPGR in China needs to be explored in more detail. 
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Almost every scholar who is interested in Chinese bioethics would notice the 
specific view of Chinese people on autonomy or informed consent. For example, 
Bowman and Hui described this issue as follows: 
The concept of autonomy best highlights the contrast between 
Western and Chinese cultures. In the West, the principle of autonomy 
implies that every person has the right to self-determination. In the 
context of healthcare, this means that the patient is the best person 
to make healthcare decisions. Within Chinese culture, however, the 
person is viewed as a ‗relational self‘ – a self for whom social 
relationships, rather than rationality and individualism, provide the 
basis for moral judgement. From this perspective, an insistence on 
self-determination erodes the value placed on personal 
interconnectedness and the social and moral meaning of such 
relationships. In traditional Chinese society, the influences of which 
still endure, the family is based on an extended or clan structure and 
plays a central role in an individual‘s life…. All major decisions made 
by the family are thus informed by these hierarchical structures… In 
Chinese culture, the family functions as collective decision maker and 
also as a powerful conduit for moral, religious, and social norms. The 
family‘s role in self-determination is, therefore, integral to any notion 
of Chinese bioethics.103 
What is more, they also argued that respect for an individual‘s right to self-
determination is not prominent in traditional Chinese culture, because ‗the 
Confucian concept of relational personhood challenges the assumption that the 
patient should be given the diagnosis and prognosis and the opportunity to make 
his or her own medical decisions,‘ as well as the fact that ‗social and moral 
meaning rests in interdependence, which overrides self-determination.‘ 104 
Consequently, before making decision, many Chinese patients, by contrast to 
Western ones, would consider not only the influence to her/him, but also 
disclose relevant information to who are important to her/him and consult 
opinion of them. When making decision, they would also take account to the 
potential affects to her/his family or community as well as potential influence to 
her/him. Sometimes, they would also like to regard family or community ideas 
as her/his decision, even when they themselves are competent.  
Currently, Chinese culture is characterized by strong communal values and an 
emphasis on social harmony. As Fan has pointed out, ‗[s]ince, compared to 
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Western societies, East Asian states are still homogeneous in their conceptions of 
the good, a set of values relating to clinical decision making is generally 
accepted by various communities, families and individuals, thus serving as an 
objective or impersonal conception of the good.‘105 For example, in the clinical 
context, this feature can be reflected by the following example: if a patient 
refuses treatment because he judges his life is no longer worth living, when the 
relevant others do not agree in terms of the objective conception of the good, 
the patient‘s wishes would not be followed, whether or not the patient is 
competent.106  
Another example is provided by Fan, a bioethics scholar who labelled the East 
Asian principle of autonomy as ‗a family-determination-oriented principle.‘107 
She offered a description of the principle of autonomy in East Asia, which is that 
‗[p]ositively: every agent should be able to make his or her decisions and actions 
harmoniously in cooperation with other relevant persons; and negatively: no 
harmoniously made decisions and actions should be subjected to controlling 
constraints by others.‘ 108  She also provided a clinical care decision-making 
process in East Asia to illustrate the distinction between the understanding of 
Western and East Asia on autonomy as following: 
For instance, when a patient requests or refuses a treatment while a 
relevant family member holds an opposite opinion, the physician 
generally should not simply follow the patient‘s wish as in the West, 
even if the patient is evidently competent. Instead, the physician 
should tell the patient and the family members to negotiate and 
provide an agreement to him before he can undertake a medical act. 
Indeed, on the one hand, East Asian people make a clear distinction 
between intra-familial and extra-familial authority. On the other hand, 
it is not a sick family member him/herself but the entire family that 
has real authority in clinical decision making. Western people might 
be concerned about this claim of the family-sovereignty. But the 
family under this notion can be viewed as an autonomous social unit 
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from the physician and the state, analogous to the autonomous 
individual in the West.109 
She also pointed out that the basis for this distinction is the Confucian 
understanding of the nature of the family and individuals. In Confucianism, it is 
the arrangement of Heaven (tian) that every individual is born to a family; hence, 
there are special relations that exist between family members and one‘s life is 
lived inseparably from the family. Familial relationships are three of the five 
basic human relations in Confucianism. Thus, Confucian morality requires that 
one should consider one‘s family as an autonomous unit from the rest of society, 
flourishing or suffering as a whole.110 Although her argument emphasized only 
one of the Chinese traditional moral ideologies - Confucianism - which centred 
on the family, Fan has pointed out an essential characteristic of Chinese ethical 
understanding on autonomy; which is a decision should not be taken in isolation 
based on the individual‘s own interests. In Western countries, some groups also 
have similar relational perspectives.111 However, in the West, in most cases, if 
possible, a competent patient generally has the final word regarding medical 
decisions about his or her care, while in China both the patient and family 
members tend to reach an agreement before a clinical decision can be made. 
This tendency makes China in a better position to adopt a relational autonomy 
model in HPGR. 
Therefore, the major value advocated by Chinese culture can be described as 
‗harmonious dependence.‘ 112  According to Chinese people‘s understanding, 
individuals are not only independent persons, but also members of certain 
families, groups/communities; thus, their decisions, especially medical decisions, 
require a full range consideration of the interests of all relevant parties who 
would be affected by this decision. This feature means that, whatever the 
relevant guidelines say, the Chinese may not apply the individualised Western 
bioethical standard directly. For example, Engelhardt, through analysis of 
difficult cases on medical consent, concluded that when making a medical 
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decision on a patient, even the patient is competence, the family would play an 
important role in securing patient consent and others, such as community and 
fellow-work would also be involved, rather than the patient make it 
independently.113 Hence, it is reasonable to agree with some Chinese scholars 
who consider that transplanting Western medical morality would be practically 
impossible and also dangerous in theory. 114 It needs to be clarified that this 
assertion does not means that it is useless to seek informed consent from 
participants of HPGR in the PRC, but is intended to highlight the significance of 
seeking informed consent through a mechanism which is suitable to the specific 
situation and is sensitive to cultural values.  
There may also be difficulties posed by the background and experience of 
potential research participants. For example, a study on informed consent 
strategies, which was conducted in three areas south-west of Shanghai, in an 
epidemiological project approved by the regional research ethics committees in 
Sweden and China115 found that although informed consent was adopted in the 
epidemiological project, even where the informed consent procedures in the 
PRC were sought to be conducted to the same standard enforced in the Western 
countries, it was not always easy to convey information and obtain real consent, 
since the educational level and background knowledge of these subjects of 
biomedical research were not the same as those in the West. Furthermore, the 
study was conducted in Shanghai, which is the most modernized city in the PRC, 
where the average educational level is higher than the average level of the PRC. 
Due to the generally low level of education of large populations in the rural 
areas of mainland China, and the influence of traditional cultural sensitivities, 
more problems could emerge in the practice of informed consent in HPGR. For 
example, in 2005, the well-known scientific journal ‗Nature‘ published a story of 
the unethical conduct of a clinical trial for a drug called VGV-1 on HIV-positive 
farmers from Henan province by a collaborate research project of Beijing‘s Ditan 
                                         
113
 Engelhardt, H. T. 1980, "Bioethics in the People's Republic of China", Hastings Centre Report, 
vol. 10, no. 2, pp. 7-10, at 8. 
114
 Qiu, Qiangxin. 1999. Medical Ethics. Beijing: People‘s Health Press. 
115
 Lynoe, N., Sandlund, M., Jacobsson, L., Nordberg, G., & Jin, T. 2004, "Informed Consent in 
China: Quality of Information Provided to Participants in a Research Project", Scandinavian 
Journal of Public Health, vol. 32, no. 6, pp. 472-475, at 472. 
Chapter 4 
People‘s Republic of China: A Mother Lode of Genes? 191 
 
Hospital and Viral Genetics of Azusa which is a US drug company. 116  In this 
research project, participants said that they had been told that they would be 
injected with a new drug which would keep them in good health for 20 years 
without further treatment and were not notified that there were also associated 
risks.117 The known risks of harm of this drug trial were not disclosed to the 
participants, but participants then ‗signed informed-consent forms that they 
could not understand and that doctors made no effort to explain.‘118 The other 
inappropriate issues in the trial included that ‗copies of the forms had to be paid 
for; expenses were not covered as agreed; participants weren‘t informed of the 
trial‘s results, despite asking.‘119 The potential participants in HPGR are more 
vulnerable to failing to understand the relevant information and making poor 
decisions even than the participants in the study above. The use of language 
with adequate accuracy and articulation, easily understood by people with a low 
level of education, and with respect for cultural sensitivities is crucially 
important for appropriate information disclosure and consent; it is particularly 
important when the researchers come from other countries.  
Therefore, in the context of HPGR in the PRC, rather than applying Western 
frameworks slavishly, in order to protect the interests of target group it would 
be better to consider and give respect to the specific needs and cultural 
sensitivities of target groups in the PRC, which are highly influenced by the 
traditional Chinese Confucian moral order. The need for cultural sensitivity 
makes Chinese target groups in HPGR more appropriately considered under a 
relational autonomy model, rather than a purely individualistic model. The 
following three examples can illustrate this viewpoint: 
Firstly, possible risks of harm that may be posed by HPGR to both individual 
participants and target groups should be disclosed to the potential participants. 
In some communities or groups according to traditional customs, individuals 
would be likely to wish to consider both the interests of their group/community 
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as well as their own private interests. Evaluating the interests and preferences 
of the group/community before decision-making is their cultural approach. 
Secondly, where decisions may be relevant to the interests of a 
group/community, individuals‘ may seek or rely on group/community leaders‘ 
opinions in forming their own decisions. Again, this may be part of the cultural 
norms of members of a group, so that seeking or accepting such views cannot be 
regarded as being undue influence.  This suggests that community/group leaders 
should be consulted where HPGR is proposed. 
Thirdly, in some Chinese groups/communities, if issues are relevant to the 
interests of the group/community as a whole, there is a cultural tradition and 
expectation of group consultation and involvement. This custom would suggest 
the involvement of members of target group in research design and at the 
ethical review stage to help to correctly identify and avoid potential risks of 
harm. This might take the form of the involvement of community leaders or a 
wider range of people from the target group, depending on the scope of the 
study and cultural norms within the target group. 
In this vein, target groups in HPGR from the PRC are quite suitable to be 
considered in terms of relational autonomy. Unfortunately, current legal 
regulations and ethical guidelines in the PRC do not take this approach. 
Nevertheless, the protection of minorities is seen as an important concern, 
which suggests that extension of consideration to the protection of target groups 
would not be such a substantial leap. 
4.3.2 Legal Regulations and Public Policies on Ethnic Minorities 
Developing legal regulation and public policies concerning ethnic minorities is 
one of the basic principles of the legal system in the PRC. The Government 
white paper ‗China‘s Ethnic Policy and Common Prosperity and Development of 
All Ethnic Groups‘120 noted in its preface that 
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China is a unified multi-ethnic country jointly created by the people 
of all its ethnic groups. In the long course of historical evolution 
people of all ethnic groups in China have maintained close contacts, 
developed interdependently, communicated and fused with one 
another, and stood together through weal and woe, forming today‘s 
unified multi-ethnic Chinese nation, and promoting the development 
of the nation and social progress.121 
It also describes the current make-up of ethnic minorities in the PRC as follows: 
Over the past 60 years, the total population of the ethnic minorities 
has been on a constant increase, comprising a rising proportion in 
China's total population. The five national censuses that have been 
conducted show that the total population of ethnic minorities was 
35.32 million in 1953, 6.06 percent of the total population; 40.02 
million in 1964, 5.76 percent of the total; 67.30 million in 1982, 6.68 
percent of the total; 91.20 million in 1990, 8.04 percent of the total; 
and 106.43 million in 2000, 8.41 percent of the total. The populations 
of the ethnic groups vary greatly from one to another. For example, 
the Zhuang has a population of 17 million, far more than that of the 
Hezhe, numbering only some 4,000.122 
The Constitution provides that China practises a certain degree of regional 
autonomy, which may have an ethnic basis. Regional autonomy is exercised and 
organs of self-government are established in areas where various ethnic 
minorities live in compact communities. National autonomous areas are 
classified into autonomous regions, autonomous prefectures and autonomous 
counties. There are in total five autonomous regions (the Inner Mongolia 
Autonomous Region, the Xinjiang Uygur Autonomous Region, the Guangxi Zhuang 
Autonomous Region, the Ningxia Hui Autonomous Region and the Tibet 
Autonomous Region), 30 autonomous prefectures, 116 autonomous counties and 
three autonomous banners in the whole country. 123  All national autonomous 
areas are integral parts of the People‘s Republic of China. According to statistics 
revealed in the fifth national census, conducted in 2000, of the country‘s 55 
ethnic minorities, 44 had their own autonomous areas. The population of ethnic 
minorities practising regional autonomy accounted for 71 percent of the total 
population of ethnic minorities, and the area where such regional autonomy was 
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practised accounted for 64 percent of the entire territory of China. In addition, 
China has established 1,100 ethnic townships, as a supplement to the system of 
regional ethnic autonomy.124 
The PRC has its unique regional national autonomy system; and regional national 
autonomy policy is also a basic policy, which the PRC adopts to handle problems 
among its ethnic groups, as well as a fundamental political system for this 
country. The establishment of the regional national autonomy system is 
determined by the relationships among its local ethnic groups, the economic 
development of the locality, and its historical background: First, as far as history 
and traditions are concerned, the long-term existence of a unified multi-ethnic 
country is the historical background for implementing regional ethnic 
autonomy.125 The white paper on Chinese ethnic minorities noted that ‗[a]s early 
as in the pre-Qin Dynasty times before 221 BC the concepts of ‗country‘ and 
‗unification‘ had taken shape in the minds of the Chinese people.‘126 Second, as 
far as ethnic relationships are concerned, the Chinese people consist of multi-
ethnic groups, and the close and extensive ties among them are the economic 
and cultural base for the implementation of regional ethnic autonomy.127 Third, 
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the distribution of ethnic groups plays a large part in determining the scope of 
regional autonomy. Some of China‘s ethnic groups inhabit vast areas, while 
others live in individual compact communities in small areas or live in a mixture 
of each. 128  Fourthly, as far as economic developments are concerned, the 
previous and current economic conditions of ethnic minorities led to the policy 
of regional ethnic autonomy to deal with poverty, which is still the key issue in 
ethnic minority areas.129 Hence, ethnic minorities are believed to need special 
policies and support from the State. 
Therefore, in 2001, in consideration of the actual conditions when the socialist 
market economy was established, the Standing Committee of the NPC made 
revisions to the Law on Regional Ethnic Autonomy. 130  Subsequently, the 
Provisions of the State Council on Implementation of the Law of the People‘s 
Republic of China on Regional Ethnic Autonomy,131 issued by the State Council in 
2005, defined the duties of governments at higher levels to support and help the 
organs of self-government in ethnic autonomous areas. 132 The organs of self-
government of national autonomous areas are the People‘s Congresses and 
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People‘s Governments of autonomous regions, autonomous prefectures and 
autonomous counties.133  
In addition to the functions and powers of other ordinary local organs of the 
State, the organs of self-government of national autonomous areas exercise the 
power of autonomy in accordance with the law and implement the laws and 
policies of the State in the light of existing local conditions.134 The people‘s 
congresses of national autonomous areas have the power to enact regulations on 
the exercise of autonomy and separate regulations in light of the political, 
economic and cultural characteristics of the nationality or nationalities in the 
areas concerned.135 The organs of self-government of the national autonomous 
areas independently arrange for and administer local economic development 
under the guidance of State plans; the organs of self-government of the national 
autonomous areas have the power of autonomy in administering the finances of 
their areas. The organs of self-government of the national autonomous areas 
independently administer educational, scientific, cultural, public health and 
physical culture affairs in their respective areas. 136 
What is more, the State is responsible for promoting the development of ethnic 
minorities. In exploiting natural resources and building enterprises in the 
national autonomous areas, the State gives due consideration to the interests of 
those areas; the State provides financial, material and technical assistance to 
the minority nationalities to accelerate their economic and cultural 
development; the State helps the national autonomous areas train large number 
of cadres at various levels and specialised personnel and skilled workers of 
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various professions and trades from among the nationality or nationalities in 
those areas.137 
Although these specific regional powers and laws may provide some protection 
to ethnic minorities in the PRC, it cannot be said that there is adequate 
protection for the target groups in HPGR in the PRC for the following reasons: 
1) All such laws are focused on the interests of official ethnic minorities, 
which cannot include all the target groups of HPGR.  
HPGR researchers hope that identifying differences in genetic sequences 
between peoples will help to determine what makes certain groups of people 
different from others. In fact, there are a number of factors that are 
relevant to the delineation of populations for HPGR. These criteria need a 
balance between linguistic and genetic development, or environmental 
isolation and genetic development. Hence, Cavalli-Sforza states that the 
methods used by HPGR researchers to identify target populations include 
genealogical records and linguistics. The use of these methods, however, 
leads to research problems closely related to history and culture, which do 
not assume languages to be static: languages migrate and change, and are 
not necessarily aligned with the biological make-up of genetic groups.138 This 
means that the target subjects that the Chinese legislation and policies on 
ethnic minority intend to protect are not necessarily the same as the target 
groups in HPGR. 
In the PRC, the official definition of ‗ethnic minorities‘ was created in the 
1950s by a political decision.139 The specific standards for the division of 
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 The definition of ethnic minorities has had a tortuous history: in the 1950s, China began to 
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agencies for the minorities (for instance, nationality commissions, institutes, schools, etc.) were 
disbanded. The minorities were to be treated as the Han, and all special privileges were 
eliminated in this class-free society: a proletarian dictatorship in which only one form of lifestyle 
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ethnic minorities include not only the genetic make-up of peoples, but also 
other factors, such as their living environment and traditional customs. Thus, 
Sleeboom-Faulkner claims that ‗[i]deas about genetic particularity in the PRC 
have roots in ethnic and socio-biological views about national minorities and 
mountainous populations in remote areas...‘ 140  Hence, national ethnic 
minorities share characteristics that make them important as genetic targets 
to researchers, thus, some ethnic minorities could be the research target 
groups in HPGR. Meanwhile, except ethnic minorities, some genetic 
populations from remote, mountainous and isolated areas also have those 
characteristics and could be excellent research targets of HPGR. 
Unfortunately, those isolated groups are not protected by the legislation on 
ethnic minorities. For example, the Harvard study involved HPGR conducted 
on the people of Anhui rural areas, who are Han people, not an ethnic 
minority. 
As suggested above, the research subjects of HPGR are not only official 
ethnic minorities, but also other rural and isolated group in the PRC: thus, 
the special legislation on ethnic minorities cannot provide protection for all 
the research subjects of the HPGR in the PRC. 
2) The majority of the regulations or legislation on ethnic minority 
protection in the PRC are on a macro level, and most of them focus on 
political rights. This means that they do not pay any attention to ethnic 
minorities‘ interests and rights as groups concerning issues such as 
participation in biomedical research.  
The legislative purpose of the Law of the People‘s Republic of China on 
Regional Ethnic Autonomy, clearly stated in its Preface, is ‗critical to 
enhancing the relationship of equality, unity and mutual assistance among 
different ethnic groups, to upholding national unification, and to 
accelerating the development of places where regional autonomy is 
                                                                                                                           
was recognized. After the Deng-ist reforms in 1978, however, the special nature of the national 
minorities was gradually recognized. See supra note 140, at 407.  
140 Sleeboom-Faulkner, M. 2006, "How to Define a Population: Cultural Politics and Population 
Genetics in the People's Republic of China and the Republic of China", BioSocieties, vol. 1, pp. 
399-419, at 404. 
Chapter 4 
People‘s Republic of China: A Mother Lode of Genes? 199 
 
practiced and promoting their progress.‘141 Therefore, it can be seen as a 
law which is used to construct an essential part of the basic political 
system of the PRC. It is not difficult to understand why it concentrated on 
regulations on how to build a regional autonomous government and its 
functions. However, there was a lack of regulation on how to provide 
adequate protection to ethnic minorities and their interests in other 
aspects of their lives. Thus, in the context of HPGR in the PRC, although 
some ethnic minorities would likely be involved as target groups, their 
interests, which might be harmed in HPGR, cannot be protected by the 
legal regulations on ethnic minorities. 
In summary, According to the analysis above, although there are special laws 
and rules which aim to provide protections to ethnic minorities and regulate the 
ethical conduct of biomedical research involving human subjects in the PRC, 
they all have some deficiencies and therefore fail to provide adequate 
protections to research subjects of the HPGR. At the same time, given the 
practical situation and the distinctive cultural sensitivities of target groups in 
the PRC, the values of Western bioethical principles and guidelines may not all 
work well in the PRC. Nonetheless, the PRC, which has rich human genetic 
resources, seems to be an ideal mother lode of human genes for HPGR. 
Therefore, to further the goals of the ethical conduct of HPGR and enhance the 
protection of target groups and individual participants in the PRC, it is essential 
to continue to clarify how legal and ethical frameworks can be amended to 
adapt to the Chinese situation. 
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Chapter 5 – Conclusion 
In the thirteenth century, the English philosopher Roger Bacon had already 
pointed out that developments in medicine would never be the same as in the 
natural sciences because scientists could ‗multiply their experiments till they 
get rid of deficiency and errors.‘ On the other hand, the physician was unable to 
do this ‗because of the nobility of the material in which he works.‘ 1  This 
assertion illustrates that issues concerning the ethics of research involving 
human beings have been raised for centuries. In the absence of effective ethical 
and legal regulations on the conduct of biomedical research involving human 
subjects, the welfare of human subjects could be harmed or ignored. Therefore, 
all of the existing international declarations, ethical guidelines and national 
legislation on biomedical research are dedicated to the development and 
improvement of human subject protection in an effort to avoid or minimize 
harms to their interests. With the development of genetic science and 
technology, research on the human genome and the collection and use of 
genetic information are the new ‗hotspots‘ of biomedical research. Unlike the 
Human Genome Project (HGP) which focused on completing the ‗map‘ of the 
‗common‘ human genome,2 human population genetic research (HPGR) projects‘ 
main purpose of is to identify the diversity and variation of the human genome 
and how human group and individual genetic diversity has developed. However, 
concerns have arisen about the application of the current dominant Western 
ethical and legal frameworks on human subject protection to HPGR. This has 
been the focus of this thesis. It has discussed target group protection in HPGR 
and examined it in the context of developing countries, specifically, the 
People‘s Republic of China. 
In order to identify the difficulties of applying Western standards to HPGR, 
Chapter 2 of this thesis firstly adopted a theoretical analysis approach to 
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 Rothman, D. J. 1998, "The Nuremberg Code in Light of Previous Principles and Practice in 
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evaluate the current individual autonomy model and challenges posed to it by a 
relational autonomy model. It was followed by the discussion on the role and 
general rules of consent in the medical context, as well as the specific rules of 
consent to medical research involving human subjects, including ethical and 
professional guidance and legal principles. It then addressed risks that human 
subjects might be exposed to as a result of participation in medical research, 
and introduced the legal regulations and ethical guidelines on the well-being of 
human subjects from an international perspective. It came to the conclusion 
that currently, according to these international declarations and ethical 
guidelines, there are two basic values that are central to Western legal and 
ethical frameworks on biomedical research involving human subjects: namely, 
the autonomy of the human subject and the well-being of the human subject. In 
order to protect the autonomy and well-being of human subjects, there are two 
critical steps in determining whether biomedical research involving them can be 
conducted in an ethical manner: obtaining individual potential subjects‘ 
informed consent and assessing risks and potential benefits to them. These two 
steps work at two different levels. At one level, individual research subjects 
should be fully informed about the nature, scope, and risks of the research, and 
consent to participation should be informed and voluntary. This requirement is 
based on the basic ethical principle of ‗respect for autonomy‘ or ‗respect for 
persons‘. It focuses on the liberty and free choice of the individual. At another 
level, existing regulations require researchers to submit proposals for research 
involving human subjects to expert committees, which must judge those 
proposals based on their adherence to current legal regulations and ethical 
guidelines for the protection of human subjects, as well as ensuring the validity 
of the process of information disclosure and consent. However, current Western 
dominant frameworks are highly focused on the individual participant and fail to 
give adequate consideration to the interests of other relevant parties and 
relevant groups, or to the interests of individuals in taking account of the 
interests of others in their own decision-making. In current Western dominant 
research ethics, there is a strong common moral conviction that every individual 
has a fundamental right to self-determination with respect to his or her body.3 
Thus, in biomedical research ethics, individual consent is a significant element. 
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It is, therefore, clear that current Western dominated ethical and legal 
frameworks on human subject protection are based on individualised informed 
consent and ethical review of the risk-benefit analysis of the interests of 
individual human subjects. Since the subject of the protection provided by the 
Western ethical and legal frameworks on biomedical research is the individual 
participant, the interests of other parties, such as groups which might be 
affected, however indirectly, by some types of biomedical research, are 
generally not addressed by these standards.4  
This thesis, then, concentrated on the specific concerns raised by genetic 
research, which become even more prominent in HPGR. It was argued  that 
genetic information has some unique qualities when compared with other health 
information, in the sense that certain types of genetic information, such as 
group collective genetic information, can be gained from any individual, but may 
reveal the collective information of a certain family; even a group/community. 
Hence, the main risks of harm in genetic research are primarily related to the 
disclosure of information and research results that could lead to discrimination, 
social stigmatization, familial disruption, or psychological distress to the human 
subject and her/his family or community members. 5  For example, genetic 
research might lead to risks of harm including ‗inadvertent disclosure of painful 
facts about family relationships (such as non-paternity); stigmatization 
associated with having a genetic abnormality; and intra-familial discord.‘6 The 
inappropriate publication or misuse of an individual‘s genetic information would 
violate not only her/his interests but also the interests of his/her family 
members, even group/community members. In the context of HPGR, the 
concerns or interests of groups become important. Since HPGR focuses on the 
collective genetic information of specific target groups/communities rather than 
individual human subjects, the information collected by HPGR is 
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group/community collective genetic information. Hence, this thesis then turned 
to a discussion of potential harms to target groups in HPGR. 
A detailed explanation was given of the potential risks of harm that the target 
group as a whole might be exposed to upon the disclosure of information or 
research results of HPGR. Such harms might be external harms, such as genetic 
discrimination and stigmatization of the whole target group, as well as threats to 
national security and the survival of certain groups/communities. There might 
also be internal harms, which may occur inside the target group of HPGR, such 
as harm to the constitution of the group itself, and challenges to or 
disparagement of target groups‘ spiritual traditions, historical narratives, or 
traditional beliefs.  It was contended that the application of current legal 
regulations and ethical guidelines is problematic, since they do not provide 
protections against these types of risk of harms.  
In Chapter 3, discussion concentrated on the target groups in HPGR, who are 
frequently ethnic minorities and isolated groups in rural areas of developing 
countries. Give the common features of these target groups, such as poverty, 
low-educational level and lack of social and medical resources, this thesis 
argued that they have three different kinds of vulnerabilities in HPGR. In this 
chapter, the concept of human vulnerability and its relationship to HPGR was 
addressed. It was argued that vulnerability should be examined from three 
distinct perspectives — consent-based, risk-based, and justice-based. 7  In 
addition, in developing countries, it is common that there is a lack of effective 
legislation and regulations on biomedical research governance and human 
subject protection. This situation, together with poor law enforcement in most 
developing countries, makes target groups of HPGR more vulnerable. Hence, 
target groups in HPGR should be treated as vulnerable groups and they need 
specific protection to eliminate or reduce their vulnerabilities.  
However, through the analysis, this thesis concluded that the vulnerability of 
target groups in HPGR cannot be eliminated or reduced by current ethical 
frameworks. Currently, most guidelines for the protection of 
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groups/communities in research have been drafted for research involving 
specific indigenous peoples, such as American Indians. Although almost all of the 
guidelines require that researchers respect the culture of the community, none 
of these guidelines provides guidance on how to cope with circumstances when 
it may be unclear who represents a particular group/community. There is no 
guideline that provides for a specific, clear guidance and standard for 
group/community involvement. It is also rare to see any requirement that 
group/community representatives be involved in the conduct and ethical review 
of research. Therefore, it is concluded that these guidelines are inadequate to 
protect the special vulnerabilities of the target groups in HPGR.  
There are a great many arguments and supporting evidence to provide a 
justification for group collective rights in international law, human rights law 
and even medical law itself. For example, as has been illustrated in Chapter 3, 
in the context of medical law, there are arguments concerning collective human 
rights to public health in order to advance health rights in a globalized world. 
While, this thesis then, argued that although viewing target groups as holders of 
legally enforceable rights in respect of HPGR is not feasible under current 
dominant (Western) legal and ethical regulations, it can surely be agreed that 
their interests should and could be protected in other ways. 
In Chapter 4, the PRC has been used as an example to examine whether or not 
current legal and ethical frameworks could provide adequate protections to 
vulnerable target groups, with specific consideration of relevant cultural 
sensitivities. In China, target groups in HPGR are more likely to be influenced by 
traditional Confucianism and Marxism. According to these traditions, individuals 
would not only take their own interests into account when making decisions 
about issues relevant to the interests of their group/community, but would also 
be likely to wish  to consider these wider interests. In some groups, individuals 
would also wish to rely on the views of group or community leaders. It is part of 
their cultural traditions which ought to be respected and should not be seen as 
undue influence. However, under current ethical frameworks, researchers and 
IRBs/RECs from Western countries may not appreciate these facets of decision-
making. Therefore, although individual informed consent has its own 
justification in bioethics, even if the informed consent procedures in developing 
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countries were conducted to the same standards that are enforced in Western 
countries, the simple application of individualised informed consent may not fit 
into the cultural context of decision-making in the PRC, particularly in the 
context of HPGR. 
Following the above discussion, it became necessary to propose some 
recommendations on how to reconstruct a legal and ethical framework in HPGR. 
As has been argued in Chapter 2,8 it would be appropriate to adopt the relational 
autonomy model in HPGR. It needs to be highlighted that the adoption of this 
model does not means that obtaining group consent instead of individual consent 
from participants should be a legal obligation in HPGR. Rather, relational 
autonomy requires that the interests of all relevant parties need to be 
considered during the design of research, ethical review, the consent process 
and the conduct and monitoring of research.  In order to protect the interests of 
target group in HPGR, both researchers and IRBs or RECs need to take 
responsibility for ensuring adequate target group protection. To provide 
adequate protections for human subjects in HPGR, this thesis suggests that high 
level legislation needs to play an active role in the protection of participants and 
that the basic protections offered by the international guidelines need to be 
reconstructed into a form which is appropriate to the specific situation in any 
developing country in which this kind of research is undertaken or proposed. 
While this thesis specifically focused on HPGR in the context of the PRC, it is 
evident from examples provided of HPGR conducted in other developing 
countries that the same kinds of concerns would arise more widely, 9  it is 
therefore proposed that the following approaches should be adopted by both 
international ethical guidelines and domestic legal regulations on target group 
protection in all HPGR: 
1) Enhancing researchers‘ responsibilities for group protection 
The general obligations of researchers in HPGR should include the following. 
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Firstly, researchers in HPGR should undertake consultation with target groups 
about relevant cultural issues at the stage of research design. There are several 
obstacles that can interfere with HPGR being conducted in an ethical way by 
researchers from developed countries. These are caused by distinctions between 
researchers and target groups in HPGR, such as marked inequality of power and 
resources and a lack of cultural sensitivity regarding decision-making. In the 
context of HPGR, target groups should be involved in the development, design 
and conduct of the research, since the process of consultation could offer a 
potential mechanism to protect communities against exploitation. Consultation 
on research design should be a necessary prerequisite to ensuring that the HPGR 
is undertaken in a way that respects the cultural norms of the target 
group/community and alerts the group/community to the possibility of harms 
arising from the research questions or findings. The content of the researchers‘ 
consultation in all HPGR projects should include the following three main 
aspects:  
a) In order to establish a proper research protocol, researchers should 
investigate the basic social, economic and average educational 
background of the target group.  
b) To identify the possible external and internal harms relevant to HPGR, 
social and cultural concerns should also be investigated by researchers 
intending to conduct HPGR. These may include harms including 
discrimination and stigmatisation and disruption of the group‘s common 
beliefs, traditions or narratives. The bioethical background of the 
target group, which may be very different from the Western standard 
of research ethics, should be investigated and taken into account of by 
researchers.  
c) Researchers in HPGR also have an obligation to investigate the 
culturally appropriate form of decision-making. In addition, in order to 
ensure the quality of group consultation, researchers in HPGR ought to 
collaborate with the group/community to define how the research 
problem might be approached and explained to participants and, where 
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relevant, oral traditions and other sources of group collective beliefs or 
common culture ought to be used in a respectful manner. 
Secondly, researchers should obtain a collective permission from a target group 
leader or recognized authority for HPGR, if the target group has the cultural 
tradition of collective decision-making. The mechanism of group approval in 
HPGR should respect the cultural sensitivities or customs in collective decision- 
making, which should be based on the results of group consultation. Target 
groups in HPGR may have their own specific means of collective decision-making. 
If there is a community authority or community leader who can represent the 
target group to make collective formal and explicit approval or disapproval, such 
as in the case of the Apache Business Committee which represents the Apache 
Tribe of Oklahoma when making fundamental collective decisions, 10  group 
approval or disapproval should be sought from these community authorities or 
community leaders. Similarly, in developing countries like the PRC, most of the 
target groups have their own group leaders or authorities which should be the 
agent to provide group approval/disapproval. While such collective approval or 
disapproval would not obviate the need to obtain consent from individual 
participants, it would be a highly relevant factor in determining whether the 
study should proceed – and if there is collective disapproval, this should be 
regarded as determinative. Potential participants may wish to rely upon the 
views of community leaders in making their own decisions and information about 
them should be made available to them.  
Thirdly, in order to eliminate or reduce the vulnerabilities of members of target 
groups in HPGR, at the stage of individual information disclosure, researchers 
should consider the potential participants‘ cultural traditions and educational 
level. Researchers should pay careful attention to the method of communication 
with individuals. Researchers should use communication measures which are 
appropriate giving adequate time to potential participants to ask questions 
about the HPGR, and providing adequate time for consideration of their 
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decisions. Information should be provided in language and concepts that are 
understandable to them and which enable a meaningful consent to be given.  
2) Considering the Interests of Groups in Ethical Review 
In the context of HPGR in developing countries, ethical review committees 
should accept additional responsibilities to ensure the interests of target groups 
are safeguarded and avoid the risk of exploitation. The ethical review should be 
conducted by an independent ethical review committee including members from 
target groups, rather than simply an institutional ethical review committee.  
In order to consider the interests of the group, the following measures should be 
included in domestic legislation on ethical review for all HPGR projects:   
Firstly, ethical review committees in HPGR should include members from the 
target group with varying genders, age groups and educational levels. The 
number of representatives should be decided by the population size of the 
target group. If there are group leaders or recognized authorities in target 
groups, they must be included in ethical review committees. If there is no group 
leader or group recognized authorities, the representatives should include the 
most affected members, the most educated members and some other random 
members. Some would argue that it can never be certain that the 
representatives will really voice the real opinion of the target group they 
represent. However, these selective representatives are members of the target 
group and may be expected to share common traditions and beliefs. It is 
reasonable to expect that their opinions could reflect the views of the target 
group members and their participation would also help to examine whether or 
not certain HPGR may lead to potential risks of harm that research participants 
and other members of the target group view as important. 
Secondly, those responsible for administering RECs should provide proper 
training to members from target groups to assure the competence and quality of 
their ethical review participation. The training for review of HPGR should 
emphasize the development of the ability of members from target group to 
evaluate scientific issues in HPGR and to make complex risk-benefit assessments. 
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The training should at least include the following content: background scientific 
knowledge of HPGR, potential risks of harm of HPGR, appropriate harm 
minimization measures, general research ethical principles, and standard ethical 
review procedures in a way that is understandable to target group members.  
Thirdly, in addition to risk-benefit assessments concerning individual human 
subjects, risk-benefit evaluations on the interests of target groups of the 
proposed HPGR should also be conducted, with emphasis on the assessment of 
potential collective risks of harm related to HPGR and awareness of the specific 
cultural sensitivities of target groups. It should identify how various social, 
religious, economic, cultural, and political communities/groups view the risks 
related to the proposed HPGR. The standard of ethical review of group risks of 
harm in HPGR should include the following factors: (a) the group risks of harm 
related to HPGR must be minimized, to the extent that doing so is consistent 
with sound scientific design. (b) The group risks of harm posed by HPGR must be 
reasonable in relation to the knowledge that is expected to be gained from the 
study. (c) The group risks of harms of HPGR must be no more than a minor 
increase over the minimal group risks of daily life for the identified group. 
Fourthly, ethical review committees should be responsible for determining any 
proposed compensation or payment based on the degree of risk and other 
burdens of HPGR in developing countries. Given the different levels of economic 
development between researchers from developed countries and target groups 
in HPGR from developing countries, there may be a dilemma for researchers in 
offering compensation or payment to target groups: offer too little and the 
participants are exploited, offer too much and their participation may be unduly 
influenced. Independent ethical review committees with members from target 
groups are more capable of identifying the appropriate level of compensation or 
payment which fits into the specific economic development levels of the target 
groups.  
3) Highlighting the involvement of target groups at all stages of the research 
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In addition to representatives from target groups being included in ethical 
review committees, target groups should also be involved in other stages of 
HPGR. 
a) At the stage of research design in HPGR, how to deal with the research 
data and samples should also be discussed by the researchers and 
target groups, including where data or samples will be stored, whether 
or not any will be destroyed, and who ultimately controls them after 
the completion of the research. 
b) At the stage of publication of the HPGR results, the opinion of target 
groups should be respected. Before publication, group representatives 
should be carefully informed of the potential contents‘ relevance to 
the target group and their potential implications and any objections 
noted. A consultation to avoid harms caused by publication should be 
made between researchers and target group. 
c) The mechanism of choosing group representatives to consider such 
issues should follow the rules of group representatives involved in the 
ethical review committees.  
As Western developed countries gain economic and technological ascendance, 
they need human population genetic resources which some developing countries 
have in abundance; accordingly, most HPGR will likely be conducted by 
researchers from developed countries in developing countries. Some developing 
countries, such as China, which is both engaged in HPGR and contains 
groups/communities with specific cultural sensitivities, have realized the need 
for specific protection in HPGR and made some legislative attempts to do so. 
However, after a critical analysis of these documents, it became clear that such 
regulations as do exist have borrowed their terminology and conceptual basis 
directly from Western ideologies, despite different cultural and philosophical 
traditions. Yet, as has been argued above, Western ethical and legal frameworks, 
which focus on individual autonomy and the welfare of individual participants, 
do not provide adequate protection for target groups in HPGR. Therefore, these 
legal regulations, copied word by word from Western frameworks, are not 
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culturally appropriately in China, where the traditional ethic emphasises social 
harmony over individual interests. Although there are special legislation and 
rules which aim to provide protections to ethnic minorities and regulate the 
ethical conduct of biomedical research involving human subjects in the PRC, 
they all have some deficiencies and therefore fail to provide adequate 
protections to research subjects of the HPGR. In addition, of the laws and 
regulations related to human subject protection which were analyzed in detail in 
Chapter 4, most turn out not to be promulgated by the highest level of the 
legislature, which in the PRC is the Chinese Congress and Its Standing Committee. 
They are, therefore, not powerful enough. In the context of PRC, human subject 
and target group protection need a firm foundation in high level legislation if 
they are to be effective and sensitive to cultural practices and norms. In 
addition, the concept of vulnerable group protection should also be introduced 
in Chinese high level legislation on human subject protection. Therefore, this 
thesis suggests that the PRC should establish a comprehensive legislation relating 
specifically to HPGR, which highlights vulnerable population protection. This 
legislation should be formulated by the Chinese Country Legislature – the 
Chinese Congress and Its Standing Committee. 
According to the analysis presented in this thesis, in order to provide adequate 
protections for target groups in HPGR, it has been argued that developing 
countries need to play an active role in the protection of the target group, and 
that the protections offered need to be reconstructed into a form which is 
appropriate to the specific situation and cultural context of that country. This 
thesis has analyzed the specific situation of China; thus, it is suggested that the 
following two aspects of regulation should be developed in the proposed 
domestic legislation on human subject protection in China. However, a noted, it 
can be further proposed that in order to eliminate or reduce the vulnerabilities 
of target groups in other developing countries where similar concerns are likely 
to arise, these two aspects of regulation should also be adopted by all 
developing countries.  
1) Double Review in International Collaborative HPGR 
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In order to ensure the welfare and interests of vulnerable target groups in HPGR, 
international collaborative HPGR must be regulated by both Western frameworks 
and legislation of host developing countries. This proposed legislation would, for 
example, require that foreign researchers or research institutions who conduct 
HPGR in China, no matter whether or not it has been reviewed according to the 
legal regulations or ethical guidelines of their own countries, also obtain 
approval from ethical review committees which are in conformity with the 
standard required by relevant laws, regulations and rules on biomedical research 
of the PRC, which would be more aware of the cultural sensitivities of target 
groups in HPGR and be able to take account of their vulnerabilities. This double 
review principle would play the role of preventing researchers from developed 
countries from taking advantage of loopholes in their own countries‘ regulations 
to exploit target groups in the host country. Significantly, if the approach to 
ethical review I have advocated is adopted, such double review would in fact 
provide additional protections for participants and target groups to those 
currently existing in the Western research ethics framework. 
2) Supervision  of HPGR by Developing Countries  
In consideration of the vulnerability of target groups in HPGR, it is reasonable to 
doubt that representatives from vulnerable target groups in HPGR in ethical 
review committees established by researchers have appropriate knowledge of 
regulations governing biomedical research involving human subjects. Therefore, 
using the example of the PRC, local government should play a supervisory role in 
the whole process of HPGR. The best way to achieve the supervision is to require 
that the ethical review committees of HPGR should be established by local 
government. Since the ethical review committees would be set up by local 
government, it would be helpful to deal with the issues relevant to group 
consideration, such as correctly identify the extent of dispersion within 
communities and avoid the inappropriate use of ethical review which may harm 
the target group/community. These committees need a firm foundation in law 
specific to biomedical research. Ensuring the independence and legitimacy of 
these committees requires that they operate within the proposed high level 
legislation on human subject protection, not merely national ethical guidelines 
although the latter have the advantage of ease of amendment. These 
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committees would supervise the whole process of HPGR, including the selection 
of target groups, group consultation, information disclosure, group approval, 
research results publication and further use of research samples.  
As proposed earlier, their supervision should include consideration of the wide 
range of issues which ethics review committees may have to consider in the 
context of the socio-economic factors operating in specific situations and certain 
areas. These committees should also consider the issues specific to the 
particular target groups and the particular research; for instance, determining 
whether HPGR will be harmful to a target group given the specific needs of that 
community. If these committees find that the intended HPGR fails to meet any 
legal requirement stipulated in the proposed special law on biomedical research 
relevant to HPGR, they should report this to the local government. The local 
government should then require the researchers to stop the project immediately. 
The proposed general model for additional protections for groups in HPGR in 
China is summarized in Figure 5-1. 
Chapter 5 
Conclusion  214 
 
 
Figure 5-1 General Model for Additional Protections to Groups in HPGR 
The growth of international research has given rise to increasing concern that 
international researchers may benefit excessively from conducting biomedical 
research in the developing world, and thus exploit the vulnerability of potential 
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participants and their communities. 11  Thus, attention has now turned to the 
question of how to provide adequate protection to vulnerable populations in 
developing countries with respect to their specific cultural sensitivities. This 
change makes studies on the legal and ethical protection in biomedical research 
involving human subjects in developing countries more significant than before.  
Although this thesis was intended to examine the need for an alternative model 
for group protection in HPGR in the specific situation of China, it has a broader 
application in that it throws some light on general issues of group protection in 
HPGR by examining the existing Western ethical and legal frameworks on 
biomedical research. This thesis has illustrated that in addition to risks of harm 
to individual participants, HPGR may expose target groups and other members of 
certain groups who are not directly involved to additional risks of harm. Current 
Western ethical and legal frameworks on biomedical research cannot provide 
adequate protection of the interests of target groups in HPGR. There is a need 
for additional protections which can take specific account of the special 
interests of target groups and their cultural sensitivities, such as group approval 
and community review conducted by target groups and ethical review 
committees involving target group representatives. Given the common situations 
of poverty, isolation, low-educational level and lack of social and economic 
resources, target groups in HPGR are vulnerable groups. Target groups may have 
their own traditions of decision-making which do not fit into the Western pattern. 
This thesis has sought to help legislators and policy makers to understand in a 
precise way the inadequacies of current ethical and legal frameworks on 
biomedical research in group protection in HPGR, with specific consideration of 
the vulnerabilities and cultural sensitivities of target groups in developing 
countries. 
Although there are some studies that highlight concerns about the interests of 
the third parties in biomedical research, 12  they are mostly still based on 
                                         
11
 Ballantyne, A. 2008, ""Fair Benefits" Accounts of Exploitation Required A Normative Principle of 
Fairness: Response to Gbadegesin and Wendler, and Emanuel et al.", Bioethics, vol. 22, no. 4, 
pp. 239-244, at 240. 
12
 See Resnik, D. B. & Sharp, R. R. 2006, "Protecting Third Parties in Human Subjects Research", 
IRB: Ethics and Human Research, vol. 28, no. 4, pp. 1-7. Also see Kimmelman, J. 2005, 
"Medical Research, Risk, and Bystanders", IRB: Ethics and Human Research, vol. 27, no. 4, pp. 
1-6. 
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individualised autonomy or only consider the issues of indigenous people in 
developed countries. One of the reasons why there is a lack of studies in this 
area could be the influence of Western individualism that dominates in 
biomedical research; namely, respect for (individual) persons. This can lead to 
the interests of groups being ignored. What is more, there are few scholars with 
the awareness of cultural distinctions between different cultures. Thus, it is far 
from easy for researchers in developed countries to discuss vulnerable group 
protection in biomedical research conducted in developing countries. Despite 
this difficulty, this thesis has demonstrated that studies in this area can be 
carried out by examining vulnerable target group protection in HPGR in the PRC. 
Meanwhile, the People‘s Republic of China, as an example of a developing 
country, is rich in genetic resources which lend themselves to the conduct of 
HPGR. This thesis has provided recommendations on how to reconstruct a legal 
and ethical framework for HPGR in China to ensure protection of the interests of 
target groups and eliminate or reduce their vulnerabilities, with specific 
awareness of the cultural sensitivity of target groups in China. For developing 
countries which have not adopted legal regulations or ethical guidelines on 
human subject protection, or are in the process of formulating national 
regulations, although they may not have the same legal system or cultural 
sensitivity as China, this thesis could raise the awareness of the need for target 
group protection with due consideration of their special vulnerabilities and 
group interests. For those developing countries which have already adopted legal 
regulations and ethical guidelines on human subject protection, this thesis can 
also serve to remind regulators that the existing regulations and guidelines may 
need to be amended to provide adequate protection to target groups. In 
addition, this thesis could raise the awareness of group protection in biomedical 
research conducted in developing countries, which could contribute to the 
amendment of international declarations and ethical guidelines, with specific 
consideration of the vulnerability and cultural sensitivities of target groups. 
217 
Appendix 1  
 
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI 
Ethical Principles for Medical Research Involving Human Subjects 
Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 
29th WMA General Assembly, Tokyo, Japan, October 1975 
35th WMA General Assembly, Venice, Italy, October 1983 
41st WMA General Assembly, Hong Kong, September 1989 
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 
52nd WMA General Assembly, Edinburgh, Scotland, October 2000 
53rd WMA General Assembly, Washington 2002 (Note of Clarification on paragraph 29 added) 
55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 added) 
59th WMA General Assembly, Seoul, October 2008 
A. INTRODUCTION 
1. The World Medical Association (WMA) has developed the Declaration of 
Helsinki as a statement of ethical principles for medical research involving 
human subjects, including research on identifiable human material and data. 
The Declaration is intended to be read as a whole and each of its constituent 
paragraphs should not be applied without consideration of all other relevant 
paragraphs. 
2. Although the Declaration is addressed primarily to physicians, the WMA 
encourages other participants in medical research involving human subjects to 
adopt these principles. 
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3. It is the duty of the physician to promote and safeguard the health of patients, 
including those who are involved in medical research. The physician's knowledge 
and conscience are dedicated to the fulfilment of this duty. 
4. The Declaration of Geneva of the WMA binds the physician with the words, 
―The health of my patient will be my first consideration,‖ and the International 
Code of Medical Ethics declares that, ―A physician shall act in the patient's best 
interest when providing medical care.‖ 
5. Medical progress is based on research that ultimately must include studies 
involving human subjects. Populations that are underrepresented in medical 
research should be provided appropriate access to participation in research. 
6. In medical research involving human subjects, the well-being of the individual 
research subject must take precedence over all other interests. 
7. The primary purpose of medical research involving human subjects is to 
understand the causes, development and effects of diseases and improve 
preventive, diagnostic and therapeutic interventions (methods, procedures and 
treatments). Even the best current interventions must be evaluated continually 
through research for their safety, effectiveness, efficiency, accessibility and 
quality. 
8. In medical practice and in medical research, most interventions involve risks 
and burdens. 
9. Medical research is subject to ethical standards that promote respect for all 
human subjects and protect their health and rights. Some research populations 
are particularly vulnerable and need special protection. These include those who 
cannot give or refuse consent for themselves and those who may be vulnerable 
to coercion or undue influence. 
10. Physicians should consider the ethical, legal and regulatory norms and 
standards for research involving human subjects in their own countries as well as 
applicable international norms and standards. No national or international 
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ethical, legal or regulatory requirement should reduce or eliminate any of the 
protections for research subjects set forth in this Declaration. 
B. PRINCIPLES FOR ALL MEDICAL RESEARCH 
11. It is the duty of physicians who participate in medical research to protect 
the life, health, dignity, integrity, right to self-determination, privacy, and 
confidentiality of personal information of research subjects. 
12. Medical research involving human subjects must conform to generally 
accepted scientific principles, be based on a thorough knowledge of the 
scientific literature, other relevant sources of information, and adequate 
laboratory and, as appropriate, animal experimentation. The welfare of animals 
used for research must be respected. 
13. Appropriate caution must be exercised in the conduct of medical research 
that may harm the environment. 
14. The design and performance of each research study involving human subjects 
must be clearly described in a research protocol. The protocol should contain a 
statement of the ethical considerations involved and should indicate how the 
principles in this Declaration have been addressed. The protocol should include 
information regarding funding, sponsors, institutional affiliations, other potential 
conflicts of interest, incentives for subjects and provisions for treating and/or 
compensating subjects who are harmed as a consequence of participation in the 
research study. The protocol should describe arrangements for post-study access 
by study subjects to interventions identified as beneficial in the study or access 
to other appropriate care or benefits. 
15. The research protocol must be submitted for consideration, comment, 
guidance and approval to a research ethics committee before the study begins. 
This committee must be independent of the researcher, the sponsor and any 
other undue influence. It must take into consideration the laws and regulations 
of the country or countries in which the research is to be performed as well as 
applicable international norms and standards but these must not be allowed to 
reduce or eliminate any of the protections for research subjects set forth in this 
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Declaration. The committee must have the right to monitor ongoing studies. The 
researcher must provide monitoring information to the committee, especially 
information about any serious adverse events. No change to the protocol may be 
made without consideration and approval by the committee. 
16. Medical research involving human subjects must be conducted only by 
individuals with the appropriate scientific training and qualifications. Research 
on patients or healthy volunteers requires the supervision of a competent and 
appropriately qualified physician or other health care professional. The 
responsibility for the protection of research subjects must always rest with the 
physician or other health care professional and never the research subjects, 
even though they have given consent. 
17. Medical research involving a disadvantaged or vulnerable population or 
community is only justified if the research is responsive to the health needs and 
priorities of this population or community and if there is a reasonable likelihood 
that this population or community stands to benefit from the results of the 
research. 
18. Every medical research study involving human subjects must be preceded by 
careful assessment of predictable risks and burdens to the individuals and 
communities involved in the research in comparison with foreseeable benefits to 
them and to other individuals or communities affected by the condition under 
investigation. 
19. Every clinical trial must be registered in a publicly accessible database 
before recruitment of the first subject. 
20. Physicians may not participate in a research study involving human subjects 
unless they are confident that the risks involved have been adequately assessed 
and can be satisfactorily managed. Physicians must immediately stop a study 
when the risks are found to outweigh the potential benefits or when there is 
conclusive proof of positive and beneficial results. 
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21. Medical research involving human subjects may only be conducted if the 
importance of the objective outweighs the inherent risks and burdens to the 
research subjects. 
22. Participation by competent individuals as subjects in medical research must 
be voluntary. Although it may be appropriate to consult family members or 
community leaders, no competent individual may be enrolled in a research study 
unless he or she freely agrees. 
23. Every precaution must be taken to protect the privacy of research subjects 
and the confidentiality of their personal information and to minimize the impact 
of the study on their physical, mental and social integrity. 
24. In medical research involving competent human subjects, each potential 
subject must be adequately informed of the aims, methods, sources of funding, 
any possible conflicts of interest, institutional affiliations of the researcher, the 
anticipated benefits and potential risks of the study and the discomfort it may 
entail, and any other relevant aspects of the study. The potential subject must 
be informed of the right to refuse to participate in the study or to withdraw 
consent to participate at any time without reprisal. Special attention should be 
given to the specific information needs of individual potential subjects as well as 
to the methods used to deliver the information. After ensuring that the potential 
subject has understood the information, the physician or another appropriately 
qualified individual must then seek the potential subject‘s freely-given informed 
consent, preferably in writing. If the consent cannot be expressed in writing, the 
non-written consent must be formally documented and witnessed. 
25. For medical research using identifiable human material or data, physicians 
must normally seek consent for the collection, analysis, storage and/or reuse. 
There may be situations where consent would be impossible or impractical to 
obtain for such research or would pose a threat to the validity of the research. 
In such situations the research may be done only after consideration and 
approval of a research ethics committee. 
26. When seeking informed consent for participation in a research study the 
physician should be particularly cautious if the potential subject is in a 
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dependent relationship with the physician or may consent under duress. In such 
situations the informed consent should be sought by an appropriately qualified 
individual who is completely independent of this relationship. 
27. For a potential research subject who is incompetent, the physician must 
seek informed consent from the legally authorized representative. These 
individuals must not be included in a research study that has no likelihood of 
benefit for them unless it is intended to promote the health of the population 
represented by the potential subject, the research cannot instead be performed 
with competent persons, and the research entails only minimal risk and minimal 
burden. 
28. When a potential research subject who is deemed incompetent is able to 
give assent to decisions about participation in research, the physician must seek 
that assent in addition to the consent of the legally authorized representative. 
The potential subject‘s dissent should be respected. 
29. Research involving subjects who are physically or mentally incapable of 
giving consent, for example, unconscious patients, may be done only if the 
physical or mental condition that prevents giving informed consent is a 
necessary characteristic of the research population. In such circumstances the 
physician should seek informed consent from the legally authorized 
representative. If no such representative is available and if the research cannot 
be delayed, the study may proceed without informed consent provided that the 
specific reasons for involving subjects with a condition that renders them unable 
to give informed consent have been stated in the research protocol and the 
study has been approved by a research ethics committee. Consent to remain in 
the research should be obtained as soon as possible from the subject or a legally 
authorized representative. 
30. Authors, editors and publishers all have ethical obligations with regard to the 
publication of the results of research. Authors have a duty to make publicly 
available the results of their research on human subjects and are accountable 
for the completeness and accuracy of their reports. They should adhere to 
accepted guidelines for ethical reporting. Negative and inconclusive as well as 
positive results should be published or otherwise made publicly available. 
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Sources of funding, institutional affiliations and conflicts of interest should be 
declared in the publication. Reports of research not in accordance with the 
principles of this Declaration should not be accepted for publication. 
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH 
MEDICAL CARE 
31. The physician may combine medical research with medical care only to the 
extent that the research is justified by its potential preventive, diagnostic or 
therapeutic value and if the physician has good reason to believe that 
participation in the research study will not adversely affect the health of the 
patients who serve as research subjects. 
32. The benefits, risks, burdens and effectiveness of a new intervention must be 
tested against those of the best current proven intervention, except in the 
following circumstances: 
• The use of placebo, or no treatment, is acceptable in studies where no current 
proven intervention exists; or 
• Where for compelling and scientifically sound methodological reasons the use 
of placebo is necessary to determine the efficacy or safety of an intervention 
and the patients who receive placebo or no treatment will not be subject to any 
risk of serious or irreversible harm. Extreme care must be taken to avoid abuse 
of this option. 
33. At the conclusion of the study, patients entered into the study are entitled 
to be informed about the outcome of the study and to share any benefits that 
result from it, for example, access to interventions identified as beneficial in 
the study or to other appropriate care or benefits. 
34. The physician must fully inform the patient which aspects of the care are 
related to the research. The refusal of a patient to participate in a study or the 
patient‘s decision to withdraw from the study must never interfere with the 
patient-physician relationship. 
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35. In the treatment of a patient, where proven interventions do not exist or 
have been ineffective, the physician, after seeking expert advice, with informed 
consent from the patient or a legally authorized representative, may use an 
unproven intervention if in the physician's judgement it offers hope of saving life, 
re-establishing health or alleviating suffering. Where possible, this intervention 
should be made the object of research, designed to evaluate its safety and 
efficacy. In all cases, new information should be recorded and, where 
appropriate, made publicly available. 
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Amendments to Chinese Provisions of Human subject Protection 
 
1) Better Chinese High Level Legislation on Human Subject Protection 
Of the laws and regulations related to human subject protection which were 
analyzed in detail in Chapter 4, most turn out not to be promulgated by the 
highest level of the legislature, which in the PRC is the Chinese Congress and Its 
Standing Committee. They are, therefore, not powerful enough. To provide 
adequate protections for human subjects in biomedical research, this thesis 
suggests that high level legislation needs to play an active role in the protection 
of participants and that the basic protections offered by the international 
guidelines need to be reconstructed into a form which is appropriate to the 
specific situation in that country. In the context of PRC, human subject and 
target group protection need a firm foundation in high level legislation if they 
are to be effective and sensitive to cultural practices and norms. In addition, the 
concept of vulnerable group protection should also be introduced in Chinese high 
level legislation on human subject protection. It is suggested that the legislation 
on human subject protection, which highlights vulnerable population protection 
in the PR China should be formulated by the Chinese Country Legislature – the 
Chinese Congress and Its Standing Committee. 
There is evidence that vulnerable groups, such as ethnic minorities and isolated 
groups in rural areas, tend to be underrepresented in biomedical research. 1 
However, some international declarations and ethical guidelines on human 
subject protection do pay specific attention to the issues raised by the 
participation of minorities in research. For example, the CIOMS guidelines make 
reference to this issue as follows: 
Members of vulnerable groups also have the same entitlement to 
access to the benefits of investigational interventions that show 
promise of therapeutic benefit as persons not considered vulnerable, 
                                         
1
 For discussion, see Sheikh, A. 2006, "Are Racial and Ethnic Minorities Less Willing to Participate 
in Health Research?", PLOS Medicine, vol. 3, no. 2, pp. 0166-0167.  
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particularly when no superior or equivalent approaches to therapy are 
available.2 
This statement acknowledges the dilemma that, on the one hand, it is unjust 
selectively to recruit vulnerable populations to serve as research subjects simply 
because they may be more easily induced to participate in exchange for small 
payments; on the other hand, such vulnerable populations should not be 
categorically excluded from research protocols. The concerns of vulnerable 
population protection and the benefits of participation should be considered 
together to seek to an appropriate balance. In the clinical trial setting, this 
dilemma also exists. Some countries have realized this situation and introduced 
relevant policies to promote the participation of minorities in potentially 
beneficial clinical research. For example, Noah illustrated this situation in the 
US as follows: 
Evidence suggests….that racial and ethnic minorities have less 
opportunity to participate in potentially beneficial clinical research. 
For reasons of scientific and practical convenience, minority groups 
were commonly excluded from clinical trials until the mid-1990s.  
More recently, in recognition of the fact that minority participation in 
medical research enhances scientific understanding of variations in 
disease and treatment response among races and out of concern for 
healthcare justice, the government has instituted policies designed to 
encourage the inclusion of minorities in clinical trials. Even so, the 
research community must proceed with caution in any efforts to 
equalize participation, both because of the inherent risks of medical 
research to individual participants and because some efforts at racial 
inclusion may have unintended negative consequences.3 
Therefore, it needs to be highlighted that special protections for vulnerable 
populations in biomedical research involving human subject in the PRC should 
not deliberately prohibit vulnerable populations from being the subject of those 
research projects. 
                                         
2
 International Ethical Guidelines for Biomedical Research Involving Human Subjects was prepared 
by the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with 
the WHO, Geneva, 2002. The full text of CIOMS Guidelines can be seen on the official website 
of World Heath Organization (WHO) on 
http://whqlibdoc.who.int/emro/2004/9290213639_annex2.pdf, last visited on 2010-07-27, 
Commentary and reference to Guideline 12. 
3
 Noah, B. A. 2003, "The Participation of Underrepresented Minorities in Clinical Research", 
American Journal of Law and Medicine , vol. 29, no. 2-3, pp. 221-245, at 224. 
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However, it needs to be noted that the situation of HPGR should be treated as a 
special case. Most HPGR projects are designed simply to improve scientific 
understanding and are unlikely to offer direct benefit to participating groups. 
Thus, since the target groups of HPGR are vulnerable groups, and some HPGR 
protocols pose potential risks to those groups, participation in HPGR should not 
be promoted. Meanwhile, if target groups have decided to participate in certain 
HPGR, their interests should be ensured by the provision of systematic and 
effective protection to vulnerable target groups and their members, while 
guarding against the imposition of unfair burdens or risks for any one group of 
participants.  
2) Amendment to Provisions of Researchers’ Responsibilities 
As discussed in Chapter 3, most HPGR projects are conducted by researchers 
from developed countries, while the target groups in HPGR are almost always 
isolated groups or ethnic minorities in rural areas of developing countries, such 
as PR China; thus, target groups in HPGR are almost vulnerable groups with their 
own cultural sensitivities and need additional protections. Researchers, who 
have advantages in power and resources, must accept a series of obligations to 
mitigate the vulnerabilities of target groups in the whole process of HPGR. 
(1) Group Consultation 
There are several obstacles that can interfere with HPGR being conducted in an 
ethical way by researchers from developed countries. These are caused by 
distinctions between researchers and target groups in HPGR, such as marked 
inequality of power and resources and a lack of cultural sensitivity regarding 
decision-making. In the context of HPGR, target groups should be involved in the 
development, design and conduct of the research, since the process of 
consultation could offer a potential mechanism to protect communities against 
exploitation. Consultation on research design should be a necessary prerequisite 
to ensuring that the HPGR is undertaken in a way that respects the cultural 
sensitivity of target group/community and alerts the group/community to the 
possibility of harms arising from the research questions or findings.  
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The content of the researchers‘ consultation in HPGR in the PRC should include 
the following three main aspects: 
A. In order to establish a proper research protocol, researchers should 
investigate the basic social, economic and average education background 
of the target group. Since target groups in HPGR are usually impoverished 
people, who are highly susceptible to prospects of financial rewards, even 
small financial payments can act as a coercive force, compelling the poor 
to do what the rich would be reluctant to consider. They may be unable 
to give unqualified consent to HPGR, when confronted with compensation 
for research participation. What is more, non-financial incentives that 
could improve the living standard of target groups may also be overly 
coercive. These offers might include food, clothing, basic medical 
treatment and drugs. The limits of the economic and social resources in 
developing countries can transform these simple rewards or basic 
resources into forceful incentives for target groups in HPGR. Researchers 
conducting HPGR must not assume that the incentive level should be 
based on their own standards. Any incentive level researchers offer should 
be tailored to the level of social and economic development of the target 
group. It is the obligation of researchers to identify the proper way of 
providing compensation or rewards to ensure that the human subjects 
make their own decisions on whether or not to participate without the 
pressure of undue incentives. In addition, the average educational 
background of the target group should be related to the expression of 
information disclosure, which should be clear and understandable. 
B. To identify the possible internal harms relevant to certain HPGR, cultural 
sensitivity which may be harmed by certain HPGR, such as a group‘s 
common belief, specific group traditions or group narratives, should also 
be investigated by researchers of HPGR. The cultural sensitivity such as 
bioethical background, which would be opposite to the application of 
Western standard of research ethics, should be investigated by 
researchers in HPGR. For example, for individuals in non-Western 
societies, perspectives on the nature of disease, the subject-investigator 
relationship, and the doctor-patient relationship may be entirely different 
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from those in Western societies.4 The meaning of ‗person‘ may also be 
different between Western and non-Western societies. It has been argued 
that ‗the majority viewpoint manifest in most other societies, both 
technologically developing (e.g., Central Africa) and technologically 
developed (e.g., Japan), does not reflect the American perspective of 
radical individualism.‘5 As De Craemer puts it: 
 The American notion of person has still other characteristic 
features.  It is markedly rational, and also legalistic-
prototypically expressed in  the language of rights, and 
central not only to our Declaration of  Independence and 
Constitution, but to a very wide range of issues  that find 
their way into our courts and our legislatures. 
 In turn, these rational-legal aspects of our cultural outlook on 
 personhood are associated with the voluntary, functionally 
specific,  contractual model of social relations that has a 
predominant place in  our society, particularly in 
economic and political spheres.... 
 The American view of the human person is pervaded by 
logical-rational dichotomies. This view sharply opposes body 
and mind,  thought and feeling, the conscious and 
unconscious, self and other, reality and nonreality (imagining, 
dreaming, and hearing voices, for example are not ―real‖).6 
He further argues in his summary statement that the ‗American way of 
thinking about the person represents the way men and women of all 
societies and cultures should and do think about personhood when they 
are being supremely rational and moral.‘7 In the PRC, as was discussed in 
Chapter 4, however, the culture of isolated groups in rural areas is 
characterised by communal values and highlights social harmony. In both 
Confucianism and Marxism/communism, a person cannot be seen in 
isolation. Instead, they are at the centre of relationships. A person exists 
in a social context in order to fulfil their social responsibilities, and a 
                                         
4
 Clinton, R. N. 1990, "Rights of Indigenous Peoples as Collective Group Rights", Arizona Law 
Review, vol. 32, no. 4, pp. 739-748 
5
 Levine, R. J. 1991, " Informed Consent: Some Challenges to the Universal Validity of the Western 
Model", Journal of Law, Medicine and Ethics, vol. 19, pp. 207-213, at. 209. 
6
 De Craemer, W. 1983, "A Cross-Cultural Perspective on Personhood ", The Milbank Memorial 
Fund Quarterly: Health and Society, vol. 61, no. 1, pp. 19-34, at 21. 
7
 Ibid., at 34. 
230 
person‘s nature manifests itself only through human relatedness. As has 
been said, ‗[t]he Chinese believe in the importance of individual 
autonomy, but they also believe that this right of autonomy is guided by 
social needs.‘ 8  These bioethical backgrounds should be considered by 
researchers to ethically conduct certain HPGR, with acknowledgement of, 
and respect for, target groups‘ cultural sensitivities. 
C. Researchers in HPGR also have an obligation to investigate the cultural 
sensitivity regarding decision-making. According to the result of group 
consultation on cultural sensitivity regarding decision-making, researchers 
could decide whether or not group approval/disapproval is needed. If the 
cultural sensitivity on decision-making is individual as final decision maker, 
the process of group approval/disapproval does not need to be conducted. 
If certain target group have the cultural sensitivity on group decision-
making or used to follow the decision of group leader, then, group 
approval/disapproval should be conducted. It need to be highlighted, the 
requirement on group approval/disapproval do not means the complete 
abandon of individual informed consent. It means that the result of this 
group approval/disapproval should be the precondition of whether or not 
certain HPGR could be conducted. If group approved, the individual 
informed consent should also be conducted before collect samples from 
individual participants. Rather, when conducting individual informed 
consent, the group approval should be provided to individual participants. 
For example, according to Confucianism, which is a traditional and 
influential culture in the PRC, especially in isolated rural areas, the family 
is not only a means for human flourishing, but also has its own status in 
decision-making. One‘s family members sustain an element of one‘s own 
being. This leads to the belief that one‘s choices have a profound effect 
on both the individual and the family as a whole. This understanding of 
the family is reflected in the Confucian approach to making medical 
decisions, assessing medical technology, and financing health care. 
Medical decision-making involves the whole family, since the whole 
family‘s interests as well as the individual‘s are at stake. The interests of 
                                         
8
 Doring, O. 2003, "China's Struggle for Practical Regulations in Medical Ethics", Nature Reviews: 
Genetics, vol. 4, pp. 233-239, at 236. 
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the family must also be taken into account when assessing medical 
technology. This does not mean that individual interests should always 
give way to family interests when conflicts occur. However, in most cases 
of target groups in HPGR in the PRC, the opinion of community leaders or 
senior family members (or community leaders) would be a significant 
reference for members of target groups. This opinion from a community 
leader or senior family member, which would  be likely to influence the 
decision of potential participants, is a part of the social context of an 
individual‘s decision-making; thus, it is not undue influence at least in 
this culture. Accordingly, in most cases of HPGR in the PRC, group 
approval/ disapproval should be considered. Therefore, the cultural 
sensitivities of target groups, which will influence their decision-making, 
should be identified and understood by the researcher in HPGR before the 
research design stage. 
In recognition of these issues, there should be a basic legal requirement on 
researchers in HPGR to conduct precise consultation about relevant cultural 
sensitivity issues at the stage of research design in the PRC.  
In order to ensure the quality of group consultation, researchers in HPGR ought 
to collaborate with the group/community to define how the research problem 
might be approached and, where relevant, oral tradition and other sources of 
group collective beliefs or common culture ought to be used in a respectful 
manner. The consultation process should include: (a) researchers survey and 
communication with group representatives on the cultural sensitivity of certain 
groups, for example, asking community/group leaders, affected and unaffected 
persons a series of questions about how they recognize and make decisions about 
illness; (b) dialogue or communication between researchers and group members. 
The contents of consultation should include questions regarding whom they ask 
for advice in medical decision-making, who may have assisted them in seeking 
care, who may have provided care for them, and their social relationships to 
those persons, whether there is there any group common belief or cultural 
sensitivity concerning disease, health and life. If necessary, social scientists with 
working experience of the target groups, as well as prominent community 
members, could be consulted to interpret these answers. 
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In addition, the final consultation should also be submitted to both supervision 
authorities of local government in the PRC and IRBs or RECs, for the purposes of 
scrutiny. 
(2) Group Approval /Disapproval 
The term ‗group approval / disapproval‘ is ambiguous and proponents of group 
approval do not always make clear what precisely they mean by it. In group 
approval as it is understood here, researchers should obtain a collective 
permission from a target group leader or recognized authority for HPGR, only if 
target group has the cultural tradition of collective decision-making. It needs to 
be highlighted that the collective decision, group approval / disapproval, is not 
binding on individual members who may choose to consent or refuse to 
participate in HPGR. The results of group approval/disapproval here would be 
one piece of necessary relevant information which would be provided to 
potential individual participants as a reference to help them to make their own 
decision on whether or not to participate in certain HPGR, according to their 
decision-making patterns.  
Since the main criticisms of group approval focused on giving a target group the 
authority to veto proposed HPGR involving their members,9 it is important to 
stress that the group approval/disapproval discussed here is not intended to 
extend a ‗veto power‘ to the target group in HPGR. Rather, in the context of the 
PRC, as has been discussed above, likely target groups have a culture of group 
decision making, or acceptance that the group leader has the right to decide. If 
researchers intend to achieve genuine consent from individual members of such 
target groups with cultural sensitivity regarding group decision-making, 
researchers in HPGR should obtain and provide the opinions of their group 
leaders or recognized authorities on the proposed research in order to help 
individual members to make their own decisions.  
The mechanism of group approval in HPGR should respect the cultural 
sensitivities or customs in collective decision- making, which should based on the 
                                         
9
 Juengst, E. T. 1998, "Groups as Gatekeepers to Genomic Research: Conceptually Confusing, 
Morally Hazardous, and Practically Useless", Kennedy Institute of Ethics Journal, vol. 8, no. 2, 
pp. 183-200, at 183.. 
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results of group consultation. Target groups in HPGR may have their own specific 
means of collective decision-making. If there is a community authority or 
community leader who can represent the target group to make collective formal 
and explicit approval or disapproval, such as in the case of the Apache Business 
Committee which represents the Apache Tribe of Oklahoma when making 
fundamental collective decisions, 10  group approval or disapproval should be 
sought from these community authorities or community leaders. Similarly, in the 
PRC, most of the target groups have their own group leaders or authorities, 
which should be the agent to provide group approval/disapproval.  
Therefore, if researchers obtain group approval for a particular HPGR, it implies 
that researchers can conduct this HPGR, only when it is based on informed 
consent from individual group members. If the target group considers that HPGR 
might lead to harms and does not approve it, in the context of the PR China, 
certain HPGR would not be conducted, since researchers would be unlikely to be 
able to recruit sufficient numbers of participants from target groups where the 
decision of community leaders is generally accepted as definitive. Meanwhile, 
group disapproval was also likely to lead to the project not being approved at 
ethical review and hence not proceeding. 
The legal requirement of group approval/disapproval needs to respect to the 
changes or withdrawal of group approval by target group in HPGR. If group 
approval is required for the research study to proceed, then major changes in 
the agreed-upon protocol should also be examined by the target group.  
In addition to being provided to potential individual participants in HPGR as 
necessary information for decision-making, the written result of group decision 
should also be submitted to both supervision authorities of local government in 
the PRC and IRBs or RECs. 
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 Foster, M. W., Bernsten, D., & Carter, T. H. 1998, "A Model Agreement for Genetic Research in 
Socially Identifiable Populations", American Journal of Human Genetics, vol. 63, pp. 696-702, at 
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(3) Individual Informed Consent  
The information that must be disclosed to a potential human subject who is 
considering participating in biomedical research, which he/she in turn must have 
the opportunity to evaluate (a process that includes having access to a member 
of the research team), is listed in various research guidelines and legal 
regulations. In general, this information includes a broad description of the 
nature of the study (including what part is experimental and how long the study 
will last), a description of reasonably foreseeable risks, a description of any 
potential benefits to the subject, a statement of how the confidentiality of 
records will be maintained, a statement of whether there will be compensation 
for injury, a designation of a contact person who is a member of the research 
team, and a declaration that participation is voluntary and that there is no 
penalty for withdrawal. In addition to information has been listed in current 
research guidelines, given there are additional risks of harm that may be caused 
by HPGR to the target group as a whole as discussed in Chapter 2, the special 
rules on HPGR in the PRC should require the following two additional contents: 
(a) potential benefits and risks of harm to the interests of target group in HPGR, 
which is similar to the list of information concerning disclosure with potential 
participants about anticipated benefits and potential risks to individual 
participant; (b) if has the cultural sensitivity on group decision-making, group 
decision made by group leader or group recognized authority should also be 
disclosed to potential individual participants as a reference to make their own 
decisions. 
The disclosure standard applied in HPGR in the PRC should require disclosure of 
whatever it can reasonably be concluded potential participants would consider 
significantly in their decision-making. Since target groups in HPGR may be 
vulnerable, the standard would require researchers to disclose to potential 
participants all of the relevant information that any qualified individual of a 
target group would reasonably need to know to make a decision on whether or 
not participate in the HPGR. This standard is similar to the reasonable patient 
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rule which has been used as a standard of disclosure in legal cases about medical 
treatment decisions in some countries.11 
In order to eliminate or reduce the vulnerabilities of target groups in HPGR, the 
new legal requirement in the PRC should be stipulated to a more appropriate 
way which could fit into the specific situations of target groups. The detailed 
measures include:  
A. The conduct of information disclosure needs to be undertaken in a clear 
and intelligible manner, such as using local languages where necessary. As 
O‘Neill pointed out, a normal person ‗may find that being confronted with 
the full detail of research protocols provides excess, inassimilable 
information, to which they can hardly hope to give genuinely informed 
consent.‘12 Given that the target groups in HPGR in the PRC are vulnerable 
groups with low-educated level, the situation of confusing by a thick stack 
of papers which lists of complex questions described by difficult medical 
terms would be even worse. Therefore, in order to ensure the quality of 
information disclosure, the new legal requirement also should require 
that researchers should provide information in the language of the 
potential participants and at a level appropriate to their reading level, 
where providing written information is likely to be of practical value. It 
should also provide an emphasis on process rather than mere agreement 
or signing a consent form.  
B. Considering the cultural sensitivity and educational level of the members 
of target groups in HPGR, during the process of information disclosure, 
researchers should pay attention to the method of communication with 
group members. In order to ensure the fullest possible understanding of 
relevant information, the new guideline should suggest that researchers 
use specific group communication measures which are appropriate to 
certain target groups, such as face-to-face meetings between 
communities and researchers, giving adequate time to potential 
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participants to ask questions about the HPGR, and providing adequate 
time for consideration of their decision. 
C. The new legal requirement should require researchers to clearly inform 
potential participants of the right to refuse to take part in HPGR or to 
withdraw consent to participate at any time without reprisal, as well as 
provide easy procedure to exercise the decision of refuse or withdrawal. 
As O‘Neill suggested, ethically acceptable consent should meet the 
standard that ‗the possibility of refusal should be made as clear and as 
easy to exercise as the possibility of consent.‘13 
The written informed consent forms from individual participants in HPGR should 
be submitted to both supervision authorities of local government in the PRC and 
ethical review committees. The process of individual informed consent should be 
fully reviewed by ethical review committees, and be supervised by supervision 
authorities of local government in the PRC. 
3) Amendment to Provisions of Ethical Review 
In order to ensure the welfare and well-being of human subjects, all 
international declarations and conventions, research guidelines, and some 
national regulations propose that research ethics committees (REC) or 
institutional review boards (IRB)14 should undertake a risk-benefit assessment 
and risk management of biomedical research involving human subjects. Without 
the approval of RECs or IRBs, no biomedical research can be ethically conducted, 
no matter whether or not a person consents to participate in it. RECs or IRBs 
allow biomedical researchers and bioethical experts with varying backgrounds to 
promote adequate review of research activities and weigh the merits of 
proposed biomedical research and its potential impact on the rights, safety, and 
welfare of human subjects from their own viewpoints. In general, ethical review 
committees provide ethical advice to researchers so as to assist decision-making 
on the adequacy of proposed research projects, with respect to the protection 
of potential and actual human subjects. Ethical review committees may function 
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 REC or IRB also known as an independent ethics committee (IEC) in the Declaration of Helsinki, 
ethical review board (ERB) in UK. 
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at the institutional, local, regional, or national level, and in some cases at the 
international level. For example, ethical review committees play a major part in 
the Declaration of Helsinki. 15  Article 15 of the Declaration highlights the 
requirements of ethical review in the whole process of the design and 
performance of each experimental procedure involving human subjects.16 
In the context of HPGR in developing countries like the PRC, due to the 
vulnerabilities of target groups caused by poverty, low-educational level and 
lack of social and medical resources, ethical review committees should accept 
additional responsibilities to ensure the interests of target groups and avoid the 
risk of exploitation. Therefore, this type of ethical review should be conducted 
without the researcher, the sponsor or any kind of undue influence. The Chinese 
provision in HPGR should require the ethical review in HPGR must be conducted 
by an independent ethical review committee including members from target 
groups; rather than institutional ethical review committee. 
(1) Membership and Composition of Ethical Review Committees in HPGR 
As discussed in Chapter 2, in HPGR, in addition to the potential risks of harm to 
individual human subjects, there are potential risks of harm to the target group 
as a whole. However, one important difficulty for ethical review committees is 
that members who are outsiders often struggle to identify intra-community risks, 
such as the disruption of existing social arrangements and relationships between 
members of a target group. Therefore, in the PRC, it is proposed that ethical 
review committees including members from the target group with varying 
genders, age groups and educational backgrounds should be an essential 
requirement of ethical review of IRBs or RECs in HPGR. The number of 
representatives should be decided by the population size of target group. If 
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there are group leaders or group recognized authorities of target groups, they 
must be included in ethical review committees. If there is no group leader or 
group recognized authorities, the representatives should include the most 
affected members, the most educated members and some other random 
members.  
Some would argue that it can never be certain that the representatives will 
really voice the real opinion of the target group they represent. However, these 
selective representatives are members of the target group and have common 
traditions and beliefs with members of target group. They should therefore be 
capable of making reasonable decisions on the basis of understanding the 
information relevant to the HPGR; their opinions could partly reflect the views 
of the target group members and would also help to examine whether or not 
certain HPGR may lead to potential risks of harm that research participants and 
other members of the target group view as important. If they are concerned that 
HPGR could potentially harm their internal or external interests, such as 
disrupting existing social arrangements or harming their common beliefs, then 
these risks of harm are something that ought to be taken into consideration in 
the ethical review process of the research. 
(2) Additional Assessment Contents in HPGR 
In order to provide adequate protection to target groups and reduce their 
vulnerabilities, in addition to risk-benefit assessment on individual and group-
based human subjects, the provisions on ethical review should include the 
following two additional factors: 
A. It should require risk-benefit evaluations on the interests of target groups 
of the proposed HPGR. It should highlight the assessment of potential 
group collective risks of harm related to certain HPGR, with the 
awareness of the specific cultural sensitivities of target groups. As Sharp 
and Forster have pointed out:  
Presently, little is known about how members of various 
underserved or marginalized communities weigh individual 
research risks against group risks, how salient collective risks 
are in relation to other risks encountered in daily life, or how 
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individuals attempt to reconcile potential conflicts that may 
exist between personal interests in research participation and 
collective opposition to proposed research. Because not all 
collective harms carry the same weight—that is, some group 
harms are more significant than others—it is important to 
assess how members of historically underserved communities 
evaluate collective research-related harms. Moreover, without 
such information it will be difficult, if not impossible, to tailor 
oversight processes to specific communities.17 
Thus, in order to identify how various social, religious, economic, cultural, 
and political communities/group view risks related to certain HPGR, in 
the PRC, the special rules on HPGR should require an additional risk-
benefit assessment on the interests of the target group as a whole. 
The standard of ethical review of group risks of harm in HPGR should fit 
the three ethical requirements which are required in all ethical reviews of 
non-therapeutic procedures.18 First, the group risks of harm related to 
HPGR must be minimized, to the extent that doing so is consistent with 
sound scientific design. This can involve avoiding unnecessary procedures, 
identifying less risky ways of testing a study hypothesis, or excluding 
participants who are at increased risk of being harmed. Second, the group 
risks of harm posed by HPGR must be reasonable in relation to the 
knowledge that is expected to be gained from the study. Third, since 
target groups in HPGR may be vulnerable populations, the group risks of 
harms of HPGR must be no more than a minor increase over the minimal 
group risks of daily life for the identified group in question. 
B. Ethical review committees should also be responsible for determining the 
proposed compensation or payment based on the degree of risk and other 
burdens in HPGR. In some literature on ethical conduction of biomedical 
research in developing countries, it has been argued that there was a 
tendency to exaggerate the risk of undue inducement, which would lead 
to restricting payments to participants on the grounds of potential undue 
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inducement.19 This situation would provide decreasing costs of researchers, 
while reducing the financial welfare of the participants. Therefore, it has 
been suggested that ethical review committees should undertake 
assessment of compensation, such as required infrastructure charge, as 
part of their general assessment of the acceptable standard of the 
research protocol.20 Given the different levels of economic development 
between researchers from developed countries and target groups in HPGR 
from developing countries, there would be a dilemma for researchers in 
offering compensation or payment to target groups: offer too little and 
they are exploited, offer too much and their participation may be unduly 
influenced. Independent ethical review committees with members from 
target groups are more capable of identifying the appropriate level of 
compensation or payment which fits into the specific economic 
development levels of target groups. Therefore, an additional review on 
proposed compensation or payment by researchers would be helpful to 
eliminate or reduce the vulnerabilities of target groups in HPGR in the 
PRC. 
(3) Double Review in International Collaborate HPGR 
As Western developed countries gain economic and technological ascendance, 
they need human population genetic resources which some developing countries 
like the PRC have in abundance; accordingly, most HPGR will likely be conducted 
by researchers from developed countries in developing countries. Due to the 
conflict of interests between developed and developing countries in HPGR, the 
legal regulations and ethical guidelines on biomedical research would have some 
differentiated standards on ethical review.  Therefore, the Declaration of 
Helsinki emphasized that independent committees should act in conformity with 
the laws and regulations of the country in which the research is performed.  21 
Article 15 also stipulated that the committee has the right to monitor ongoing 
trials. According to these provisions, the researcher has the obligation to provide 
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information to the committee, especially about any serious adverse events. The 
ethical committee is still there for consideration, comment and guidance, but it 
has to be told about conflicts of interests. If there is any serious adverse event, 
the ethical committee has to be notified. 22  
Therefore, in order to ensure the welfare and interests of vulnerable target 
groups in HPGR and decrease the practical burden of ethical review committees, 
the provision of ethical review in the PRC must require double review of HPGR. 
It should require that foreign researchers or research institutions who conduct 
HPGR inside the PRC, no matter whether or not it has been reviewed according 
to the legal regulations or ethical guidelines of their own countries, it should 
obtain approval from ethical review committees, which are in conformity with 
the provisions of relevant Chinese laws, regulations and rules on biomedical 
research. This double review principle would play the role of preventing 
researchers from developing countries take advantage of the legitimate loophole 
of their own countries to exploit target groups in the PRC. 
4) Amendment to Provisions of Supervision of Local Government in 
HPGR 
At present, many developing countries, such as the PRC, lack comprehensive 
legal frameworks relating specifically to research involving humans in HPGR, for 
example in  terms of adequate training or low educational standards. It is 
reasonable to doubt that representatives from vulnerable target groups in HPGR 
in ethical review committees have appropriate knowledge of regulations 
governing biomedical research involving human subjects. Therefore, this thesis 
suggests, in addition to independent ethical review committees, local 
government of the PRC should also undertake the responsibility of supervision on 
all HPGR conducted in the PRC. The detailed rules should include a provision 
that every HPGR conducted in the PRC must be registered with the local 
government before it is conducted, and the whole process of HPGR should be 
recorded and supervised by local governments. 
                                         
22
 Ibid. 
242 
In particular, in the context of international HPGR conducted in the PRC, local 
government in the PRC should play a supervisory role in the whole process of 
ethical review, as an additional protection to vulnerable target groups and to 
ensure the ethical conduct of HPGR in the PRC. The approach of local 
government supervision in international HPGR could be to establish independent 
local ethical review committees. These committees need a firm foundation in 
special law on biomedical research to carry out their functions effectively, in 
the absence of which they would operate from a weak and dependent position. 
Ensuring the independence and legitimacy of these committees requires that 
they operate within a legal framework, not merely national ethical guidelines 
although they have the advantage of ease of amendment. These committees 
would supervise the whole process of ethical review, including the selection of 
target groups, group consultation, information disclosure, group approval, 
ethical review, research results publication and further use of research samples. 
Their supervision should include consideration of the wide range of issues which 
ethics review committees may have to consider in the context of the socio-
economic factors operating in specific situations and certain areas. These 
committees should also consider the specific issues of the target groups and the 
particular research; for instance, determining whether a particular HPGR will be 
harmful to a particular target group, given the specific needs of that community. 
If these committees find that certain HPGR fails to meet any legal requirement 
stipulated in the proposed special law on biomedical research relevant to HPGR, 
they should report this to the local government. The local government should 
then request the researchers to stop the project immediately.   
Therefore, in order to protect target groups and reduce their vulnerabilities in 
HPGR, new approaches to regulation are needed in the PRC.  
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